| Excerpt | Reference |
|---|
| "Some patients with COPD are prone to frequent exacerbations, which are an important determinant of health status." | ( Wedzicha, JA, 2002) |
| "COPD is a major health problem, with patients showing a progressively declining, largely irreversible, change in lung function." | ( De Boer, WI, 2002) |
| "Cause of a COPD is a hypersensitivity of the respiratory tract to spores of fungi and thermophil actinomyces." | ( Eser, MW; Feige, K; Fürst, A, 2002) |
| "COPD is the only major chronic disease for which both the incidence and mortality are still rising worldwide." | ( Kerstjens, HA; Postma, DS, 2002) |
| "Chronic obstructive pulmonary disease is one of the commonest causes of morbidity and mortality in the world, and is increasing in prevalence." | ( Barnes, PJ, 2003) |
| "We conclude that COPD is not associated with any marked nasal inflammation." | ( Andersson, M; Greiff, L; Löfdahl, CG; Montnémery, P; Nihlén, U; Persson, CG, 2003) |
| "COPD is linked to weight loss and in particular to loss in fat-free mass by skeletal muscle wasting." | ( Bast, A; Boots, AW; Haenen, GR, 2003) |
| "The risks of COPD are related to environmental exposures in combination with the genetic makeup of the individual." | ( Abe, S; Chiba, H, 2003) |
| "COPD is characterized by significant chronic inflammation that is evident not only in the pulmonary compartment but also in the circulation." | ( Altun, C; Cildag, O; Gurgey, O; Karadag, F; Karul, AB, 2004) |
| "Lower SaO(2) and COPD are associated with more severe periventricular white matter lesions." | ( Breteler, MM; de Groot, JC; Hofman, A; Koudstaal, PJ; Oudkerk, M; Prins, ND; van de Minkelis, J; van Dijk, EJ; Vermeer, SE, 2004) |
| "Chronic obstructive pulmonary disease is a major clinical disorder usually associated with cigarette smoking." | ( Endo, K; Kimura, R; Ohmori, Y; Onoue, S; Yajima, T; Yamada, S, 2004) |
| "The chronic airflow obstruction is caused by a mixture of small airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema)." | ( Maestrelli, P, 2003) |
| "However, COPD is a heterogeneous disease in terms of clinical, physiologic, and pathologic presentation." | ( Gosman, MM; Jansen, DF; Kerstjens, HA; Lapperre, TS; Postma, DS; Snoeck-Stroband, JB; Sont, JK; Sterk, PJ; Stolk, J, 2004) |
| "COPD is characterized by bronchial neutrophilic inflammation." | ( Banerjee, D; Honeybourne, D; Khair, OA, 2004) |
| "COPD is considered a risk factor for pulmonary embolism (PE) and PE is part of the differential diagnosis of an acute exacerbation of COPD." | ( Bounameaux, H; Cornuz, J; Jounieaux, V; Perneger, T; Perrier, A, 2004) |
| "COPD is characterised by damage to small airways due to an inflammatory process as well as an imbalance between oxidants and antioxidants." | ( Asin, J; Gerritsen, WB; Haas, FJ; van den Bosch, JM; Zanen, P, 2005) |
| "Asthma and COPD are chronic inflammatory conditions that affect hundreds of millions of patients worldwide." | ( Romano, SJ, 2005) |
| "COPD is associated with an increased nasal concentration of the neutrophil chemoattractant protein IL-8, the degree of which reflects that present in the lower airway." | ( Donaldson, GC; Hurst, JR; Perera, WR; Wedzicha, JA; Wilkinson, TM, 2005) |
| "Chronic obstructive pulmonary disease is characterized by progressive airflow limitation and pulmonary inflammation." | ( Bosse, S; John, M; Oltmanns, U; Schumacher, A; Witt, C, 2005) |
| "COPD is defined by airflow limitation that is not fully reversible and is associated with relevant risk factors." | ( Hoshi, T; Kanauchi, T; Kanazawa, M; Kurashima, K; Sato, N; Sugita, Y; Takayanagi, N; Tokunaga, D; Ubukata, M; Yanagisawa, T, 2005) |
| "In conclusion, chronic obstructive pulmonary disease is associated with elevated alveolar nitric oxide." | ( Barnes, PJ; Brindicci, C; Ito, K; Kharitonov, SA; Pride, NB; Resta, O, 2005) |
| "Patients with chronic obstructive pulmonary disease are generally subjected to multiple regimens of antimicrobial treatment." | ( Ercibengoa, M; González, A; Larruskain, J; Marimón, JM; Pérez-Trallero, E, 2005) |
| "COPD is not only a disease of the lungs but is also a systemic inflammatory disorder." | ( Rennard, SI; Spurzem, JR, 2005) |
| "Because COPD is particularly prevalent in the elderly and aging per se may also affect glutamate metabolism, 2 male control groups were included: 8 healthy elderly (63 +/- 3 y) and 8 young (22 +/- 1 y) subjects." | ( Castro, CL; Deutz, NE; Engelen, MP; Rutten, EP; Schols, AM; Wouters, EF, 2005) |
| "COPD is not merely a neutrophil associated disease, but mast cells, eosinophils and their released mediators also actively contribute to the pathogenesis of the disease." | ( He, SH; Liu, CT; Wei, JF; Xie, H; Zhang, XJ, 2004) |
| "Since COPD is a disease characterized by a progressive and largely irreversible airflow limitation, dipyrone has no observable bronchodilator effect." | ( Beder, S; Gulmez, SE; Karnak, D; Kayacan, O; Tulunay, FC, 2006) |
| "COPD is characterized by irreversible airflow obstruction." | ( Löfdahl, M; Lundahl, J; Sköld, M; Wehlin, L, 2005) |
| "COPD is characterized by progressive airway obstruction." | ( Chen, YH; Ding, YL; Geng, B; Lu, M; Tang, CS; Yao, WZ; Zhao, MW, 2005) |
| "COPD is a major cause of death and disability worldwide." | ( Andreas, S; Anker, SD; Scanlon, PD; Somers, VK, 2005) |
| "COPD is a relentless, progressive disease." | ( Amit, O; Rennard, SI; Rickard, K; Schachter, N; Strek, M, 2006) |
| "The criteria of COPD are the critical predictor for pulmonary complications in esophageal cancer patients undergoing esophagectomy." | ( Gong, M; Jiao, WJ; Liu, YB; Liu, ZH; Pan, H; Wang, TY, 2006) |
| "Chronic obstructive pulmonary disease is now considered a chronic inflammatory disease of the lungs resulting from prolonged exposure to inflammatory agents in cigarette smoke and other environmental and occupational pollutants, and it is currently the principal target of cilomilast." | ( Schachter, EN, 2006) |
| "COPD is a progressive disease, and available treatment options provide limited efficacy." | ( Ismail, MS; Martina, SD; Vesta, KS, 2006) |
| "The incidence of COPD is substantial even in young adults." | ( Accordini, S; Ackermann-Liebrich, U; Antó, JM; Burney, P; Cerveri, I; Chinn, S; Corsico, A; de Marco, R; Gislason, T; Heinrich, J; Janson, C; Jarvis, D; Künzli, N; Leynaert, B; Neukirch, F; Schouten, JP; Sunyer, J; Svanes, C; Vermeire, P; Wjst, M, 2007) |
| "Chronic obstructive pulmonary disease is a common disease among these patients." | ( Attaran, D; Jafarzadeh, R; Khajedaloui, M; Mazloomi, M, 2006) |
| "COPD is the 5th leading cause of death in the United States." | ( Danley, SG, 2007) |
| "COPD is caused by inhaled gases and particles and therefore avoidance of inhalative smoking results in symptomatic relief and improvement of the course of the disease." | ( Kanniess, F; Magnussen, H; Watz, H, 2007) |
| "Exacerbations of chronic obstructive pulmonary disease are of major importance in terms of their prolonged detrimental effects on patients, the acceleration in disease progression and high healthcare costs." | ( Barnes, PJ; Celli, BR, 2007) |
| "COPD is associated with reduced life expectancy." | ( Cherniack, RM; Chu, FS; Coxson, HO; Criner, GJ; Elliott, WM; Hogg, JC; Luketich, JD; Make, BJ; Martinez, FJ; Pare, PD; Patel, SA; Rogers, RM; Sciurba, FC; Sharafkhaneh, A; Sin, DD; Tan, WC, 2007) |
| "COPD is prevalent in individuals 40 years of age or older in China." | ( Chen, B; Chen, P; Huang, S; Kang, J; Liu, S; Lu, J; Ni, D; Ran, P; Wang, C; Wang, D; Wang, X; Yao, W; Zheng, J; Zhong, N; Zhou, Y, 2007) |
| "COPD is a condition associated with chronic pulmonary inflammation, characterized by macrophage activation, neutrophil recruitment, and cell injury." | ( Amadei, F; Catinella, S; Civelli, M; Di Serio, C; Dragotto, A; Facchinetti, F; Geppetti, P; Gigli, PM; Patacchini, R; Tarantini, F, 2007) |
| "Nonsmokers with COPD are also more likely to be female." | ( Buist, S; Curtis, JL; Giardino, ND; Han, MK; Mannino, DM; Martinez, FJ; Postma, D, 2007) |
| "COPD is characterized by a persistent airflow limitation that is not fully reversible; thus, the reversibility of airflow limitations in response to a bronchodilator is an important component of COPD." | ( Betsuyaku, T; Hasegawa, M; Hizawa, N; Itoh, Y; Makita, H; Nagai, K; Nasuhara, Y; Nishimura, M, 2007) |
| "Chronic obstructive pulmonary disease is characterized by a rapid decline in lung function due to small airway fibrosis, mucus hypersecretion and emphysema." | ( Boswell-Smith, V; Spina, D, 2007) |
| "Patients with COPD are frequently prescribed inhaled corticosteroids (ICS); however, it is unclear whether the treatment with ICS might modify responses to inhaled bronchodilators." | ( Hodder, R; Kesten, S; Menjoge, S; Viel, K, 2007) |
| "Patients with COPD are more symptomatic and have worse outcomes that are not explained by poorer left ventricular function." | ( Anand, IS; Barlera, S; Carretta, E; Cohn, JN; Latini, R; Maggioni, AP; Masson, S; Staszewsky, L; Tognoni, G; Wong, M, 2007) |
| "COPD is characterized by episodic increases in respiratory symptoms, so-called exacerbations." | ( Groenewegen, KH; Hop, WC; Postma, DS; Schlösser, NJ; Wielders, PL; Wouters, EF, 2008) |
| "COPD is a major cause of mortality in the western world." | ( Batchelor, DV; Chavaroche, H; Dodd, PG; Hobson, TJ; Jones, RM; Keir, RF; Lemaitre, A; Mantell, SJ; Maw, GN; Monaghan, SM; Rozze, S; Selby, MD; Stephenson, PT; Stuart, EF; Trevethick, MA; Walker, DK; Wright, KN; Yeadon, M, 2008) |
| "COPD is characterised by loss of alveolar elastic fibers and by lack of effective repair." | ( Beaumont, B; Black, PN; Ching, PS; Hinek, A; Merrilees, MJ; Wight, TN, 2008) |
| "COPD is underdiagnosed and often misdiagnosed, which likely contributes to the continuing increases in the prevalence, morbidity and mortality associated with this disease." | ( Cooper, CB; Fromer, L, 2008) |
| "COPD is highly prevalent and will continue to be an increasing cause of morbidity and mortality worldwide." | ( Celli, BR, 2008) |
| "Dyspnea in chronic obstructive pulmonary disease is clearly related to hyperinflation, and lung volumes are valuable for characterizing disease." | ( Rock, LK; Schwartzstein, RM, 2007) |
| "Asthma and chronic obstructive pulmonary disease are inflammatory lung disorders responsible for significant morbidity and mortality worldwide." | ( Bartlett, NW; Belvisi, M; Birrell, M; Clarke, D; Edwards, MR; Johnston, SL, 2009) |
| "COPD and AECOPDs are characterized by an augmented inflammatory response." | ( Albert, R; Curtis, JL; Martinez, FJ, 2008) |
| "COPD (chronic obstructive pulmonary disease) is a significant health concern as the fourth leading cause of morbidity and mortality in the U." | ( Corte, TJ; Wort, SJ, 2009) |
| "Chronic obstructive pulmonary disease is typified by inflammation and airflow limitation that has an irreversible component." | ( Fernandes, LB; Goldie, RG; Henry, PJ, 2007) |
| "COPD is a common, progressively disabling disease and a major health burden worldwide." | ( Jones, JM; Spiteri, MA; Whiteman, SC; Yang, Y, 2008) |
| "Chronic obstructive pulmonary disease is an independent predictor of mortality in patients with myocardial infarction (MI)." | ( Hawkins, NM; Huang, Z; Kober, L; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Pieper, KS; Solomon, SD; Swedberg, K; Velazquez, EJ, 2009) |
| "COPD is a disease that affects a significant number of residents in nursing facilities." | ( Beecham, N; Doherty, DE, 2004) |
| "COPD is characterized by progressive airflow obstruction which does not fully reverse to inhaled or oral pharmacotherapy." | ( Cazzola, M; Khirani, S; Rossi, A, 2008) |
| "COPD is a chronic disease and, like many other chronic diseases, there is no treatment to reverse the severity of the disease except for lung transplant." | ( Oba, Y; Thameem, DM; Zaza, T, 2008) |
| "COPD is now viewed under a new paradigm as preventable and treatable." | ( Celli, BR, 2009) |
| "COPD is a disease with a multi-component pathophysiology in which inflammation plays a key role." | ( Agusti, AG; Barnes, NC; Johnson, M, 2008) |
| "COPD is a complex disease with multiple pathological components, which we unfortunately tend to ignore when spirometry is used as the only method to evaluate the disorder." | ( Dahl, M; Nordestgaard, BG, 2009) |
| "Hallmarks of COPD are matrix destruction and neutrophilic airway inflammation in the lung." | ( Blalock, JE; Dransfield, M; Gaggar, A; Jackson, PL; Noerager, B; O'Reilly, P; Parker, S, 2009) |
| "COPD is a multi dimensional disease." | ( Borrill, Z; Kolsum, U; Roy, K; Singh, D; Smith, J; Vestbo, J, 2009) |
| "COPD is a debilitating disease that is primarily caused by smoking and is therefore largely preventable." | ( Barry, M; Bennett, K; McGowan, B; O'Connor, M; Owens, M, 2009) |
| "COPD is a major cause of mortality in the western world." | ( Batchelor, DV; Chavaroche, H; Lemaitre, A; Macintyre, F; Mantell, SJ; Maw, GN; Monaghan, SM; Rozze, S; Selby, MD; Stephenson, PT; Stuart, EF; Trevethick, MA; Walker, DK; Whitlock, L; Wright, KN; Wright, PA; Yeadon, M, 2009) |
| "PH in COPD is caused by the remodelling of pulmonary arteries, which is characterized by the intimal proliferation of poorly differentiated smooth muscle cells and the deposition of elastic and collagen fibres." | ( Barberà, JA; Blanco, I, 2009) |
| "FeNO measurement in COPD is of limited value due to smoking effect." | ( Bakakos, P; Hillas, G; Kostikas, K; Loukides, S, 2009) |
| "COPD is associated with increased MUC5AC expression in submucosal glands, indicating that MUC5AC may be involved in the pathophysiology of the disease." | ( Adcock, IM; Baraldo, S; Barnes, PJ; Boschetto, P; Caramori, G; Casolari, P; Cavallesco, G; Chung, KF; Di Gregorio, C; Fabbri, LM; Ito, K; Papi, A; Saetta, M, 2009) |
| "The pathogenesis of chronic obstructive pulmonary disease is related to fibrosis around the small airways." | ( Desaki, M; Itakura, S; Kamitani, S; Kawasaki, S; Kohyama, T; Nagase, T; Takizawa, H; Yamauchi, Y, 2009) |
| "COPD is a common cause of hospitalizations and is a rapidly increasing cause of mortality worldwide." | ( Salpeter, SR, 2009) |
| "COPD is defined as an irreversible expiratory airflow limitation, which is caused by various degrees of the following two main features: First, small airway disease (SAD), which includes airway inflammation and remodelling, and second, emphysema, which is characterised by airspace enlargement." | ( Eickelberg, O; Kneidinger, N; Königshoff, M, 2009) |
| "COPD is a complex inflammatory disease involving several types of inflammatory cells and multiple inflammatory mediators." | ( Murugan, V; Peck, MJ, 2009) |
| "For patients whose COPD is not sufficiently controlled by monotherapy, combining an inhaled anticholinergic and a ss(2)-agonist is a convenient way of delivering treatment and obtaining better lung function and improved symptoms." | ( Cazzola, M; Tashkin, DP, 2009) |
| "Since COPD is a progressive inflammatory disease, elucidating the effects of bacterial colonization and exacerbation on airway inflammation is relevant to understanding disease progression in COPD." | ( Murphy, TF; Parameswaran, GI; Sethi, S; Wrona, CT, 2009) |
| "COPD is one of the most important lung diseases." | ( Górski, P; Jaeschke, R; Kurzawa, R; Mejza, F; Nizankowska-Mogilnicka, E; Wirkijowski, B, 2009) |
| "COPD is characterized by a strong and persistent up-regulation of extracellular ATP in the airways." | ( Bratke, K; Cicko, S; Di Virgilio, F; Dürk, T; Ferrari, D; Grimm, M; Idzko, M; Lommatzsch, M; Lucattelli, M; Lungarella, G; Müller, T; Sorichter, S; Stoll, P; Virchow, JC; Zissel, G, 2010) |
| "Actual treatment of COPD is not able to reduce and suppress the inflammation in small airways and lung parenchyma." | ( Płusa, T, 2009) |
| "Patients with COPD are also at increased risk of VTE, particularly during exacerbations, possibly because of a hypercoagulable state secondary to hypoxia and/or heightened systemic inflammation." | ( Collins, P; Linnane, SJ; Sabit, R; Shale, DJ; Thomas, P, 2010) |
| "The course of COPD is punctuated by acute exacerbations that are associated with an increase in the morbidity and mortality related to this chronic disease and may contribute to its rate of progression." | ( Tashkin, DP, 2010) |
| "COPD is a progressive, devastating condition of the lung associated with an abnormal inflammatory response to noxious particles and gases, particularly tobacco smoke." | ( Adnot, S; Beume, R; Hatzelmann, A; Lungarella, G; Morcillo, EJ; Sanjar, S; Schudt, C; Tenor, H, 2010) |
| "In Finland COPD is diagnosed by postbronchodilator spirometry and national reference values." | ( , 2010) |
| "These findings in COPD are in line with other studies reporting a lack of clinical efficacy with CCR1 antagonists in other therapy areas." | ( Bjermer, L; Dahlström, K; Eriksson, L; Kerstjens, HA; Vestbo, J, 2010) |
| "COPD is a major cause of chronic morbidity worldwide." | ( Cazzola, M; Matera, MG; Proietto, A, 2010) |
| "The patients with COPD are characterized by the development of malnutrition, even in the absence of body weight loss and in the presence of normal body mass index (BMI) with predominant lean body mass (LBM) loss, normal serum concentrations of adipose tissue hormones." | ( Barkhatova, DA; Kudriavtseva, VA; Luk'ianov, PA; Nevzorova, VA, 2009) |
| "COPD is under-reported on death certificates, and this under-reporting is more frequent when the primary cause of death is not pulmonary." | ( Drummond, MB; John, M; McGarvey, LP; Wise, RA; Zvarich, MT, 2010) |
| "Chronic obstructive pulmonary disease is one of the most common inflammatory diseases associated with cigarette smoke inhalation, but the underlying mechanisms are incompletely understood." | ( Boeynaems, JM; Cardini, S; Cicko, S; De Cunto, G; Di Virgilio, F; Dürk, T; Ferrari, D; Grimm, M; Idzko, M; Lommatzsch, M; Lucattelli, M; Lungarella, G; Müller, T; Sorichter, S; Sundas, W; Virchow, JC; Zeiser, R; Zissel, G, 2010) |
| "Macrophages in COPD are of a mixed phenotype and function." | ( Ahern, J; Hodge, G; Hodge, S; Holmes, M; Jersmann, H; Matthews, G; Mukaro, V; Reynolds, PN; Shivam, A, 2011) |
| "The prevalence of chronic obstructive pulmonary disease is much higher in the elderly, suggesting an age dependency." | ( Chu, HW; Day, BJ; Gauthier, S; Gould, NS; Martin, R; Min, E, 2010) |
| "Chronic obstructive pulmonary disease is one of the most common chronic diseases throughout the world affecting prevalently older people." | ( Bernabei, R; Corbo, GM; Pasciuto, G; Valente, S, 2010) |
| "COPD is a major risk factor for cognitive impairment." | ( Blanc, PD; Eisner, MD; Iribarren, C; Julian, LJ; Katz, PP; Sidney, S; Thakur, N; Yelin, EH, 2010) |
| "COPD is commonly diagnosed and treated in patients without airflow obstruction." | ( Bailey, W; Crater, G; Dransfield, MT; Emmett, A; O'Dell, DM; Yawn, B, 2011) |
| "Chronic obstructive pulmonary disease is a progressive lung disease that is punctuated by periods of exacerbations (worsening of symptoms) that are attributable to viral infections." | ( Bauer, CM; Botelho, FM; Brown, EG; Lambert, KN; Mossman, KL; Stämpfli, MR; Taylor, JD; Zavitz, CC, 2010) |
| "Pathologically, COPD is a multicomponent disease characterized by bronchial submucosal mucous gland hypertrophy, bronchiolar mucosal hyperplasia, increased luminal inflammatory mucus, airway wall inflammation and scarring, and alveolar wall damage and destruction." | ( Abraham, VM; Dronavalli, G; Hanania, NA; Mattewal, AS; Sharafkhaneh, A, 2010) |
| "Routine COPD care (RC) was compared with the inclusion of tiotropium bromide on it." | ( Iannazzo, S; Miravitlles, M; Pradelli, L; Zaniolo, O, 2012) |
| "COPD is characterized by chronic airflow limitation and inflammation of the respiratory tract." | ( Ausin, PM; Barnes, PJ; Ito, K; Kharitonov, SA; To, M, 2011) |
| "The development of COPD is associated with chronic pulmonary inflammation." | ( Aguilaniu, B; Aubier, M; Berger, P; Brillet, PY; Burgel, PR; Chambellan, A; Chanez, P; Chaouat, A; Devillier, P; Escamilla, R; Louis, R; Mal, H; Marthan, R; Muir, JF; Pérez, T; Roche, N; Similowski, T; Wallaert, B, 2010) |
| "COPD is largely underdiagnosed and even unsuspected among cases of IHD." | ( Das, S; Ghoshal, AG; Kundu, S; Mukherjee, D; Mukherjee, S; Paul, D, 2010) |
| "PH in COPD is caused by vasoconstriction and remodelling of pulmonary arteries, which is characterized by the intimal proliferation of poorly differentiated smooth muscle cells and the deposition of elastic and collagen fibres." | ( Daniil, Z; Makris, D; Papanikolaou, J; Zakynthinos, E, 2011) |
| "COPD is currently considered an inflammatory disease involving airways and lung parenchyma." | ( Aparicio, J; Izquierdo, JL, 2010) |
| "COPD is a preventable and treatable disease and is characterized by airflow obstruction that is not fully reversible." | ( Rabe, KF, 2011) |
| "Systemic effects of COPD are incompletely reflected by established prognostic assessments." | ( Holz, O; Kirsten, A; Magnussen, H; Meyer, T; Müller, KC; Waschki, B; Watz, H, 2011) |
| "Severe COPD is associated with increased levels of HDL-C, which is partially attributable to oral steroid use." | ( DeFilippis, A; Eberlein, M; Girgis, RE; Iacono, A; Jones, S; Reed, RM, 2011) |
| "COPD is basically a pulmonary disease but data are available on the existence of associated systemic inflammation." | ( del Puerto-Nevado, L; Girón-Martínez, A; Peces-Barba, G; Pérez-Rial, S, 2010) |
| "COPD is characterized by a multi-component character involving a state of low-grade systemic inflammation and an increased prevalence of cardiovascular co-morbidity." | ( Breyer, MK; Dentener, MA; Rutten, EP; Spruit, MA; van der Kallen, C; vanGreevenbroek, MM; Vernooy, JH; Wouters, EF, 2011) |
| "The presence of COPD is suggested to be a strong risk factor for proximal femur fracture or hip fracture." | ( Liu, S; Liu, Z; Sun, T; Wang, X; Zhang, J, 2011) |
| "Asthma and chronic obstructive pulmonary disease are airway inflammatory diseases characterised by airflow obstruction." | ( Belvisi, MG; Birrell, MA; Buckley, J; Clarke, DL; Maher, SA; Nials, AT, 2011) |
| "COPD is associated with increased arterial stiffness which may in part explain the cardiovascular morbidity observed in the disease." | ( Cicale, MJ; Cockcroft, JR; Coxson, HO; Crater, GD; Dransfield, MT; Emmett, AH; Martinez, FJ; Rubin, DB; Sharma, SS; Townsend, RR, 2011) |
| "Tissue damage in COPD is thought to result from an inability of the normal repair processes with accumulation of apoptotic material and impaired clearance of this material by macrophages in the airways." | ( Cordts, F; Gibbins, I; Haberberger, RV; Hodge, S; Jersmann, H; Moffat, DF; Pitson, S; Tabeling, C, 2011) |
| "COPD is characterized by chronic air-flow limitation." | ( Celik, D; Celikel, S; Doruk, S; Erkorkmaz, U; Inonu, H; Sahin, S; Seyfikli, Z, 2012) |
| "Severe chronic obstructive pulmonary disease is associated with high HDL cholesterol (HDL-C)." | ( DeFilippis, A; Eberlein, M; Girgis, RE; Hashmi, S; Iacono, A; Jones, S; Netzer, G; Reed, RM; Scharf, S; Toth, PP, 2011) |
| "Severe, early-onset COPD is characterized by a rapid decline in the lung function at an early age; however, nothing is known about neutrophil activation in COPD patients." | ( Cortijo, J; Juan, G; Milara, J; Peiró, T; Serrano, A, 2012) |
| "COPD is a complex condition with pulmonary and extrapulmonary manifestations." | ( De Nuccio, F; Gaballo, A; Nicolardi, G; Toraldo, DM, 2011) |
| "COPD is a multicomponent disease and systemic inflammation represents one of the possible mechanisms responsible for its systemic manifestations, including skeletal muscle weakness and cachexia." | ( Alchanatis, M; Bakakos, P; Gaki, E; Gourgoulianis, KI; Kontogianni, K; Kostikas, K; Loukides, S; Papaioannou, AI; Papiris, S, 2011) |
| "The management of COPD is aimed at improving the patient's quality of life and functional status." | ( Daniluk, J; Jastrzębska, I; Krawczyk, P; Milanowski, J; Szczyrek, M; Zwolak, A, 2011) |
| "COPD is a systemic disease with effects beyond the lungs." | ( Balasubramanian, V; Naing, S, 2012) |
| "Exacerbations of COPD are associated with progression of disease." | ( Chazan, R, 2011) |
| "COPD is a disease manifested as persistent airflow obstruction with an enhanced inflammatory response in the airways and lungs to noxious particles and gases which evokes symptoms of dyspnea on exertion, cough and mucus production." | ( Banerjee, A; Panettieri, R, 2012) |
| "COPD is characterized by airflow limitation that is not fully reversible." | ( Garcia, G; Perez, T; Verbanck, S, 2012) |
| "Chronic obstructive pulmonary disease is a systemic disease, and hypoxia in COPD seems to affect the retina and the optic nerve." | ( Aydın, E; Demir, HD; Doruk, S; Etikan, I; Inönü, H; Kurt, S, 2012) |
| "Exacerbations of COPD are associated with increased symptoms that persist for weeks and the course is very similar between a first and second exacerbation." | ( Creemers, JP; Hop, WC; Postma, DS; Schreurs, AJ; van den Berge, M; van der Molen, T; van Noord, JA; Wouters, EF, 2012) |
| "COPD is a condition with systemic effects of which peripheral muscle dysfunction is a prominent contributor to exercise limitation, health related quality of life (HRQoL) impairment, and is an independent predictor of morbidity and mortality." | ( Deans, A; Drost, E; Giavedoni, S; MacNee, W; McCaughey, P; Rabinovich, RA, 2012) |
| "COPD is a major cause of chronic morbidity and mortality worldwide." | ( Szelenyi, I, 2012) |
| "COPD is pathogenically associated with oxidative stress, which originates not only from cigarette smoke, but also from hypoxia, infection, inflammation, and ageing." | ( Takizawa, H; Wada, H, 2013) |
| "COPD is a worldwide public health problem that reduces the quality of life." | ( Sin, DD; Tam, A, 2012) |
| "COPD is associated with significant cardiovascular mortality." | ( Anderson, WJ; George, J; Lipworth, BJ; Rekhraj, S; Struthers, AD, 2013) |
| "Patients with COPD are associated with poor pulmonary anti-bacterial innate defenses, which increase the risk for frequent acute exacerbations caused by bacterial infection." | ( Biswal, S; Gang, X; Kim, JH; Sussan, TE; Thimmulappa, RK; Witztum, JL, 2012) |
| "In turn COPD is a major independent risk factor for lung cancer." | ( Cesario, A; Granone, P; Lococo, F; Petracca-Ciavarella, L; Russo, P, 2012) |
| "COPD is a complex condition, which cannot be considered a lung-related disorder, but rather a systemic disease also associated to increased oxidative stress." | ( Corbo, GM; Di Segni, C; Gaballo, A; Gigliotti, P; Littarru, GP; Mancini, A; Meucci, E; Pontecorvi, A; Raimondo, S; Silvestrini, A; Valente, S, 2012) |
| "Chronic obstructive pulmonary disease is a common condition which causes considerable morbidity and mortality." | ( Macklin-Doherty, A; Wilson, R, 2012) |
| "COPD is a preventable and treatable disease with some significant extrapulmonary manifestations that may contribute to its severity in some patients." | ( Liao, Z; Tong, RS; Xiao, HT, 2012) |
| "OSAS and COPD are often associated with day-time hypoxemia." | ( Aliani, M; Carone, M; Carpagnano, GE; Fanfulla, F; Foschino Barbaro, MP; Lacedonia, D; Sabato, R; Spanevello, A, 2013) |
| "Chronic obstructive pulmonary disease is characterized by poorly reversible airflow obstruction." | ( Gupta, V; Singh, D, 2012) |
| "A new diagnosis of chronic obstructive pulmonary disease is often made during the evaluation of patients requiring lung cancer surgery." | ( Inoue, M; Maeda, H; Minami, M; Nakagiri, T; Nojiri, T; Okumura, M; Sawabata, N; Shintani, Y; Takeuchi, Y; Yamamoto, K, 2014) |
| "COPD is an inflammatory lung disease largely associated with exposure to cigarette smoke (CS)." | ( Adcock, IM; Belvisi, MG; Birrell, MA; Catley, MC; Davies, M; Eltom, S; Evans, SM; Grace, M; Kilty, I; Lawrence, T; Pasparakis, M; Rastrick, JM; Stevenson, CS, 2013) |
| "A diagnosis of COPD is associated with high morbidity and escalating costs, suggesting the need for a thorough new examination of the evidence." | ( Al-Kassimi, FA; Alhamad, EH, 2013) |
| "The development of COPD is multifactorial and the risk factors of COPD include genetic and environmental factors." | ( Vijayan, VK, 2013) |
| "COPD is often regarded as a smoker's disease." | ( Black, P; Hamed, M; Kolbe, J; Metcalf, P; Milne, D; Sexton, P; Sommerville, F; Wu, L, 2014) |
| "COPD is characterized by a reduced maximum expiratory flow and slow forced emptying of the lungs, which progress over time and are not completely reversible." | ( Polese, G; Rossi, A, 2013) |
| "COPD is a risk factor for hVISA infection of the lower respiratory tract." | ( Feng, NN; He, LX; Li, HY; Song, YL; Wang, Q; Xie, HM; Zhou, CM, 2013) |
| "COPD is accepted to be a multicomponent disease with various comorbidities." | ( Buurman, WA; Lenaerts, K; Rutten, EPA; Wouters, EFM, 2014) |
| "Since COPD is an airway inflammatory disease, and heparin has shown anti-inflammatory effects in previous studies, we evaluated the clinical effect of low molecular weight heparin (LMWH; nadroparin) in COPD patients admitted into the hospital due to acute exacerbations." | ( Qian, Y; Tian, R; Wang, R; Xie, H; Yu, K, 2014) |
| "COPD is the fourth leading cause of death in the world." | ( Agabiti, N; Bauleo, L; Cascini, S; Colamesta, V; Davoli, M; Di Martino, M; Fusco, D; Kirchmayer, U; Patorno, E; Perucci, CA; Pinnarelli, L; Pistelli, R, 2014) |
| "COPD is characterized by chronic inflammation in the pulmonary compartment and in the systemic circulation." | ( Conti, V; Oriolo, F; Paone, G; Romani, S; Terzano, C, 2014) |
| "Chronic obstructive pulmonary disease is a significant syndrome of internal medicine with serious health, social and economic impacts." | ( Koblížek, V, 2013) |
| "In Sweden COPD is mostly diagnosed late in life and often not verified by lung function measurements." | ( Arvidsson, P; Jansson, SA; Larsson, K; Lundbäck, B; Nyström, L; Sundblad, BM, 2013) |
| "ABPA in COPD is uncommon, but early identification and initiation of systemic corticosteroid therapy can lead to improvement in symptoms and prognosis." | ( Jin, JM; Li, R; Liu, XF; Liu, Y; Sun, YC, 2013) |
| "POET-COPD is registered with ClinicalTrials." | ( Fabbri, LM; Glaab, T; Israel, E; Kögler, H; Rabe, KF; Riemann, K; Schmidt, H; Vogelmeier, CF, 2014) |
| "COPD is a major and increasing global health problem with enormous amount of expenditure of indirect/direct health care costs, and therefore, there is urgent need to clarify the molecular mechanism of COPD and develop novel treatments." | ( Ito, K; Mercado, N, 2014) |
| "COPD (Chronic Obstructive Pulmonary Disease) is characterized by airflow limitation that is not fully reversible and that can lead to respiratory failure." | ( Cukic, V, 2014) |
| "COPD is characterized with airflow limitation which is progressive in the course of illness, and by the changes in arterial blood gases that can lead to respiratory failure, but that course may be made slower using appropriate treatment during remission and exacerbations of diseases." | ( Cukic, V, 2014) |
| "Depression in COPD is associated with higher 24-h overall levels of sputum IL-1, TNF-α and flattened diurnal salivary cortisol." | ( Cao, YX; Dong, JC; Du, YJ; Gong, WY; Jin, HL; Li, B; Liu, BJ; Luo, QL; Lv, YB; Sun, J; Wu, JF; Wu, X; Yang, CJ; Zhang, HY, 2014) |
| "Exacerbation of COPD is associated with increasing concentrations of NO2(2) in the serum and of the levels of ΣNO2(2)/NO3(2) in the EBC, together with the changing concentration of sHLA-I and sCD95 molecules in the both biological liquid." | ( Chuchalin, A; Kubysheva, N; Maksimova, A; Novikov, V; Postnikova, L; Soodaeva, S, 2014) |
| "COPD (chronic obstructive pulmonary disease) is a common lung disease characterized by airflow limitation and systemic inflammation." | ( Hämälainen, M; Järvenpää, R; Kankaanranta, H; Kööbi, L; Lehtimäki, L; Leivo-Korpela, S; Moilanen, E; Saarelainen, S; Vuolteenaho, K, 2014) |
| "Progression of chronic obstructive pulmonary disease is associated with small airway obstruction by accumulation of inflammatory mucous exudates." | ( Guo, Y; He, B; Xu, M; Zhang, Y; Zhou, Y, 2014) |
| "COPD is a leading cause of dead worldwide and tobacco smoking is its major risk factor." | ( Aguirre-Jaime, A; Baz-Dávila, R; Casanova, C; Córdoba-Lanús, E; de-Torres, JP; Espinoza-Jiménez, A; González-Almeida, D; Rodríguez-Pérez, MC; Varo, N, 2015) |
| "COPD is characterized by not fully reversible constriction of air flow, which is a consequence of inflammation caused by noxious fumes and gases, particularly tobacco smoke." | ( Gilowska, I, 2014) |
| "Since asthma and COPD are associated with increased levels of exhaled NO, chronic inflammation and increased airway smooth muscle tone, the NO/sGC/cGMP pathway could be involved in these highly prevalent obstructive airway diseases." | ( Bracke, KR; Brouckaert, P; Brusselle, GG; Dupont, LL; Glynos, C, 2014) |
| "Bronchodilation in COPD is mainly achieved via administration of long- and ultralong-acting β2-agonists and with long-acting muscarinic antagonists." | ( Malerba, M; Morjaria, JB; Radaeli, A, 2014) |
| "COPD is an inflammatory disease usually associated with cigarette smoking (CS) with an increasing global prevalence and no effective medication." | ( Baxter, M; Belvisi, MG; Birrell, MA; Dekkak, B; Dubuis, ED; Eltom, S; Maher, SA; Yew-Booth, L, 2014) |
| "Chronic obstructive pulmonary disease is characterised by oxidative stress, but little is known about the associations between antioxidant status and all-cause mortality in adults with this disease." | ( Croft, JB; Cunningham, TJ; Ford, ES; Li, C, 2014) |
| "The pathogenesis of COPD is a multifactorial process including an inflammatory cell profile." | ( Chen, L; Huang, K; Kang, X; Li, W; Li, Z; Wang, X; Wu, X; Yang, C, 2014) |
| "COPD is associated with high serum BPA, CRP and low total thiol levels in comparison with healthy individuals." | ( Demirkose, M; Erden, ES; Gokce, C; Motor, S; Oktar, S; Okur, R; Sungur, S; Ustun, I; Yakar, Y; Yuksel, R, 2014) |
| "COPD is a chronic inflammatory disorder associated with oxidative stress." | ( Apperley, S; Connett, JE; Holmes, DT; Man, SFP; Park, HY; Sin, DD; Tashkin, D; Wise, RA, 2015) |
| "As a consequence, COPD is regarded as a complex disease with pulmonary and extra-pulmonary involvement." | ( Ferri, C, 2015) |
| "Chronic obstructive pulmonary disease is characterized by an inflammatory state of uncertain significance." | ( Cunningham, TJ; Ford, ES; Mannino, DM, 2015) |
| "COPD is currently the fourth leading cause of hospital readmission in the United States." | ( Chow, L; Hanania, NA; Parulekar, AD, 2015) |
| "COPD is largely under-diagnosed and once diagnosed usually at a late stage." | ( Abou-Badra, M; Amador, N; Bourdin, A; Gamez, AS; Ky, CL; Marin, G; Molinari, N; Vachier, I, 2015) |
| "COPD (chronic obstructive pulmonary disease) is associated with sustained inflammation, excessive injury, and accelerated lung aging." | ( Adcock, IM; Barnes, PJ; Gao, W; Huang, M; Li, L; Wiegman, CH; Yao, X; Yu, L; Yuan, C; Zhang, J, 2015) |
| "COPD is characterized by chronic airway inflammation and remodeling, with serious modifications of the extracellular matrix (ECM)." | ( Karakiulakis, G; Klagas, I; Papakonstantinou, E; Roth, M; Stolz, D; Tamm, M, 2015) |
| "AECOPDs are associated with increased HYAL activity in BAL and subsequent degradation of HA, which may contribute to airway inflammation and subsequent lung function decline during exacerbations." | ( Karakiulakis, G; Klagas, I; Papakonstantinou, E; Roth, M; Stolz, D; Tamm, M, 2015) |
| "COPD is often associated with cardiovascular comorbidity." | ( Blasi, F; Bussotti, M; Centanni, S; Di Marco, S; Raccanelli, R; Radovanovic, D; Santus, P; Valenti, V, 2015) |
| "COPD is associated with decreased leukocyte mtDNA copy number and serum glutathione." | ( Chen, YC; Huang, HT; Kuo, HC; Lin, MC; Liu, SF; Tseng, CC; Tseng, CW, 2015) |
| "Chronic obstructive pulmonary disease is characterized, in part, by chronic inflammation that persists even after smoking cessation, suggesting that a failure to resolve inflammation plays an important role in the pathogenesis of the disease." | ( Colas, RA; Hsiao, HM; Phipps, RP; Serhan, CN; Sime, PJ; Thatcher, TH, 2015) |
| "COPD is associated with elevated L-arginine, ADMA and SDMA serum levels." | ( Bogar, L; Horvath, I; Illes, B; Illes, Z; Keki, S; Molnar, T; Nagy, L; Ruzsics, I; Sarosi, V, 2016) |
| "Smoking-induced COPD is characterized by chronic airway inflammation, which becomes enhanced by bacterial infections resulting in accelerated disease progression called exacerbation." | ( Gerlach, K; Jungck, D; Knobloch, J; Knoop, H; Koch, A; Köhler-Bachmann, S; Körber, S; Kronsbein, J; Rheinländer, S; Walther, JW; Wehde, D; Yanik, S, 2015) |
| "COPD is a progressive condition involving chronic inflammation and parenchymal destruction with resulting airflow limitation." | ( Calverley, PM; Rabe, KF; Wedzicha, JA, 2016) |
| "The pathologies of COPD are due to an abnormal immune response." | ( Chen, YG; Chuang, YH; Tsao, CC; Tsao, PN, 2016) |
| "COPD is a highly heterogeneous disease that has a serious impact on affected populations." | ( Alcázar-Navarrete, B; Romero-Palacios, PJ; Ruiz-Rodriguez, O; Ruiz-Sancho, A, 2016) |
| "Chronic obstructive pulmonary disease is a common comorbidity in HIV, with prevalence and severity of disease incompletely explained by risk factors such as smoking and age." | ( Camp, D; Clarke, A; Fitzpatrick, ME; Gingo, MR; Kessinger, CJ; Kingsley, L; Kleerup, EC; Morris, A; Nouraie, M; Ries, JW; Sincebaugh, JB, 2016) |
| "COPD is a progressive chronic lung disease characterized by pulmonary inflammation." | ( Brandsma, CA; Gosens, R; Menzen, MH; Middag, LD; Spanjer, AI; van Dijk, EM, 2016) |
| "Chronic obstructive pulmonary disease is generally progressive and associated with reduced physical activity." | ( Bourbeau, J; De Sousa, D; Erzen, D; Hamilton, A; Lavoie, KL; Leidy, N; Maltais, F; Sedeno, M; Troosters, T, 2016) |
| "COPD is characterized by chronic inflammation." | ( Agusti, A; Barnes, PJ; Córdova, R; Cosío, BG; Gea, J; Iglesias, A; Palou, A; Pascual, S; Peces-Barba, G; Rodriguez-Roisin, R; Shafiek, H; Sibila, O; Yanez, A, 2016) |
| "COPD is characterized by persistent airflow limitation, neutrophilia and oxidative stress from endogenous and exogenous insults." | ( Bos, IS; Graaf, AC; Halayko, AJ; Han, B; Henning, RH; Krenning, G; Maarsingh, H; Meurs, H; Poppinga, WJ; Schmidt, M; Smit, M; Stienstra, S; van Vliet, B; Vogelaar, P; Zuidhof, AB; Zuo, H, 2016) |
| "COPD is the third leading cause of death worldwide." | ( Chang, S; Fu, C; Li, S; Shi, J; Wu, X, 2016) |
| "COPD is associated with elevated cardiovascular risk and a potentiated ventilatory response to exercise." | ( Bhutani, M; Byers, BW; Edgell, H; Fuhr, DP; Steinback, CD; Stickland, MK; Wong, EY, 2016) |
| "Muscle wasting in COPD is complex, with contributions from a number of factors including inflammatory cytokines, oxidative stress, growth and anabolic hormones, nutritional status, and physical activity." | ( Bozinovski, S; Hansen, MJ; Holland, AE; McDonald, CF; Passey, SL; Vlahos, R, 2016) |
| "COPD is the fifth leading cause of death in the world and smoking leads to COPD in more than 80% of cases." | ( Ojo, O; Temitayo Orisasami, I, 2016) |
| "Additionally, COPD is a common respiratory morbidity in former BPD patients." | ( Barrios, R; Reynolds, CL; Shivanna, B; Shrestha, AK; Zhang, S, 2016) |
| "COPD is mainly caused by tobacco smoking and is associated with a high frequency of coronary artery disease." | ( Funamoto, M; Hasegawa, K; Imaizumi, A; Kakeya, H; Katanasaka, Y; Komiyama, M; Miyazaki, Y; Morimoto, T; Satoh-Asahara, N; Sunagawa, Y; Wada, H; Yamakage, H, 2016) |
| "In conclusion, COPD is associated with increased 2-year rates of all-cause death, cardiac death, and stent thrombosis after stent implantation." | ( Biering-Sørensen, T; Galatius, S; Hansen, KW; Jatene, T; Jeger, R; Jensen, JS; Jørgensen, PG; Kaiser, C; Mangione, FM; Nochioka, K; Pfisterer, M; Sørensen, R, 2017) |
| "Smoking and COPD are risk factors for cardiovascular disease, and the pathogenesis may involve endothelial dysfunction." | ( Ament, Z; Cheriyan, J; Griffin, JL; Gutterman, DD; Lazaar, AL; Mayer, RJ; Newby, DE; Tal-Singer, R; Wilkinson, IB; Yang, L, 2017) |
| "The pathogenesis of COPD is closely linked with aging, as well as with cardiovascular, endocrine, musculoskeletal, renal, and gastrointestinal pathologies, decreasing the quality of life of patients with COPD and, furthermore, complicating the management of the disease." | ( Botnaru, V; Corlateanu, A; Covantev, S; Mathioudakis, AG; Siafakas, N, 2016) |
| "Chronic obstructive pulmonary disease is associated with significant morbidity and mortality." | ( Bennett, N; Buhl, R; Clerisme-Beaty, E; Ferguson, GT; Grönke, L; Karpel, J; Voß, F, 2017) |
| "COPD is accompanied by limited physical activity, worse quality of life, and increased prevalence of depression." | ( Erdei, T; Gesztelyi, R; Juhasz, B; Kardos, L; Pak, K; Papp, C; Seres, I; Szentpéteri, A; Szilasi, M; Zsuga, J, 2017) |
| "COPD is the fourth leading cause of death in the world." | ( Huang, X; Xiao, Z; Yang, D; Zeng, Z, 2017) |
| "Chronic obstructive pulmonary disease is associated with a high healthcare resource and cost burden." | ( Birk, R; Brealey, N; Ismaila, AS; Lipson, DA; Risebrough, NA; Shah, D; Tabberer, M; Zhang, S; Zhu, CQ, 2017) |
| "However, in Poland COPD is rarely recognized as an occupational disease." | ( Kleniewska, A; Lipińska-Ojrzanowska, A; Szcześniak, K; Walusiak-Skorupa, J; Wiszniewska, M, 2018) |
| "COPD is an inflammatory airway disease characterised by progressive airflow limitation and air trapping, leading to lung hyperinflation and exercise limitation." | ( Calzetta, L; Cardaci, V; Cazzola, M; di Toro, S; Page, CP; Shute, JK, 2018) |
| "COPD is characterised by a progressive airflow limitation in the lungs." | ( Abdulsalim, S; Alrasheedy, AA; Godman, B; Manu, MK; Morisky, DE; Unnikrishnan, MK, 2018) |
| "The incidence of COPD is increasing as the US population grows older." | ( Mowery, NT, 2017) |
| "COPD is a chronic inflammatory disease characterized by partially reversible airflow limitation." | ( Calzetta, L; Cavalli, F; Cazzola, M; Matera, MG; Ora, J; Puxeddu, E; Rogliani, P, 2018) |
| "Chronic obstructive pulmonary disease is progressive and in its advanced stage is associated with major disability." | ( Ecenarro, PS; Iguiñiz, MI; Imizcoz, MA; Malanda, NM; Marlasca, LA; Navarrete, BA; Tejada, SP, 2018) |
| "COPD is a complicated disease." | ( Aftab, B; Amir, N; Fayyaz, A; Hanif, M; Ijaz, H; Mustafa, MI; Qureshi, J; Rasul, A, 2018) |
| "COPD is a common, highly debilitating disease of the airways, primarily caused by smoking." | ( Adcock, I; Caramori, G; Casolari, P; Chung, KF; Halayko, AJ; Papi, A; Perry, MM; Rempel, KL; Tildy, B, 2018) |
| "COPD is characterized by several comorbidities, it hypothesized the treatment of cardiovascular co-morbidities that may reduce morbidity and mortality." | ( Cardaci, V; Fini, M; Lamonaca, P; Prinzi, G; Russo, P, 2019) |
| "COPD is highly prevalent in the US and globally, requiring new treatment strategies due to the high disease burden and increase in the aging population." | ( Ferguson, GT; Kerwin, E, 2018) |
| "COPD is a progressive disease in which many patients develop an acute or sustained deterioration." | ( Altman, P; Bader, G; D'Urzo, A; Goyal, P; Shen, S, 2018) |
| "A reduced risk of COPD is observed in metformin users with T2D." | ( Tseng, CH, 2019) |
| "COPD is characterised by oxidative stress and an increased risk of lung carcinoma." | ( Abdulmwli, M; Anderson, D; Demir, E; Habas, K; Jacob, BK; Najafzadeh, M, 2018) |
| "COPD is a known risk factor for incident T2DM, however few studies have examined the relationship in reverse." | ( Correa, A; Creagh-Brown, B; de Lusignan, S; Gatenby, P; McGovern, AP; Rayner, LH; Sherlock, J, 2018) |
| "COPD is associated to a chronic inflammatory response with infiltration of inflammatory cells in the surface epithelium of large airways and abnormalities in structure and functions of cilia." | ( Amantini, C; Iannarelli, R; Maggi, F; Marinelli, O; Morelli, MB; Nabissi, M; Nicotra, G; Santoni, G, 2018) |
| "Patients with COPD are at a higher risk of prostate cancer, particularly those using SAMAs or SABAs." | ( Chen, HC; Huang, SW; Lin, HW; Lin, LF; Liou, TH, 2018) |
| "COPD is a common preventable and treatable disease, characterized by persistent and progressive airflow limitation." | ( Foschino Barbaro, MP; Paleari, D; Pirina, P; Spanevello, A, 2018) |
| "The main causes of COPD are tobacco smoking (COPD-TS) and biomass smoke exposure (COPD-BS)." | ( Barrientos-Gutiérrez, T; Buendía-Roldan, I; Camacho-Priego, M; Montaño, M; Pérez-Bautista, O; Pérez-Padilla, R; Ramos, C; Velasco-Torres, Y; Zúñiga-Ramos, J, 2018) |
| "COPD is unique among complex genetic diseases where an environmental risk factor is known and the level of exposure can be documented with some precision." | ( Campos, MA; Cartujano-Barrera, F; Córdoba-Lanús, E; Cupertino, P; Falfán-Valencia, R; Pérez-Rubio, G, 2019) |
| "Chronic obstructive pulmonary disease is present in about 20% of nursing home residents, most often in women, and accounts for significant healthcare utilization including acute care visits for exacerbations and pneumonia, as well as worsening heart disease and diabetes mellitus." | ( Davidson, HE; Pleasants, RA; Radlowski, PA, 2019) |
| "COPD is a common disease and exacerbations are a leading cause of hospital admission in the UK and worldwide, with a sizeable mortality." | ( Barrett, NA; Camporota, L; Douiri, A; Hart, N; Kostakou, E, 2019) |
| "COPD is one of the major causes of morbidity and mortality worldwide and represents one of the most important issues for public health." | ( Flore, MC; Graziani, C; Lanata, L; Palermo, P; Paone, G; Puglisi, G; Ramaccia, M; Saibene, F; Toti, S, 2019) |
| "Patients with COPD are less physically active." | ( Anzai, T; Gon, Y; Hirata, K; Ichinose, M; Minakata, Y; Motegi, T; Nakamura, S; Ueki, J, 2019) |
| "COPD is associated with alterations in the serum metabolome, including a disruption in the histidine-histamine and creatine metabolic pathways." | ( Diao, W; Guo, C; Han, MK; He, B; Kim, JH; Labaki, WW; Lu, M; McHugh, C; Shen, N; Smiley, Z; Standiford, TJ; Stringer, KA; Sun, X; Sun, Y; Xiang, P; Yeomans, L, 2019) |
| "COPD is associated with disturbed tissue repair, possibly due to TGF-β-regulated miRNA changes in fibroblasts." | ( Brandsma, CA; Faiz, A; Kluiver, J; Kok, K; Ong, J; Terpstra, MM; Timens, W; van den Berg, A; van den Berge, M, 2019) |
| "COPD is a heterogeneous disease demonstrating inter-individual variation." | ( Abisheganaden, JA; Chotirmall, SH; Hui, DSC; Kamaruddin, NH; Ko, FWS; Koh, MS; Lapperre, TS; Loh, LC; Mac Aogáin, M; Narayana, JK; Neo, HY; Ong, CK; Poh, ME; Sim, GJH; Tan, JHY; Tee, A; Tiew, PY; Tsaneva-Atanasova, K; Xu, H, 2020) |
| "Etiologically, COPD is mediated by toxic gases and particles, eg, cigarette smoke, while the pathogenesis of the disease is largely unknown." | ( Dong, X; Gupta, Y; Hu, Y; Krauss-Etschmann, S; Li, J; Ludwig, RJ; Ma, A; Petersen, F; Riemekasten, G; Wen, L; Yin, J; Yu, X; Yue, X, 2020) |
| "COPD is a multisystem disease and there is a need for clinical serum markers that can assess the decline in lung and muscle function in COPD." | ( Karim, A; Muhammad, T; Qaisar, R, 2020) |
| "COPD is a heterogeneous disease and patients may respond differently to therapies depending on baseline symptom burden." | ( Banerji, D; Frent, SM; Gupta, P; Kostikas, K; Mackay, AJ; Olsson, P; Patalano, F; Pfister, P; Roche, N; Wedzicha, JA, 2020) |
| "COPD is associated with nighttime respiratory symptoms, poor sleep quality, and increased risk of nocturnal death." | ( Ayoo, GA; Crinion, SJ; Di Luch, AT; Domnik, NJ; Driver, HS; Elbehairy, AF; James, MD; Milne, KM; Neder, JA; O'Donnell, DE; Phillips, DB; Scheeren, RE; Taylor, SM; Vincent, SG, 2021) |
| "Exacerbations of COPD are now the second largest cause of emergency hospitalisation in the UK." | ( Moore, D, 2020) |
| "COPD is highly prevalent in patients with pneumoconiosis, especially patients with silicosis and coal workers' pneumoconiosis." | ( Fan, Y; Wang, Y; Xu, W; Ye, Q; Yu, S, 2020) |
| "COPD is an inflammatory lung disease, which is often exacerbated with microbial infections resulting in worsening of respiratory symptoms." | ( Dharwal, V; Naura, AS; Puri, G; Singla, E, 2021) |
| "Chronic obstructive pulmonary disease is characterized by progressive, irreversible airflow obstruction resulting from an abnormal inflammatory response to noxious gases and particles." | ( Knoell, D; Nitz, M; Smith, D; Wysocki, B; Wysocki, T, 2021) |
| "Patients with COPD are often prescribed ICS therapy, which, when used over a long term, can be associated with local and systemic adverse effects." | ( Criner, G; Duffy, S, 2021) |
| "COPD is a complicated disease that deteriorates over time." | ( Chalmers, JD; de la Hoz, A; Ferguson, GT; Kocks, JWH; Miravitlles, M; Rabe, KF; Singh, D; Tsiligianni, I; Wedzicha, J; Xue, W, 2021) |
| "Asthma and COPD are common chronic airway inflammatory diseases having incompletely illustrious pathophysiology and clinical manifestations." | ( Bodkhe, S; Khan, T; Nikam, M; Patel, K; Sherje, AP; Suvarna, V, 2020) |
| "COPD is characterized by progressive airflow limitation and intermittent acute exacerbations of symptoms, which contribute to disease progression, worsening of comorbidities, and reduced health-related quality of life." | ( Williams, D, 2022) |
| "COPD is involved with systemic and pulmonary inflammation, which may be attenuated with antidiabetic agents exerting anti-inflammatory effects." | ( Huang, YL; Kuo, FC; Lai, JH; Tsai, CL; Tu, MY; Wang, MT; Wang, YH, 2020) |
| "COPD is the second leading cause of death and disability adjusted life years (DALYs) in India, yet, it remains poorly recognized." | ( Barne, MS; Doke, PPR; Ghorpade, DD; Kale, NV; Londhe, JD; Madas, SJ; Patil, RS; Raghupathy, A; Salvi, SS; Singh, NAP, 2021) |
| "COPD is a leading cause of death globally, with the majority of morbidity and mortality occurring in low- and middle-income country (LMIC) settings." | ( Alupo, P; Barnes, PJ; Checkley, W; Dowdy, D; Hurst, JR; Jackson, P; Kalyesubula, R; Kirenga, B; Namazzi, E; Padalkar, R; Pollard, SL; Rahman, N; Robertson, NM; Sekitoleko, I; Siddharthan, T; Wise, R; Wosu, AC, 2021) |
| "Severe COPD is associated with a clinically significant reduction in oral drug clearance." | ( Doogue, MP; Epton, MJ; McNeill, RP; Zhang, M, 2021) |
| "Emphysematous COPD is characterized by aberrant alveolar repair." | ( Brandsma, CA; Cool, RH; Gosens, R; Habibie, H; Haisma, HJ; Liu, B; Melgert, BN; Poelarends, GJ; Smit, MJ; Song, S; van den Bor, J; Wu, X, 2021) |
| "COPD is a common chronic condition in older age that impacts on daily activities and quality of life." | ( Alessi, A; Ceolin, C; Guarnieri, G; Maggi, S; Noale, M; Seccia, DM; Sergi, G; Trevisan, C; Vianello, A; Zanforlini, BM, 2022) |
| "Chronic obstructive pulmonary disease is a complex condition with multiple etiologies, including inflammation." | ( Hao, B; Hong, W; Huang, P; Li, B; Liang, C; Lin, B; Lin, Z; Pu, J; Ran, P; Yi, E; Zhang, J; Zhang, Y; Zheng, M; Zhou, Y, 2021) |
| "Many patients with COPD are smokers, and smoking is one of the most common causes of COPD." | ( Bjermer, LH; Boucot, IH; Compton, C; Jones, PW; Kerwin, EM; Lipson, DA; Maltais, F; Tombs, L; Vogelmeier, CF, 2021) |
| "The progression of COPD is not confined to the lungs but includes extrapulmonary involvement that reduces the functional capacity and quality of life." | ( Bhadra, R; Bhattacharya, S; D'Souza, GA; Sambashivaiah, S; Schols, AMWJ, 2021) |
| "COPD is a heterogeneous disorder with varied phenotypes." | ( Annangi, S; Flenaugh, E; Foreman, M; Nutalapati, S; Sturgill, J, 2022) |
| "Patients with COPD are frequently excluded from clinical trials of treatments aimed at reducing cardiac morbidity and mortality, which has led to undertreatment of cardiovascular disease in patients with COPD." | ( Aggarwal, A; Balicki, G; Beasley, R; Chang, CL; Cochrane, B; Di Tanna, GL; Dobler, CC; Farah, CS; Galgey, S; Hancox, RJ; Hillis, GS; Jenkins, C; Martin, A; McDonald, V; Scowcroft, CP; Wrobel, J; Yang, IA, 2021) |
| "Patients with COPD are known to have lower socio-economic status and to be more nicotine-dependent than most other smokers and therefore face difficulties when attempting to quit smoking." | ( Andelius, DK; Hilberg, O; Ibsen, R; Løkke, A, 2021) |
| "Chronic obstructive pulmonary disease is the second leading cause of mortality and disability-adjusted life years in India." | ( Gudi, N; Mahmood, A; Nagaraja, R; Nayak, P; Roy, MP; Verma, A; Yadav, UN, 2021) |
| "The pathogenesis of COPD is complex; however, recent studies suggest autoimmune changes, characterized by the presence of autoantibodies to elastin and collagen, may contribute to disease status." | ( Angel, P; Atkinson, C; Christie, JD; Drake, RR; Langerude, L; Machuca, T; McQuiston, A; Mehta, A; Nord, D; Pelaez, A; Scott, D, 2022) |
| "COPD is expected to be 7th leading cause of disease burden till 2030." | ( Abbas, G; Alsaedi, A; Dar, M; Hayat, K; Iqbal, MO; Muhammad, SA; Rasool, MF; Rehman, AU; Shah, S; Shakeel, S; Tasleem, Z, 2021) |
| "COPD is characterized by irreversible lung tissue damage." | ( Arevalo Gomez, K; de Bruin, HG; Heijink, IH; Jonker, MR; Kruk, DMLW; Nizamoglu, M; Noordhoek, JA; Pouwels, SD; Ten Hacken, NHT; Wisman, M, 2021) |
| "Development of COPD is also a risk factor for lung cancer." | ( Siegfried, JM, 2022) |
| "Undiagnosed COPD is highly prevalent and independently associated with worse outcome amongst patients with SOB referred for DSE." | ( Alati, E; Bashar, I; Giannoglou, D; Kipourou, K; Madden, B; Marciniak, A; O'Driscoll, JM; Sharma, R, 2022) |
| "Chronic obstructive pulmonary disease is associated with progressive symptoms and increased treatment burden, especially at the end of life." | ( Hunt, K; Jarrett, N; Tavares, N; Wilkinson, T, 2022) |
| "Chronic obstructive pulmonary disease is a common respiratory disease." | ( Chen, H; Fan, D; Fan, J; Min, Q; Xie, X, 2022) |
| "Occupational COPD is still underdiagnosed, mainly due to the challenges of assessing the occupational component of the disease in clinical settings, especially if other risk factors are present." | ( Gambelunghe, A; Murgia, N, 2022) |
| "COPD is a disease of the small airways (SA)." | ( Asare, PF; Hodge, G; Hodge, S; Holmes, M; Jayapal, M; Jersmann, H; Reynolds, PN; Tran, HB, 2022) |
| "Among these, COPD is more prominent worldwide." | ( Kumar, G; Pathak, K; Sharma, A; Virmani, R; Virmani, T, 2022) |
| "COPD is a progressive inflammatory disease of the lungs, characterized by acute exacerbations that may lead to increased mortality." | ( Alston, M; Bazell, C; Caplen, M; Comellas, AP; Feigler, N; Hansen, D; Pollack, M; Pyenson, B; Sethi, S; Staresinic, A; Styczynski, J, 2022) |
| "Asthma and chronic obstructive pulmonary disease are currently diagnosed and treated after the demonstration of variable airflow limitation and symptoms." | ( Couillard, S; Molfino, NA; Petousi, N; Smigiel, KS, 2023) |
| "COPD is a lifestyle-related disease resulting from irreversible damage to respiratory tissues mostly due to chronic exposure to environmental pollutants, including cigarette smoke." | ( Fukuda, R; Hinata, D; Okiyoneda, T, 2023) |
| "The etiology of COPD is complex, but exposure to tobacco smoke and other inhaled lung oxidants are major risk factors." | ( Cheng, SL; Gomes, F, 2023) |
| "COPD is often accompanied by hypertension, and β-blockers and amlodipine are commonly used antihypertensive drugs for these patients." | ( Hsieh, PC; Lan, CC; Su, WL; Tzeng, IS; Wu, CW; Wu, YK; Yang, MC, 2023) |
| "COPD is a major cause of morbidity and mortality worldwide and results in an economic and social burden that is both substantial and increasing." | ( Akhter, S; Faysal, MR; Hoque, MR; Krishna, SP; Momo, FR; Nessa, A; Saha, BK; Sarkar, S; Sultana, I, 2023) |
| Excerpt | Reference |
|---|
| "It is concluded that in severe chronic obstructive pulmonary disease, maintenance treatment with oral glucocorticoids is associated with increased mortality in a dose-dependent manner." | ( de Vries, G; Kester, AD; Mostert, R; Schols, AM; Slangen, J; Wesseling, G; Wouters, EF, 2001) |
| "Sixty-four COPD patients with respiratory failure and diaphragm fatigue were randomly divided into 2 groups: (1) SM group (33 patients), treated with oxygen inhalation and anti-infection agents, and SM injection (SM 40 ml + 10% glucose 100 ml), (2) AP injection group (31 patients), treated with AP 0." | ( Niu, R; Xiong, S; Zhang, X, 2000) |
| "Since in COPD the severely obstructed segments of the lung may not be reached by inhaled medication, we reasoned that drug efficiency may be enhanced by intravenous administration of the agent." | ( Alvisi, R; Alvisi, V; Ferri, E; Marangoni, E; Milic-Emili, J; Ragazzi, R; Righini, ER; Verri, M; Volta, CA, 2001) |
| "To assess whether patients with chronic obstructive pulmonary disease treated with heliox have a better prognosis than those treated with standard therapy." | ( Arnal, JM; Boussuges, A; Gainnier, M; Gerbeaux, P; Jean, P; Nelh, P; Rakotonirina, J; Torro, D, 2001) |
| "Patients hospitalized for COPD exacerbations can be successfully (and potentially less expensively) treated with an oral/MDI treatment regimen." | ( Blum, J; Branscombe, JM; Harrow, EM; Oldenburg, FA; Rodgerson, L; Shortall, SP, 2002) |
| "This article reviews the management of chronic obstructive pulmonary disease and looks at the place of long-acting beta 2-agonists as a first-line treatment option." | ( Llewellyn-Jones, C, 2002) |
| "The prospect for better treatment of chronic obstructive pulmonary disease looks brighter than ever." | ( Rennard, SI, 2002) |
| "Acute exacerbations of chronic obstructive pulmonary disease (COPD) are managed with increased doses or frequency of the patient's existing bronchodilator therapy." | ( Calderaro, E; Califano, C; Cazzola, M; D'Amato, G; D'Amato, M; Di Perna, F; Matera, MG, 2002) |
| "A 58-y-old man with chronic obstructive pulmonary disease (COPD) was admitted for treatment of an acute exacerbation of his illness." | ( Ares Ares, M; Carrascosa Porras, M; Corral Mones, J; Herreras Martínez, R; Rüchel, R; Zabaleta Murguiondo, M, 2002) |
| "Treatment of chronic obstructive pulmonary disease (COPD) with inhaled corticosteroids does not appear to be as effective as similar treatment of asthma." | ( Bogaard, JM; Hegmans, JP; Hoogsteden, HC; Mulder, PG; Prins, JB; Verhoeven, GT, 2002) |
| "Patients had mild to moderately severe COPD (FEV(1) 25-80% of predicted) and were given 3 months treatment with ICS, fluticasone propionate (FP; 500 micro g twice daily, n=14) or placebo (n=10)." | ( Barnes, N; Gizycki, MJ; Hattotuwa, KL; Jeffery, PK, 2002) |
| "Chronic obstructive pulmonary disease (COPD) is characterized by inflammation of the respiratory tract in which macrophages are the predominant inflammatory cell and for which the efficacy of treatment with corticosteroids is controversial." | ( Barnes, PJ; Culpitt, SV; De Matos, C; Donnelly, LE; Rogers, DF; Russell, RE; Shah, P, 2003) |
| "Ten patients (five with COPD receiving long term oxygen therapy and five normal individuals) were studied." | ( Brown, A; Patel, KR; Peacock, AJ; Raeside, DA; Welsh, D, 2002) |
| "The need to manage the key symptoms of chronic obstructive pulmonary disease (COPD) (breathlessness, cough and sputum) is an important treatment objective." | ( Byrne, N; Celli, B; Goldman, M; Halpin, D; Hepburn, R; Keating, ET, 2003) |
| "Thirty COPD patients divided in to 3 groups (10 in each) were treated with ligustrazine, nitrendipine and ligustrazine plus nitrendipine respectively, and the changes of hemorrheologic parameters, plasma endothelin (ET-1), thromboxane A2(TXA2) and platelet-P-selectin (CD62P) before and after treatment were observed." | ( Lin, CL; Xu, YJ; Zhang, ZX, 2001) |
| "The total costs of treatment of COPD exacerbation with azithromycin is lower than with cefoperazone." | ( Faber, M; Jahnz-Rózyk, K; Mamełka, B; Targowski, T, 2003) |
| "Exacerbations of COPD and health resource usage were positively affected by daily treatment with tiotropium." | ( Brusasco, V; Hodder, R; Kesten, S; Korducki, L; Miravitlles, M; Towse, L, 2003) |
| "In the treatment of COPD, long-acting beta(2)-adrenoceptor agonists (LABAs) given twice daily cause the same degree of bronchodilation as tiotropium bromide given once daily." | ( Barnes, PJ; Erin, EM; Hansel, TT; Tennant, RC, 2003) |
| "Two weeks after placebo treatment, the COPD control group did not show such changes." | ( Fang, H; Liu, J; Ni, W; Xu, Y; Zhang, N; Zhang, Z, 1999) |
| "Five horses with moderate to severe chronic obstructive pulmonary disease (COPD) were treated with 0." | ( Kolm, G; Riedelberger, K; Schmid, R; Van den Hoven, R; Zappe, H, 2003) |
| "With very few exceptions, COPD is caused by tobacco smoking, and smoking cessation is the only truly effective treatment of COPD available." | ( Adcock, I; Caramori, G, 2003) |
| "86 patients with chronic obstructive pulmonary diseases (COPD) and tuberculosis in combination with COPD complicated by chronic pulmonary heart (CPH) received a 18-month continuous treatment with enalapril (enap, D." | ( Degtiareva, SA; Demikhova, OV; Serebrianaia, BA, 2003) |
| "Clinical trials with tiotropium in COPD patients over a maximum treatment duration of one year have confirmed a persisting bronchodilator effect of tiotropium compared with placebo and ipratropium, as well as meaningful clinical improvements in lung function, hyperinflation, exercise tolerance, symptom control and quality of life." | ( Beeh, KM; Buhl, R; Welte, T, 2003) |
| "Patients with stable COPD (n=121, FEV1=41% predicted) underwent spirometric tests every 3 hours for 24 hours at baseline and after 6 weeks of treatment." | ( Calverley, PM; Kelsen, S; Lee, A; Towse, L; van Noord, J; Witek, TJ, 2003) |
| "for 4 weeks) was administered to COPD patients." | ( Barnes, PJ; Hattori, T; Ichinose, M; Koarai, A; Komaki, Y; Ogawa, H; Shirato, K; Sugiura, H; Tomaki, M; Yamagata, S, 2003) |
| "Pharmacologic treatment of chronic obstructive pulmonary disease (COPD) has evolved considerably during the past several decades." | ( Faulkner, MA; Hilleman, DE, 2003) |
| "Non-pharmacological therapy of COPD has been receiving more interest and has been evolving rapidly in the last decade as an essential part of COPD treatment." | ( Clini, E; Costi, S; Lodi, S; Rossi, G, 2003) |
| "Chronic obstructive pulmonary disease(COPD) is a chronic airway disorder characterized by obstructive airflow limitation which is not completely reversible with treatment." | ( Takizawa, H, 2003) |
| "Management of patients with stable COPD is consisted with education for smoking cessation, pharmacologic therapy and non-pharmacologic therapy." | ( Toyoshima, H; Yoshida, M, 2003) |
| "Treatment of chronic obstructive pulmonary disease (COPD) exacerbations improves outcomes; however, responses to treatment are variable, and patients with COPD often delay presentation or fail to seek therapy." | ( Donaldson, GC; Hurst, JR; Seemungal, TA; Wedzicha, JA; Wilkinson, TM, 2004) |
| "This study shows that NAC treatment in COPD reduced basal disturbance in the prooxidant system, improved endurance time, and prevented exercise-induced oxidative stress." | ( Bellet, H; Couillard, A; Cristol, JP; Hayot, M; Koechlin, C; Prefaut, C; Simar, D, 2004) |
| "Of assessable COPD patients, 109/121 (90%) treated with ertapenem and 78/87 (90%) treated with ceftriaxone achieved a favorable clinical response (odds ratio 1." | ( DiNubile, MJ; Friedland, IR; McCarroll, KA; Woods, GL, 2004) |
| "Asthma and chronic obstructive pulmonary disease (COPD) can be effectively treated by the use of bronchodilator therapies delivered by inhalation." | ( Bateman, ED; Hodder, R; Kässner, F, 2004) |
| "For patients with chronic obstructive pulmonary disease, quick-relief and long-acting bronchodilators are primarily used in the maintenance and treatment of associated symptoms, including shortness of breath." | ( Dalonzo, GE, 2004) |
| "The treatment of patients with COPD with oral glucocorticoids decreases the activation of neutrophils, which may be partially responsible for clinical improvement in these patients." | ( Barczyk, A; Pierzchala, W; Sozañska, E; Trzaska, M, 2004) |
| "In patients with moderate-to-severe COPD, twice-daily inhaled salmeterol/fluticasone propionate 50/250 or 50/500 microg for 24-52 weeks improves predose forced expiratory volume in 1 second (FEV1) significantly more than salmeterol monotherapy, improves postdose or postbronchodilator FEV1 significantly more than fluticasone propionate monotherapy and results in clinically significant improvements in health-related quality of life." | ( Fenton, C; Keating, GM, 2004) |
| "The group of COPD patients who received 8 months of continuous treatment with erdosteine had significantly fewer exacerbations and spent fewer days in the hospital than did the placebo group; furthermore, they had no loss of lung function." | ( Bottrighi, P; Da Porto, R; Dallari, R; De Gugliemo, M; Dolcetti, A; Garuti, G; Grandi, P; Guffanti, E; Moretti, M; Potena, A; Roversi, P, 2004) |
| "Antioxidant treatment in subjects with COPD is effective in reducing oxidant stress as shown by the decrease of urinary isoprostane, a reduction that correlates with the severity of the disease, as indicated by changes in Pa(O(2)) and FEV(1)." | ( Carlucci, P; Carnini, C; Centanni, S; Di Gennaro, A; Fumagalli, F; Mondoni, M; Sala, A; Santus, P; Sola, A, 2005) |
| "Chronic obstructive pulmonary disease (COPD) is a common, progressive respiratory disease that causes great morbidity and mortality despite treatment." | ( Belleguic, C; Bertrand, C; Brinchault, G; Depincé, A; Lagente, V; Leportier-Comoy, C; Martin-Chouly, CA; Ouagued, M; Pruniaux, MP, 2005) |
| "In patients with COPD after the treatment with prednisone statistical significant increase quality of life (QOL) was obtained." | ( Bijata-Bronisz, R; Dziedziczko, A, 2004) |
| "In patients with COPD after the treatment with prednisone: the significant improvement QOL and lung function were found; the significant higher correlation between QOL and lung function then before treatment was determined." | ( Bijata-Bronisz, R; Dziedziczko, A, 2004) |
| "Deaths of COPD generated from the cohort of 135,871 patients for whom at least one prescription for drugs used to treat COPD had been dispensed between 1997 and 1999 entered into the study as cases." | ( Bagnardi, V; Corrao, G; Faini, S; Leoni, O; Suissa, S; Zambon, A, 2005) |
| "The diagnosis of COPD rests on the presence of airway obstruction, which is only partially reversible after bronchodilator treatment." | ( Alvisi, R; Alvisi, V; Capuzzo, M; Marangoni, E; Petrini, S; Ragazzi, R; Volta, CA; Zardi, S, 2005) |
| "Chronic obstructive pulmonary disease (COPD) is a condition characterized by airflow obstruction only partially reversible with usual bronchodilator therapy." | ( Brusasco, V; Crimi, E; Palange, P; Pellegrino, R, 2005) |
| "Treatment of COPD with clarithromycin during the clinical stable state yields no clinical advantages and therefore cannot be recommended as means of eliminating sputum bacteria or preventing infective exacerbations." | ( Banerjee, D; Honeybourne, D; Khair, OA, 2005) |
| "Patients with chronic obstructive pulmonary disease (COPD) often report greater relief of breathlessness with nebulised bronchodilators than with the same medicine administered from a metered dose inhaler (MDI)." | ( Black, PN; Brodie, SM; Poole, PJ; Saini, R, 2005) |
| "Forty patients with COPD in stable phase were randomly divided into two groups, the treated group and the control group." | ( Chen, W; Ji, HY; Ren, W; Wang, S; Zhang, NZ; Zhao, LP; Zhu, HZ; Zhuo, XZ, 2005) |
| "The Global Initiative for Chronic Obstructive Lung Disease guidelines recommend bronchodilator reversibility testing to guide treatment decisions." | ( Bourcereau, J; Bourdeix, I; Le Gros, V; Molimard, M, 2005) |
| "Some patients with COPD present with significant reversibility of airflow limitation after receiving bronchodilation therapy." | ( Gaga, M; Karamanis, T; Kostikas, K; Loukides, S; Orphanidou, D; Papatheodorou, G, 2005) |
| "Consecutive COPD patients presenting with intractable cough were randomly assigned to receive lidocaine or terbutaline inhalation treatments for cough suppression." | ( Chen, CC; Chen, YC; Chong, CF; Ma, HP; Wang, TL; Wu, YC, 2005) |
| "The therapy for chronic obstructive lung disease (COPD) is largely symptomatic in nature, involving the use of bronchodilators and steroids, and the judicious use of antibiotics." | ( Mancini, GB, 2005) |
| "In both groups of COPD patients inhaled corticosteroids (ICS) therapy caused a significant decrease in F(ENO) without significant changes in FEV1." | ( Bodzenta-Lukaszyk, A; Kucharewicz, I; Zietkowski, Z, 2005) |
| "Patients with moderate and severe COPD were treated with azithromycin (500 mg, n=16) or placebo (n=8) once daily for 3 days in a randomized, double blind design, to compare effects on inflammation markers with those seen in a previous study in healthy volunteers." | ( Barisić, K; Bosnar, M; Brajsa, K; Cepelak, I; Culić, O; Cuzić, S; Eraković, V; Glojnarić, I; Manojlović, Z; Munić, V; Novak-Mircetić, R; Oresković, K; Parnham, MJ; Pavicić-Beljak, V; Popović-Grle, S; Radosević, S; Sucić, M, 2005) |
| "Patients with chronic obstructive pulmonary disease are generally subjected to multiple regimens of antimicrobial treatment." | ( Ercibengoa, M; González, A; Larruskain, J; Marimón, JM; Pérez-Trallero, E, 2005) |
| "Patients (n = 30) with chronic obstructive pulmonary disease under inhaled corticosteroid therapy for at least 1 year were compared with sex- and age-matched healthy controls (n = 30)." | ( Akkaya, A; Buyukkaplan, US; Komerik, N; Kuru, L; Yildiz, M, 2005) |
| "The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends long-acting bronchodilators as first-line maintenance treatment for patients with chronic obstructive pulmonary disease (COPD)." | ( Bhattycharya, S; Briggs, DD; Cassino, C; Covelli, H; Kesten, S; Lapidus, R, 2005) |
| "It has additional off-label uses for coadministration with local, regional, and general anesthesia." | ( Rich, JM, 2005) |
| "We aimed to study: whether stable chronic obstructive pulmonary disease (COPD) patients present an unbalance in the blood redox status; the effect of oxygen administration on blood redox balance; the efficacy of N-acetyl-cysteine (NAC) treatment against the oxidative stress-induced by oxygen administration and whether it is dose-related." | ( Altomare, E; Elisiana Carpagnano, G; Foschino Barbaro, MP; Resta, O; Rollo, T; Serviddio, G; Tamborra, R; Vendemiale, G, 2005) |
| "In conclusion, stable state III COPD patients present an unstable redox balance; long term low flow oxygen administration induces systemic oxidative stress, which is prevented by NAC treatment." | ( Altomare, E; Elisiana Carpagnano, G; Foschino Barbaro, MP; Resta, O; Rollo, T; Serviddio, G; Tamborra, R; Vendemiale, G, 2005) |
| "Treatment of COPD improves lung function but is unlikely to slow the steady downhill course of the disease or reduce mortality." | ( Andreas, S; Anker, SD; Scanlon, PD; Somers, VK, 2005) |
| "In 20 COPD patients (FEV(1) < or =65% predicted, IC<80% predicted), we evaluated changes in the degree of pulmonary hyperinflation after acute administration of tiotropium 18 microg or budesonide/formoterol 320/9 microg." | ( Cazzola, M; Centanni, S; Di Marco, F; Matera, MG; Santus, P; Verga, M, 2006) |
| "Chronic obstructive pulmonary disease (COPD) management guidelines recommend regular treatment with one or more long-acting bronchodilators for patients with moderate to severe COPD." | ( Harnest, U; Magnussen, H; Mücke, M; Richter, K; Schmidtmann, S; Sieder, C; Stenglein, S; Weidinger, G, 2006) |
| "In the treatment of COPD, there is benefit from adding formoterol once or twice daily to tiotropium once daily in terms of improvement in airflow obstruction, resting hyperinflation, and the use of rescue salbutamol." | ( Aumann, JL; Cornelissen, PJ; Janssens, E; Mueller, A; Smeets, JJ; van Noord, JA; Verhaert, J, 2006) |
| "PBMCs of COPD patients showed clear functional T-lymphocyte abnormalities that are rescued by AM3 treatment." | ( Alvarez-Mon, M; Alvarez-Sala, JL; Alvarez-Sala, R; de la Hera, A; de Lucas, P; Prieto, A; Reyes, E, 2006) |
| "One patient with COPD did not demonstrate a favourable response although their cardiac output increased on sildenafil therapy." | ( Allenby, M; Loke, TK; Madden, BP; Sheth, A, 2006) |
| "In the ex-smokers with COPD, the albuterol responsiveness measurement was repeated after 4 weeks of treatment with fluticasone/salmeterol and after a drug washout period of 4 or 8 weeks." | ( Campos, MA; Mendes, ES; Wanner, A, 2006) |
| "Recent guidelines define chronic obstructive pulmonary disease (COPD) as a preventable and treatable disease characterized by airflow limitation and systemic consequences." | ( Rennard, SI, 2006) |
| "Some patients with COPD exacerbation have a favorable physiologic response to heliox therapy, but predicting who will be a responder is difficult." | ( Hess, DR, 2006) |
| "The goals of COPD management according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guideline are: prevention of disease progression, relief of symptoms, improvement of exercise tolerance and the quality of life, prevention and treatment of exacerbations and complications, and reduction of mortality and adverse effects." | ( Dekhuijzen, PN; Schermer, TR; Schuurbiers, OC; van Weel, C, 2006) |
| "Treatment for chronic obstructive pulmonary disease (COPD) had no effect and lung function worsened in the following years." | ( Aliredjo, RP; Cox, AL; Dekhuijzen, PN; Majoor, CJ, 2006) |
| "The survey included 104 patients with COPD (31 on concentrator treatment and 73 on liquid oxygen)." | ( Charisis, A; Constantopoulos, SH; Daskalopoulos, G; Katsenos, S; Vassiliou, MP, 2006) |
| "Many patients with chronic obstructive pulmonary disease (COPD) are treated with high dose beta(2)-adrenoceptor agonists, which can increase ventilation/perfusion mismatching, and tremor and cardiac output, thereby increasing oxygen uptake and carbon dioxide output (VCO(2))." | ( Cooper, S; Harrison, TW; Mortimer, K; Oborne, J; Sovani, MP; Tattersfield, AE; Whale, CI, 2006) |
| "Conventional treatment for OSA and COPD, has a positive effect on concurrent ED on the minority of patients." | ( Alchanatis, M; Athanasopoulos, A; Karkoulias, K; Konstantinopoulos, A; Perimeni, PP; Perimenis, P; Spyropoulos, K, 2007) |
| "At baseline doxazosin treated COPD patients had less advanced disease than COPD control patients (FVC 2." | ( Lewczuk, J; Ludwik, B; Nowak, M; Piszko, P; Wrabec, K, 2006) |
| "The treatment of chronic obstructive pulmonary disease (COPD) has improved substantially over recent years, and is increasingly based on evidence from prospective studies." | ( Hamm, H, 2006) |
| "Forty-six patients with severe COPD treated with inhaled long-acting beta(2) agonists and corticosteroids (LABA/CS) were enrolled." | ( Lee, YC; Perng, DW; Perng, RP; Su, KC; Tao, CW; Wu, CC, 2006) |
| "Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease in which patients experience a progressive decline in lung function." | ( Anzueto, A, 2006) |
| "A 78-year-old man with severe chronic obstructive pulmonary disease presented to our pain medicine clinic for treatment of post herpetic neuralgia." | ( Kwei, PL; Visser, EJ, 2006) |
| "In patients with chronic obstructive pulmonary disease (COPD) classified as moderate onwards, Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines recommend regular treatment with one or more long-acting bronchodilators, such as beta(2)-agonists or anticholinergics." | ( Bao, W; Beier, J; Chanez, P; Higgins, M; Jack, D; Martinot, JB; Schreurs, AJ; Tkácová, R, 2007) |
| "Anti-inflammatory therapy in COPD may be more effective at an early stage of this disease." | ( Kunicina, YL; Shmelev, EI, 2006) |
| "For many with Chronic Obstructive Pulmonary Disease (COPD), arterial oxygen saturation while receiving Long-Term Oxygen Therapy (LTOT) falls below an acceptable threshold (SpO(2) < 90%) for extended periods during routine daily activities." | ( Dickinson, RJ; Iobbi, MG; Simonds, AK, 2007) |
| "Baseline data set from the COPD on Primary Care Treatment (COOPT) trial was used." | ( Chavannes, NH; Dekhuijzen, PN; Saris, CG; Schermer, TR; van den Bosch, WJ; van Schayck, CP; van Weel, C, 2006) |
| "Treatment of moderate or severe chronic obstructive pulmonary disease (COPD) with combinations of inhaled corticosteroids, long-acting beta-agonists, and long-acting anticholinergic bronchodilators is common but unstudied." | ( Aaron, SD; Anthony, J; Balter, M; Bishop, G; Bleskie, D; Bourbeau, J; Chapman, K; Cowie, R; Cox, G; Doucette, S; Fergusson, D; Field, S; FitzGerald, M; Ford, G; Fox, G; Goldstein, R; Hernandez, P; Hirsch, A; Hodder, R; Hoffstein, V; Maltais, F; Marciniuk, D; Mayers, I; McCormack, D; McIvor, A; O'Donnell, D; Prins, HB; Rivington, R; Road, J; Sharma, S; Vandemheen, KL; Zamel, N, 2007) |
| "The vast majority of patients with AECOPD presenting to our university teaching hospital receive oxygen therapy outside of internationally accepted guidelines, often without monitoring of ABG levels." | ( Bu, X; Irving, LB; Joosten, SA; Koh, MS; Smallwood, D, 2007) |
| "QAW is normal in COPD patients and is not affected by therapy with inhaled corticosteroids or beta(2)-agonists." | ( Barnes, PJ; Cramer, D; Kharitonov, SA; Paredi, P; Ward, S, 2007) |
| "Patients over 50 years old with COPD were randomized into 3 groups: nebulizer, inhaler, or concomitant treatment." | ( Colman, SS; Klein, GL; Schonfeld, WH; Tashkin, DP; Zayed, H, 2007) |
| "All patients who were diagnosed with COPD between September 1, 2000 and August 31, 2001 and who had at least 3 months treatment with either a combined fluticasone/salmeterol inhaler (FSI, N=866), any ICS used with a LABA (ICS/LABA, N=525), ICS alone (N=742), LABA alone (N=531), or a short-acting bronchodilator alone (SABD, N=1832), were included." | ( Davis, KJ; Lydick, E; Mapel, DW; Nelson, LS; Soriano, J; Yood, MU, 2007) |
| "Chronic obstructive pulmonary disease (COPD) is defined by the presence of airflow limitation, measured by the forced expiratory volume in 1 second (FEV1) after the administration of bronchodilator." | ( Kanazawa, M; Sato, N, 2007) |
| "A cohort of 36,492 chronic obstructive pulmonary disease (COPD) patients aged > or =50 years was reconstructed from the health administrative databases of the province of Quebec, Canada, between 1 January 1995 and 31 December 2002 to compare users of theophyllines with users of inhaled corticosteroids (ICS) and users of long-acting beta(2)-agonists (LABA) on their rate of moderate to severe COPD exacerbations." | ( Beauchesne, MF; Blais, L; Cyr, MC; Lemière, C, 2008) |
| "Chronic obstructive pulmonary disease (COPD) and asthma have different diagnostic criteria and treatment paradigms." | ( Bugnas, B; Gerken, F; Kesten, S; Magnussen, H; Schmidt, P; van Noord, J, 2008) |
| "Physician diagnosis of COPD and asthma, age >or= 40 years, smoking >10 pack years, post-bronchodilator forced expiratory volume in 1s (FEV(1))<80% predicted, FEV(1)/forced vital capacity (FVC)<70%, >or= 12%, and >or= 200 ml increase in FEV(1) following inhaled bronchodilator, treatment with inhaled steroids >or= 1 year." | ( Bugnas, B; Gerken, F; Kesten, S; Magnussen, H; Schmidt, P; van Noord, J, 2008) |
| "Patients with COPD receiving regular treatment with TB, during 2004." | ( de Haro-Martí, L; Llopart-López, JR; Navarro-Artieda, R; Sicras-Mainar, A; Velasco-Velasco, S, 2007) |
| "We hypothesise that early detection of COPD and confrontation with spirometry for smoking cessation may be effective when applying an approach we have termed "confrontational counselling"; a patient-centred approach which involves specific communication skills and elements of cognitive therapy." | ( Huibers, MJ; Kotz, D; van Schayck, OC; Wesseling, G, 2007) |
| "New pharmacological strategies for COPD need to be developed because the current treatment is inadequate." | ( Montuschi, P, 2006) |
| "Patients with COPD are frequently prescribed inhaled corticosteroids (ICS); however, it is unclear whether the treatment with ICS might modify responses to inhaled bronchodilators." | ( Hodder, R; Kesten, S; Menjoge, S; Viel, K, 2007) |
| "Patients with COPD were older, more symptomatic, and less likely to be receiving beta-blocker therapy, and had a higher mortality (27." | ( Anand, IS; Barlera, S; Carretta, E; Cohn, JN; Latini, R; Maggioni, AP; Masson, S; Staszewsky, L; Tognoni, G; Wong, M, 2007) |
| "41 patients with COPD participated in a randomised, double blind, double dummy, three way crossover study with 2 week washout periods between treatments." | ( Brooks, J; Cahn, A; Hagan, G; O'Connor, BJ; Singh, D, 2008) |
| "Forty stable tiotropium-free COPD patients (FEV1: 27%-78% predicted) were studied before and 90 min after administration of tiotropium bromide on visit0, and following 3 and 6 weeks of tiotropium bromide treatment (visit3wks, visit6wks)." | ( Schuermans, D; Verbanck, S; Vincken, W, 2007) |
| "After a 1-week washout, 8 steroid-naïve COPD patients with AATD (ZZ genotype), within a double-blind randomized cross-over study, were assigned to one of the following 16-week treatments: (1) HFA-BDP 400 microg b." | ( Bertella, E; Boni, E; Corda, L; La Piana, GE; Redolfi, S; Tantucci, C, 2008) |
| "Treatment of COPD patients with TP is more effective than with theophylline." | ( Aizawa, H; Gohara, R; Ichiki, M; Iwanaga, T; Kawayama, T; Kinoshita, M; Koga, H; Minami, S; Nishiyama, M; Sueyasu, Y, 2008) |
| "In patients with COPD, after azithromycin therapy, we observed significantly improved AM phagocytic ability (pre: 9." | ( Ahern, J; Hodge, G; Hodge, S; Holmes, M; Jersmann, H; Matthews, G; Reynolds, PN, 2008) |
| "Fenspiride addition to COPD treatment improves efficacy of the standard treatment and is recommended for treatment of COPD of stage I and II in combination with broncholytic drugs." | ( Bodrug, NI; Butorov, IV; Butorov, SI; Krushka, SI; Tofan, EF, 2008) |
| "We present a patient with COPD, in whom interstitial pneumonitis with radiologic features of organizing pneumonia developed after one year of amiodaron treatment due to supraventricular and ventricular arrhythmias." | ( Burakowska, B; Fijałkowska, A; Paczek, A; Szturmowicz, M; Torbicki, A; Wiatr, E, 2008) |
| "Sixty-one COPD patients completed the trial (31 combination therapy, 30 theophylline alone; mean age 70 years; 58 males; mean dyspnea score 2." | ( Aizawa, H; Hoshino, T; Ichiki, M; Iwanaga, T; Kawayama, T; Kinoshita, M; Koga, T; Takata, S; Tsuda, T, 2008) |
| "Patients with COPD have to be comprehensively evaluated to determine the extent of disease so that therapy can be adequately individualized." | ( Celli, BR, 2008) |
| "To examine the role of increased NO in COPD, we administered a relatively selective iNOS inhibitor, aminoguanidine, by nebulization in a double-blind, placebo-controlled study in COPD patients, healthy smokers, and healthy nonsmoking subjects." | ( Barnes, PJ; Brindicci, C; Ito, K; Kharitonov, SA; Torre, O, 2009) |
| "In patients with moderate to severe COPD, combination therapy with tiotropium administered in the morning (Tr4) was the most effective; in patients with prevailing night-symptoms, treatment with tiotropium in the evening (Tr5) reduced symptoms and use of salbutamol." | ( Ceccarelli, D; Conti, V; D'Avelli, S; Graziani, E; Petroianni, A; Sanduzzi, A; Terzano, C, 2008) |
| "Cost-effective treatments for chronic obstructive pulmonary disease (COPD) are needed to reduce the burden on the Medicare system." | ( Akazawa, M; Blanchette, CM; Dalal, A; Simoni-Wastila, L, 2008) |
| "Patients with chronic obstructive pulmonary disease (COPD) are often given admixtures of nebulizable drugs to minimize the time of administration in treatment regimens." | ( Akapo, S; Gupta, J; Martinez, E; McCrea, C; Roach, M; Ye, L, 2008) |
| "Hypoxemic patients with chronic obstructive pulmonary disease (COPD) are at risk of carbon dioxide (CO(2)) retention during oxygen therapy and hypercapnia in COPD is associated with an ominous prognosis." | ( Beaucage, F; Berckmans, D; Decramer, M; Fremault, A; Silva, M, 2008) |
| "In patients with COPD, therapy with tiotropium was associated with improvements in lung function, quality of life, and exacerbations during a 4-year period but did not significantly reduce the rate of decline in FEV(1)." | ( Burkhart, D; Celli, B; Decramer, M; Kesten, S; Menjoge, S; Senn, S; Tashkin, DP, 2008) |
| "Only 58% of patients with COPD were correctly identified in the ambulance and 73% of these patients were treated with flow rates >4 l/min (equivalent to >35% oxygen)." | ( Gavin, C; Hale, KE; O'Driscoll, BR, 2008) |
"The use of Oxy-Gen lite in COPD patients with hypoxemia and LTOT | ( Born, T; Hirche, H; Hirche, TO; Jungblut, S; Kenn, K; Köhnlein, T; Sczepanski, B; Wagner, TO, 2008) | |
"Treatment of COPD with fluticasone propionate/salmeterol 500/50 microg appears to be cost-effective (| ( Chambers, MG; Dalal, AA; Earnshaw, SR; Jhingran, P; Mapel, DW; Stanford, R; Wilson, MR, 2009) | |
| "In conclusion, in this large cohort of COPD patients with no or stable cardiac comorbidities, a high proportion ( approximately 40%) of patients were observed to have atrial tachycardia before treatment, which increased by 2%-5% with LABA treatment." | ( Baumgartner, RA; Cheng, H; Grogan, DR; Hanrahan, JP; Morganroth, J; Wilson, A; Zimetbaum, PJ, 2008) |
| "Many patients with chronic obstructive pulmonary disease (COPD) are treated with twice daily (BID) inhaled corticosteroids (ICS)." | ( Abbate, EH; Calverley, PM; Karpel, JP; Nelson, HS; Rennard, S; Staudinger, H; Stryszak, P, 2008) |
| "Chronic obstructive pulmonary disease (COPD), which comprises emphysema and chronic bronchitis resulting from prolonged exposure to cigarette smoke (CS), is a major public health burden with no effective treatment." | ( Bedja, D; Biswal, S; Blake, DJ; Champion, HC; El-Haddad, H; Gabrielson, KL; Kensler, TW; Kombairaju, P; Liby, KT; Malhotra, D; Rangasamy, T; Sporn, MB; Sussan, TE; Tuder, RM; Yamamoto, M; Yates, MS, 2009) |
| "35 patients hospitalised with ECOPD and treated according to international guidelines (including systemic steroids) were randomised to receive or not to receive low-dose oral theophylline (100 mg twice daily)." | ( Agusti, A; Barnes, PJ; Cosio, BG; Iglesias, A; Ito, K; Noguera, A; Rios, A; Sala, E, 2009) |
| "The pharmacological treatment of chronic obstructive pulmonary disease (COPD) can significantly improve quality of life by reducing exacerbations, dyspnea and exercise intolerance, thereby limiting the degree of handicap and improving daily activities." | ( Allain, YM; Giraud, F; Huchon, G; Roche, N, 2009) |
| "In the treatment of COPD corticosteroid therapy commonly has little or no anti-inflammatory effect." | ( Chen, J; Li, B; Luo, J; Ran, P, 2009) |
| "In clinically stable COPD, long-term treatment is associated with a reduction in acute exacerbation and hospitalization rate and a significant improvement of quality of life." | ( Moretti, M, 2009) |
| "The treatment of chronic obstructive pulmonary disease in acute aggravated stage with Tanreqing Injection can have noticeable effect, and can prohibit the release of above cell factors." | ( Gong, G; Li, X, 2009) |
| "Our data suggest that COPD patients benefit from the addition of Ismigen on top of the routine maintenance treatment with SFC." | ( Cazzola, M; Di Perna, F; Noschese, P, 2009) |
| "Influencing the progression of COPD has long been an elusive goal of drug therapy." | ( Anzueto, A; Miravitlles, M, 2009) |
| "In chronic diseases such as chronic obstructive pulmonary disease (COPD), patients may not perceive all of the benefits of drug therapy until withdrawal." | ( Adams, SG; Anzueto, A; Briggs, DD; Kesten, S; Leimer, I, 2009) |
| "Current guidelines for the treatment of chronic obstructive pulmonary disease (COPD) recommend the use of long-acting bronchodilators in the maintenance management of COPD." | ( Boota, A; Denis-Mize, K; Hanania, NA; Kerwin, E; Tomlinson, L, 2009) |
| "Both asthma and chronic obstructive pulmonary disease (COPD) are often underdiagnosed and undertreated among the elderly." | ( Berger, WE, 2005) |
| "Patients with chronic obstructive pulmonary disease (COPD) have few options for treatment." | ( Brose, M; Bundschuh, DS; Calverley, PM; Fabbri, LM; Izquierdo-Alonso, JL; Martinez, FJ; Rabe, KF, 2009) |
| "Sixty patients with COPD and lung cancer at the upper pulmonary lobes eligible for lobectomy were enrolled and randomly assigned either to standard treatment (ST) with stapling device or to electrocautery dissection and application of a collagen patch coated with human fibrinogen and thrombin (TachoSil) (experimental treatment [ET]) for the intra-operative completion of their fused fissures." | ( Casadio, C; Massera, F; Mineo, TC; Papalia, E; Pirondini, E; Rena, O; Turello, D, 2009) |
| "Because acute exacerbations of chronic obstructive pulmonary disease (AECOPDs) are major causes of morbidity and mortality in COPD, they must be prevented when possible and when they occur, treated aggressively." | ( Anzueto, AR, 2009) |
| "Patients with moderate to most severe COPD who were on maintenance therapy with tiotropium and other long-acting bronchodilators were studied." | ( Endo, Y; Hasegawa, T; Iwashima, A; Nakayama, H; Satoh, H; Suzuki, E, 2009) |
| "Prevention and treatment of COPD exacerbations are recognized as key goals in disease management." | ( Anzueto, A; Chinsky, K; Crater, G; Emmett, A; Feldman, G; Ferguson, GT; Kalberg, C; Knobil, K; O'Dell, D; Seibert, A, 2009) |
| "For patients whose COPD is not sufficiently controlled by monotherapy, combining an inhaled anticholinergic and a ss(2)-agonist is a convenient way of delivering treatment and obtaining better lung function and improved symptoms." | ( Cazzola, M; Tashkin, DP, 2009) |
| "The current mainstream treatment for COPD is bronchodilators alone or in combination." | ( Fukuchi, Y; Ichinose, M; Kubo, K; Mishima, M; Nagai, A; Nishimura, M; Seyama, K, 2010) |
| "For many years, chronic obstructive pulmonary disease (COPD) was considered a disease of fixed airflow obstruction for which there was no good treatment." | ( Gordon, E; Lazarus, SC, 2009) |
| "The effective management of dyspnea in COPD remains a significant challenge for caregivers but recent treatment innovations such as helium-oxygen, inhaled furosemide and breathing feedback techniques have yielded early positive results." | ( Jensen, D; O'Donnell, DE; Ora, J, 2010) |
| "Several COPD treatment guidelines recommend increasing oxygen flow during sleep to avoid nocturnal desaturation." | ( Antón, A; Farrero, E; Güell, R; Martí, S; Mayos, M; Samolski, D; Tárrega, J, 2010) |
| "Actual treatment of COPD is not able to reduce and suppress the inflammation in small airways and lung parenchyma." | ( Płusa, T, 2009) |
| "Increased FKBP51 in COPD patients treated with formoterol/ budesonide/theophylline may be important in altering signaling from corticosteroid receptors." | ( Braszko, JJ; Chyczewska, E; Holownia, A; Kolodziejczyk, A; Mroz, RM, 2009) |
| "In patients with COPD who are not on maintenance therapy, tiotropium is associated with significant benefits in disease progression." | ( Celli, B; Decramer, M; Kesten, S; Lystig, T; Mehra, S; Tashkin, DP; Troosters, T, 2010) |
| "In both groups, CHD and COPD were treated by the generally accepted standards, Group I patients were additionally given IBB at a water temperature of 37 degrees C; the concentration of iodine and bromine was 10-15 and 30-40 m/I, respectively; the duration was 10-15 min for 2 consecutive days, followed by a rest day or every second day; the course comprised 10-12 sessions." | ( Zunnunov, ZR, 2010) |
| "in patients with stable COPD, after tiotropium bromide treatment, the percentage of CD(4)(+) T cells was increased from (28 +/- 10)% to (36 +/- 6)%, and the difference was significant (t = 3." | ( Deng, L; Ma, WL; Shi, HZ; Wang, P; Xin, JB; Xiong, XZ; Zhang, JC, 2010) |
| "Atypical presentation is common among COPD patients, and this may result in delayed therapy." | ( Al Habib, K; Al Mahmeed, W; Al Suwaidi, J; Alsheikh-Ali, AA; Assad, N; El-Menyar, AA; Hadi, HA; Ridha, M; Singh, R; Zubaid, M, 2010) |
| "Recent advances in chronic obstructive pulmonary disease (COPD) treatment offer symptom relief, but disease modification remains an unmet goal of pharmacotherapy." | ( Giembycz, MA; Gross, NJ; Rennard, SI, 2010) |
| "Relieving dyspnoea when chronic obstructive pulmonary disease (COPD) no longer responds to disease-modifying therapy is challenging, with limited evidence to provide guidance." | ( Horton, R; Rocker, G, 2010) |
| "Coexistence of COPD with acute MI may be associated with less frequent transfer for invasive treatment, less aggressive pharmacotherapy, and higher in-hospital mortality in patients admitted to community hospitals without on-site invasive facilities." | ( Brzeziński, M; Dubiel, JS; Dudek, D; Dziewierz, A; Mielecki, W; Rakowski, T; Siudak, Z; Zdzienicka, J, 2010) |
| "Long-term treatment of COPD with tiotropium improves lung function, exacerbations and health status in men and women, with similar magnitudes of benefit." | ( Celli, B; Decramer, M; Kesten, S; Lystig, T; Tashkin, D, 2010) |
| "For patients in late stages of chronic obstructive pulmonary disease (COPD), dyspnea is often refractory to conventional treatment." | ( Goodridge, D; Lawson, J; Marciniuk, D; Rennie, D; Rocker, G, 2010) |
| "These findings in COPD are in line with other studies reporting a lack of clinical efficacy with CCR1 antagonists in other therapy areas." | ( Bjermer, L; Dahlström, K; Eriksson, L; Kerstjens, HA; Vestbo, J, 2010) |
| "beta2-agonists are mainstay of COPD and asthma therapy, but whether beta2-agonists directly affect airway epithelial host defense functions is unclear." | ( Bowler, RP; Chu, HW; Green, RM; Gross, CA; Schnell, C; Weinberger, AR, 2010) |
| "The use of Ambroxol in COPD exacerbations corrected AOF production in the blood of the patients and enhanced the efficiency of their treatment." | ( Farkhutdinov, RR; Farkhutdinov, ShU; Farkhutdinov, UR; Mirkhaĭdarov, AM; Petriakov, VV, 2010) |
| "Patients with asthma or COPD (n = 198), who were hepatitis B surface antigen-seropositive and had been treated with ICS, were identified retrospectively." | ( Chang, YS; Cho, SH; Kim, KM; Kim, MN; Kim, SH; Kim, TW; Kim, W; Kim, YY; Kwon, JW; Min, KU; Park, HW, 2010) |
| "In patients with COPD, treatment with a combination of the inhaled corticosteroid fluticasone propionate (250 microg) and the long-acting beta(2)-agonist salmeterol (50 microg) in a single inhaler (250/50 microg) is an effective therapy option that has been shown to reduce the frequency of exacerbations, to improve lung function, dyspnea and health status, and to be relatively cost-effective as a COPD maintenance therapy." | ( Dalal, AA; Hurley, JS; Raphiou, I; Yawn, BP, 2010) |
| "We conclude that coadministered FOR + TIO significantly improves lung function compared with TIO treatment alone in COPD patients regardless of differences in patient subgroups." | ( Tashkin, DP; Varghese, ST, 2011) |
| "These COPD patients treated with BUD/FM were less likely to have ED visits and hospitalizations for COPD and used fewer doses of anticholinergic medication than patients treated with FP/SM in the year after treatment initiation." | ( Blais, L; Forget, A; Ramachandran, S, 2010) |
| "Patients with moderate-to-severe COPD were randomised to 6 months double-blind treatment with indacaterol (150 μg once daily), salmeterol (50 μg twice daily) or placebo." | ( Centanni, S; Dahl, R; Dogra, A; Kornmann, O; Kramer, B; Lassen, C; Owen, R, 2011) |
| "Despite the increasing burden of chronic obstructive pulmonary disease in older people, underdiagnosis and undertreatment in this age group are still common problems." | ( Bernabei, R; Corbo, GM; Pasciuto, G; Valente, S, 2010) |
| "Some treatments for chronic obstructive pulmonary disease (COPD) can reduce exacerbations, and thus could have a favourable impact on overall healthcare costs." | ( Lydick, E; Mapel, DW; Marton, JP; Schum, M, 2010) |
| "Patients with COPD (n = 1074) enrolled in a regional managed care system in the US were identified using administrative data and divided by their medication use into three groups (salbutamol, ipratropium and salmeterol)." | ( Lydick, E; Mapel, DW; Marton, JP; Schum, M, 2010) |
| "Chronic obstructive pulmonary disease (COPD) therapy is complicated by corticosteroid resistance of the interleukin 8 (IL-8)-dependent and granulocyte macrophage-colony stimulating factor (GM-CSF)-dependent chronic airway inflammation, for whose establishment human airway smooth muscle cells (HASMCs) might be crucial." | ( Jungck, D; Knobloch, J; Koch, A; Lin, Y; Sibbing, B; Stoelben, E; Strauch, J; Urban, K, 2010) |
| "In patients with established COPD, we evaluated the impact of disease severity and impairment of respiratory physiology on cognitive impairment and the potential mitigating role of oxygen therapy." | ( Blanc, PD; Eisner, MD; Iribarren, C; Julian, LJ; Katz, PP; Sidney, S; Thakur, N; Yelin, EH, 2010) |
| "Thirty-six COPD patients were randomized to treatment with oral erythromycin (125 mg, three times/day) or placebo." | ( Bai, J; Deng, JM; He, ZY; Li, MH; Liu, GN; MacNee, W; Ou, LM; Zhang, JQ; Zhong, XN, 2010) |
| "Erythromycin treatment in COPD patients can reduce airway inflammation and decrease exacerbations and may therefore be useful in the management of COPD." | ( Bai, J; Deng, JM; He, ZY; Li, MH; Liu, GN; MacNee, W; Ou, LM; Zhang, JQ; Zhong, XN, 2010) |
| "Many COPD patients receiving LABD monotherapy continue to suffer significant symptoms, exacerbations and poor quality of life." | ( Bailey, W; Crater, G; Dransfield, MT; Emmett, A; O'Dell, DM; Yawn, B, 2011) |
| " Forty male COPD patients were randomly divided into two groups; group 1 (n=20) were treated with long-acting ß2-agonist, and group 2 (n=20) with long-acting ß2-agonist and inhaled glucocoticoid each day for 3 months." | ( Boskabady, M; Boskabady, MH; Mansori, F; Nemat Khorasani, A, 2010) |
| "Tiotropium therapy for COPD patients is recommended in all GOLD stages." | ( Iwashiro, M; Yoshizawa, A; Yoshizawa, T, 2010) |
| "The overall rate of COPD exacerbations/patient/year was similar and not statistically significantly different among treatments (beclomethasone/formoterol 0." | ( Brusasco, V; Calverley, PM; Costantini, M; Kuna, P; Monsó, E; Papi, A; Petruzzelli, S; Sergio, F; Varoli, G, 2010) |
| "Chronic obstructive pulmonary disease (COPD) is associated with neutrophil-mediated inflammation, a potential target for treatment in COPD." | ( Bernstein, JA; Greenberg, S; Hanley, WD; Knorr, BA; Liu, N; Reiss, TF; Smugar, SS, 2011) |
| "Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease of the lung caused primarily by exposure to cigarette smoke." | ( Abraham, VM; Dronavalli, G; Hanania, NA; Mattewal, AS; Sharafkhaneh, A, 2010) |
| "Therapeutic interventions in chronic obstructive pulmonary disease (COPD) shown to reduce exacerbations include smoking cessation, vaccination and appropriate pharmacological therapy." | ( Chisholm, A; Crockett, A; Jones, R; Price, D; Ryan, D, 2010) |
| "The aim of pharmacological treatment of COPD is best possible disease control." | ( Ulrik, CS, 2010) |
| "Twelve weeks of tiotropium therapy in COPD patients improves clinical indices of lung function and involves alterations in sputum cell chromatin acetylation and also increased cholinergic M3 receptor internalization." | ( Braszko, JJ; Chyczewska, E; Holownia, A; Kielek, A; Kolodziejczyk, A; Mroz, RM; Skopinski, T, 2010) |
| "To evaluate chronic obstructive pulmonary disease (COPD)-related expenditure and hospitalisation in COPD patients treated with tiotropium versus alternative long-acting bronchodilators (LABDs)." | ( Baker, CL; Cao, Z; Durden, E; Paulose-Ram, R; Shah, H; Shi, N; Su, J; Zou, KH, 2011) |
| "Time-to-first COPD-related health care event beginning 30 days following therapy initiation with FSC (n = 16,684), ipratropium alone or in fixed dose combination with albuterol (n = 14,449), or tiotropium (n = 12,659) was estimated using Cox proportional hazard models that controlled for differences in patient demographic characteristics, health care utilization, and comorbidities at baseline." | ( Blanchette, CM; Dalal, AA; Mapel, DW; Petersen, HV; Roberts, MH, 2010) |
| "Subjects with moderate to severe COPD who completed a 26-week, randomized, double-blind study were eligible for enrollment in an extension, during which treatment with double-blind indacaterol, 150 or 300 μg once daily, or placebo was continued for a further 26 weeks." | ( Chapman, KR; Dogra, A; Kramer, B; Lassen, C; Owen, R; Rennard, SI, 2011) |
| "In one study, patients with chronic obstructive pulmonary disease reported consistently higher ratings of breathlessness after administration of naloxone, an opioid receptor antagonist, compared with physiological saline during high-intensity treadmill exercise." | ( Mahler, DA, 2011) |
| "Fifty-two COPD in-patients with an exacerbation, treated with amoxicillin clavulanic acid, were included in this cohort study." | ( Brusse-Keizer, M; Hendrix, R; Kerstjens, H; Movig, K; ten Bokum, L; van der Palen, J; van der Valk, P, 2011) |
| "For improving effectiveness of chronic obstructive pulmonary disease (COPD) therapy is necessary to influence on pharmacologic receptors in the complementary way and to reduce the dose frequency." | ( Płusa, T, 2011) |
| "Patients with moderate-to-severe COPD were randomised to treatment with indacaterol 150 μg q." | ( Amos, C; Buhl, R; Disdier, C; Dunn, LJ; Henley, M; Kramer, B; Lassen, C, 2011) |
| "Seventy-two patients with stable COPD treated with tiotropium (n = 41) or salmeterol (n = 31) were evaluated for pulmonary function, dynamic hyperinflation following metronome-paced incremental hyperventilation, six-minute walking distance, and St George's Respiratory Questionnaire (SGRQ) before and 2-3 months following treatment with tiotropium or salmeterol." | ( Fujimoto, K; Hanaoka, M; Kanda, S; Kitaguchi, Y; Kubo, K; Urushihata, K, 2011) |
| "Introducing the SOP for patients with aeCOPD did not significantly improve adherence to valid national guidelines, but did help to improve specific elements of therapy." | ( Bosse, G; Bubser, F; Francis, RC; Kerner, T; Krebs, M; Schmidbauer, W; Sörensen, M; Spies, CD, 2011) |
| "Patients with COPD represent a heterogeneous population in terms of their reporting of symptoms and response to treatment." | ( Capkun-Niggli, G; Gale, R; Houghton, K; Jones, P; Stull, DE; Wiklund, I, 2011) |
| "Fourteen ex-smokers with COPD provided written informed consent to a local ethics board-approved and Health Insurance and Portability Accountability Act-compliant protocol and underwent hyperpolarized ³He and hydrogen 1 MR imaging, spirometry, and plethysmography before and a mean of 25 minutes ± 2 (standard deviation) after administration of 400 μg salbutamol." | ( Etemad-Rezai, R; Heydarian, M; Kirby, M; Mathew, L; McCormack, DG; Parraga, G, 2011) |
| "The recent therapeutic developments in COPD underscore a shift from short-acting bronchodilators with multiple dosings per day to reduced dosing frequency and prolonged duration of action, including once-daily treatment, with more consistent effects on various clinical outcomes." | ( Beeh, KM; Beier, J, 2011) |
| "In patients with more severe chronic obstructive pulmonary disease (COPD), the benefits of rehabilitation might not be clear and, therefore, new treatment options have been developed to increase the benefits of rehabilitation." | ( Wempe, JB; Wijkstra, PJ, 2011) |
| "Patients with COPD were randomized 1:1 to enter a 12-week treatment period and receive either oral roflumilast, 500 µg once daily, or placebo, following a single-blind, 4-week baseline period in which all patients received placebo." | ( Bredenbröker, D; Goehring, UM; Hui, DS; Kuo, HP; Kwa, KH; Lee, SD; Mahayiddin, AA; Roa, CC, 2011) |
| "Use of short-acting β(2)-agonists in chronic obstructive pulmonary disease (COPD) during treatment with long-acting β(2)-agonists is recommended as needed, but its effectiveness is unclear." | ( Bertella, E; Corda, L; La Piana, GE; Montemurro, LT; Pini, L; Tantucci, C, 2011) |
| "Ten patients with COPD underwent a dose-response curve to salbutamol (until 800 μg of cumulative dose) after a 1-week washout (baseline), 8 hours after the first administration of formoterol 12 μg (day 1), and after a 12-week and 24-week period of treatment with formoterol (12 μg twice daily by dry powder inhaler)." | ( Bertella, E; Corda, L; La Piana, GE; Montemurro, LT; Pini, L; Tantucci, C, 2011) |
| "In patients with stable COPD, the maximal effect of salbutamol on peak expiratory flow, FEV(1), and forced vital capacity was unchanged after either acute or chronic treatment with formoterol." | ( Bertella, E; Corda, L; La Piana, GE; Montemurro, LT; Pini, L; Tantucci, C, 2011) |
| "Among selected subjects with COPD, azithromycin taken daily for 1 year, when added to usual treatment, decreased the frequency of exacerbations and improved quality of life but caused hearing decrements in a small percentage of subjects." | ( Albert, RK; Anthonisen, NR; Bailey, WC; Casaburi, R; Connett, J; Cooper, JA; Criner, GJ; Curtis, JL; Dransfield, MT; Han, MK; Lazarus, SC; Madinger, NE; Make, B; Marchetti, N; Martinez, FJ; McEvoy, C; Niewoehner, DE; Porsasz, J; Price, CS; Reilly, J; Scanlon, PD; Scharf, SM; Sciurba, FC; Washko, GR; Woodruff, PG, 2011) |
| "The risk of COPD exacerbation (moderate, severe, and any), COPD-related health care utilization, and COPD-related costs (overall and by service setting) were assessed over 12 months after the initiation of treatment with FSC or TIO in commercially-insured patients > or =40 years old diagnosed with COPD." | ( Candrilli, SD; Dalal, AA; Davis, KL, 2011) |
| "Patients with severe chronic obstructive pulmonary disease who are symptomatic and who suffer repeated exacerbations are recommended to add inhaled corticosteroids to their bronchodilator treatment." | ( Cates, CJ; Karner, C, 2011) |
| "A retrospective cohort study assessed COPD-related outcomes using administrative claims data among ICS/LABA-naïve patients." | ( Blanchette, C; Mapel, D; Petersen, H; Ramachandran, S; Roberts, M, 2011) |
| "Our findings of reduced S1PR5 in COPD and the correlation with other S1P receptors in COPD identify S1PR5 as a possible novel target for pharmacotherapy." | ( Cordts, F; Gibbins, I; Haberberger, RV; Hodge, S; Jersmann, H; Moffat, DF; Pitson, S; Tabeling, C, 2011) |
| "The addition of FSC to subjects with COPD treated with TIO significantly improves lung function without increasing the risk of adverse events." | ( Crater, GD; Emmett, AH; Hanania, NA; Morris, AN; Niewoehner, DE; O'Dell, DM, 2012) |
| "The rats in the COPD model group showed sign of less activity, loss of appetite and weight, dry and yellow hair, and sometimes wheezing, which were less or milder in the group treated with erythromycin." | ( He, BM; Luo, BL; Yuan, H, 2011) |
| "Stable severe chronic obstructive pulmonary disease (COPD) patients with chronic hypercapnic respiratory failure treated by nocturnal bi-level positive pressure non-invasive ventilation (NIV) may experience severe morning deventilation dyspnea." | ( Adler, D; Espa, F; Janssens, JP; Pépin, JL; Perrig, S; Rodenstein, D; Takahashi, H, 2012) |
| "The subgroup of COPD patients treated by home NIV, who present marked deventilation dyspnea and unrewarded efforts may benefit from adjustment of ventilator settings under PSG or polygraphy." | ( Adler, D; Espa, F; Janssens, JP; Pépin, JL; Perrig, S; Rodenstein, D; Takahashi, H, 2012) |
| "The primary aim of pharmachotherapy in COPD is improvement of exertional dyspnea and quality of life through its bronchodilator effects." | ( Nishimura, M; Shimizu, K, 2011) |
| "The plasma MDA in AECOPD patients before treatment was significantly higher than that after treatment (P < 0." | ( Bao, HR; Huang, J; Liao, JM; Liu, XJ; Tan, EL; Zhang, Y, 2011) |
| "In patients with confirmed bacterial AECOPD, moxifloxacin led to significantly lower clinical failure rates than amoxicillin/clavulanic acid (in the intent-to-treat with pathogens, 62 (19." | ( Alder, J; Anzueto, A; Arvis, P; Haverstock, D; Miravitlles, M; Sethi, S; Trajanovic, M; Wilson, R, 2012) |
| "Nevertheless, many patients with COPD remain incapacitated by dyspnea and exercise intolerance despite optimal therapy." | ( Alsuhail, A; Dudgeon, DJ; Jensen, D; O'Donnell, DE; Viola, R; Webb, KA, 2012) |
| "Patients with moderate to severe COPD were randomized to receive double-blind treatment with indacaterol 75 μg once daily (n = 163 and 159) or placebo (n = 160 and 159) for 12 weeks." | ( Gotfried, MH; Kerwin, EM; Kramer, B; Lassen, C; Lawrence, D, 2011) |
| "Mean duration of COPD was 7 years; smoking history was 52 pack-years; and 45% and 37% of patients were receiving inhaled corticosteroid therapy." | ( Gotfried, MH; Kerwin, EM; Kramer, B; Lassen, C; Lawrence, D, 2011) |
| "patients with moderate COPD, patients aged ≥50 years, patients not receiving maintenance therapy at baseline)." | ( Keating, GM, 2012) |
| "Eight patients with PH-COPD were treated with DHEA (200mg daily orally) for 3 months." | ( Baulieu, EÉ; Billes, MA; Doutreleau, S; Dromer, C; Dumas de La Roque, E; Fayon, M; Jougon, J; Kraemer, JP; Marthan, R; Metivier, AC; Moore, N; Savineau, JP, 2012) |
| "For the treatment of COPD, roflumilast was associated with a significant improvement in lung function (increase in FEV(1) of 36-88 mL) when compared with placebo." | ( Hamilton, LA; Hughes, A; Pinner, NA, 2012) |
| "In all the patients with COPD in remission phase with Hypoxen prescription, the LM-dependent CL (LM-CL) with ZM and LC-enhanced CL (LC-CL) decreased after the treatment." | ( Berdnikova, NG; Lyusina, OY; Minh, HD; Muhitova, OG; Novikov, AK; Novikov, KN; Voeikov, VL; Yablonskaya, OI, 2012) |
| "Treatment of moderate-to-severe COPD patients with twice-daily aclidinium 200 μg and 400 μg was associated with significant improvements in bronchodilation, health status, and COPD symptoms." | ( Caracta, CF; D'Urzo, AD; Garcia Gil, E; Gelb, AF; Kerwin, EM; Lakkis, H, 2012) |
| "Smoking is the main cause of chronic obstructive pulmonary disease (COPD), and smoking cessation is the only treatment shown to be effective in arresting the progression of COPD." | ( Cicero Guerrero, A; Cristobal Fernández, M; Jiménez Ruiz, CA; Lopez Gonzalez, G; Mayayo Ulibarri, M; Ramos Pinedo, A, 2012) |
| "Smokers with severe or very severe COPD (Global Initiative for Chronic Obstructive Lung Disease stages III and IV) received treatment for smoking cessation." | ( Cicero Guerrero, A; Cristobal Fernández, M; Jiménez Ruiz, CA; Lopez Gonzalez, G; Mayayo Ulibarri, M; Ramos Pinedo, A, 2012) |
| "To develop an efficient therapy for chronic obstructive pulmonary disease (COPD), N-acetylcysteine (NAC) has been tested as a medication that can suppress various pathogenic processes in this disease." | ( Sadowska, AM, 2012) |
| "The number of COPD exacerbations per patient-treatment year was low and similar across genotypes for the active treatment groups (both studies)." | ( Bailey, WC; Bleecker, ER; Bujac, SR; Goldman, M; Martin, UJ; Meyers, DA; Sims, AM, 2012) |
| "Exacerbations of chronic obstructive pulmonary disease (COPD) and responses to treatment are heterogeneous." | ( Bafadhel, M; Barer, MR; Brightling, CE; Johnston, SL; Lomas, DA; McKenna, S; Mistry, V; Pancholi, M; Pavord, ID; Terry, S; Venge, P, 2012) |
| "Subjects with COPD exacerbations were entered into a randomized biomarker-directed double-blind corticosteroid versus standard therapy study." | ( Bafadhel, M; Barer, MR; Brightling, CE; Johnston, SL; Lomas, DA; McKenna, S; Mistry, V; Pancholi, M; Pavord, ID; Terry, S; Venge, P, 2012) |
| "In subjects with mild to moderate COPD and airway hyperresponsiveness to mannitol, quality of life and airway responsiveness improved after treatment with inhaled corticosteroids added to long-acting bronchodilator therapy." | ( Chhajed, PN; Jochmann, A; Leuppi, JD; Maier, S; Miedinger, D; Schafroth Török, S; Scherr, A; Taegtmeyer, AB; Tamm, M, 2012) |
| "One hundred and fifty cases of COPD at stable stage, which were in accordance with the inclusive standard were randomly divided into three groups, named group A (treatment in dog days and the three nine-day periods after the winter solstice), group B (treatment in dog days) and group C (treatment in the three nine-day periods after the winter solstice), 50 cases in each group." | ( Cao, Y; Huang, XH; Li, JX; Li, W; Li, XP; Liu, XP; Lou, BD; Shi, WY; Yang, LB; Yang, SQ; Zhang, W, 2012) |
| "Treatment-naïve patients with COPD (n = 36) were prospectively treated with two kinds of LABA--inhaled salmeterol and transdermal tulobuterol patch--for 12 weeks in crossover study, and changes in pulmonary function data and 6-minute walk distance (6 MWD) were compared between groups stratified by the CysGlyGln." | ( Kawate, E; Mochizuki, H; Nanjo, Y; Takahashi, H; Tsuda, Y; Yamazaki, M, 2012) |
| "Hypercapnic Chronic Obstructive Pulmonary Disease (COPD) exacerbation in patients with comorbidities and multidrug therapy is complicated by mixed acid-base, hydro-electrolyte and lactate disorders." | ( Conti, V; Di Nicola, M; Di Stefano, F; Paone, G; Petroianni, A; Ricci, A; Terzano, C, 2012) |
| "The CCMP included COPD education during 4 individual sessions and 1 group session, an action plan for identification and treatment of exacerbations, and scheduled proactive telephone calls for case management." | ( Adams, SG; Bourbeau, J; Colling, C; Fan, VS; Fiore, L; Gaziano, JM; Huang, GD; Leatherman, S; Lew, R; Liang, MH; Mador, MJ; Mazzuca, SA; Niewoehner, DE; Panos, RJ; Rastogi, P; Robbins, R; Sarosi, G; Shannon, C; Sharafkhaneh, A; Sriram, PS; Stoller, JK; Thwin, SS; Wagner, TH, 2012) |
| "A cohort analysis compared COPD exacerbation rates and associated costs during a variable-length follow-up period between patients initiating maintenance therapy with FSC or ACs." | ( Crater, GD; D'Souza, AO; Dalal, AA; Lunacsek, OE; Nagar, SP; Shah, MB, 2012) |
| "Thirty eight patients with COPD were randomized to a 2 week treatment with FOR 12 μg twice a day plus TIO 18 μg once a day (FOR + TIO) or FOR 12 μg twice a day plus placebo (FOR + PLA) once a day, using a double-blind crossover design." | ( Canto, ND; Chiappa, GR; Neder, JA; Ribeiro, JP, 2012) |
| "Several clinical trials on chronic obstructive pulmonary disease (COPD) have suggested a relationship between COPD treatment and occurrence of respiratory infections." | ( Braido, F; Canonica, GW; Chiappori, A; De Ferrari, L; Folli, C; Garelli, V; Pellegrini, M; Riccio, AM, 2012) |
| "Many patients with chronic obstructive pulmonary disease (COPD) continue to suffer exacerbations, even when treated with maximum recommended therapy (eg, inhaled combinations of long-acting β2-agonist and high dose inhaled corticosteroids, with or without a long-acting anticholinergic [long-acting muscarinic antagonist])." | ( Calverley, PM; Fabbri, LM; Goehring, UM; Martinez, FJ; Rabe, KF, 2012) |
| "Thirty-one very severe COPD patients undergoing oxygen-therapy were recruited." | ( Carpio, C; Casitas, R; Galera, R; García-Río, F; Llontop, C; Lores, V; Martínez, E; Rojo, B, 2012) |
| "Thirty-six AECOPD patients received VRI at three time points: before NPPV treatment (T1), at 15 min of NPPV treatment (T2), and at 15 min after the end of NPPV treatment (T4)." | ( Bing, D; Hong-wen, Z; Jian, K; Long-feng, S; Wei, T, 2012) |
| "Oxygen has been widely used for COPD patients because long-term oxygen therapy can improve survival duration of COPD patients with severe hypoxemia." | ( Lee, GJ; Lee, TS; Oh, SK; Oh, YM; Shin, CS, 2013) |
| "Ninety-eight patients with chronic obstructive pulmonary disease and/or chronic bronchitis (n=78), or bronchiectasis (n=20), with a peak cough expiratory flow >150 l/min and sputum production >30 ml/day, randomly included into two treatment groups." | ( Ambrosino, N; Balbi, B; Berrighi, D; Bianchi, L; Cavicchioli, PP; Clini, EM; Crisafulli, E; Dabrosca, F; DeBiase, A; Galimberti, V; Iattoni, A; Paneroni, M; Righi, D; Schiavoni, G; Vagheggini, G; Venturelli, E; Vitacca, M; Zaurino, M, 2013) |
| "Patients with mild chronic obstructive pulmonary disease (COPD) present abnormal ventilatory mechanics during exercise and may require bronchodilator therapy." | ( Bourbeau, J; Gagnon, P; Maltais, F; Martel, S; Milot, J; Provencher, S; Saey, D; Tan, WC, 2012) |
| "A previously published, validated COPD progression model was updated with new exacerbation data and adapted to the Dutch setting by including Dutch estimates of healthcare use for COPD maintenance treatment and Dutch unit costs." | ( Hoogendoorn, M; Kappelhoff, BS; Overbeek, JA; Rutten-van Mölken, MP; Wouters, EF, 2012) |
| "This article reviews the COPD management potential of aclidinium bromide, a LAMA administered twice daily (BID) by a multidose dry powder inhaler that is indicated for maintenance treatment of COPD." | ( Maltais, F; Milot, J, 2012) |
| "Primary COPD and normal human airway epithelial cells were treated with quercetin, LY294002 or erlotinib for 2 weeks." | ( Angel, KA; Comstock, AT; Ganesan, S; Mancuso, P; Martinez, FJ; Sajjan, US; Unger, BL, 2013) |
| "In patients with COPD, the factors associated with the risk of discontinuing the treatment with tiotropium within 12 months following initiation were identified (12-month persistence)." | ( Devouassoux, G; Hartwig, S; Laforest, L; Licaj, I; Marvalin, S; Van Ganse, E, 2013) |
| "In addition, a model of COPD complicated with hypoxia was established by administering lipopolysaccharides to the airways of rats, smudging and hypoxia (group C)." | ( Jiang, M; Wang, CM; Wang, HJ, 2013) |
| "In subjects with COPD and chronic respiratory failure undergoing treatment with noninvasive ventilation and LTOT, high Hb levels are associated with better long-term survival." | ( Budweiser, S; Jörres, RA; Kollert, F; Müller, C; Pfeifer, M; Porzelius, C; Tippelt, A, 2013) |
| "Thirty-two patients with stable COPD who had been treated with long-acting bronchodilators, including long-acting muscarinic antagonists (LAMA), were examined by pulmonary function tests, dynamic hyperinflation evaluated by the method of step-wise metronome-paced incremental hyperventilation, and the incremental shuttle walking test before and after inhalation of SABA or SAMA." | ( Fujimoto, K; Hanaoka, M; Honda, T; Kitaguchi, Y; Komatsu, Y; Kubo, K, 2013) |
| "Untreated chronic obstructive pulmonary disease (COPD) co-existing with obstructive sleep apnea (OSA), also known as overlap syndrome, has higher cardiovascular mortality than COPD alone but its underlying mechanism remains unclear." | ( Bakker, JP; Kwong, RY; Malhotra, A; Mandry, D; McSharry, D; Neilan, TG; Owens, RL; Sharma, B, 2013) |
| "The current mainstay of therapy for chronic obstructive pulmonary disease (COPD) is long-acting bronchodilators." | ( Gabazza, EC; Hataji, O; Ito, K; Naito, M; Taguchi, O; Watanabe, F, 2013) |
| "In all, 16 patients with severe COPD grade 4 who were on long-term oxygen treatment were included in the study." | ( Boltz, A; Frantal, S; Garhöfer, G; Hammer, M; Kaya, S; Lasta, M; Marzluf, B; Palkovits, S; Popa-Cherecheanu, A; Schmetterer, L; Schmidl, D, 2013) |
| "Patients with exacerbated COPD were unresponsive to VGVAPG treatment." | ( Antonicelli, F; Deslée, G; Dupont, A; Dury, S; Gafa, V; Guenounou, M; Le Naour, R; Lebargy, F, 2013) |
| "For patients with severe COPD and repeated exacerbations, the standard treatment remains an inhaled bronchodilator combined with an inhaled corticosteroid, or oxygen therapy in some cases." | ( , 2013) |
| "Incidences of COPD-related adverse events were similar for active and placebo treatments." | ( Decramer, ML; Hanania, NA; Lötvall, JO; Yawn, BP, 2013) |
| "Guidelines for chronic obstructive pulmonary disease (COPD) recommend that treatment choices be based partly on symptoms." | ( Buhl, R; Lawrence, D; Mahler, DA; McBryan, D, 2013) |
| "In the treatment of chronic obstructive pulmonary disease (COPD), tiotropium bromide has a longer duration of action than ipratropium bromide; however, tiotropium bromide is a more expensive alternative treatment." | ( Bassett, K; Dormuth, CR; Kawasumi, Y; Miller, TA; Morrow, RL; Paterson, MJ; Wright, JM, 2013) |
| "Patients with physician-diagnosed COPD and a record of postdiagnosis treatment with a fixed combination of budesonide/formoterol or fluticasone/salmeterol were included." | ( Janson, C; Johansson, G; Jørgensen, L; Larsson, K; Lisspers, K; Ställberg, B; Stratelis, G; Telg, G, 2013) |
| "Time to first COPD exacerbation was slightly longer in the CVT-R group compared to the other treatment groups, although it did not reach statistical significance (CVT-R versus CVT-MDI, P = 0." | ( Dai, L; Dunn, LJ; Ferguson, GT; Ghafouri, M, 2013) |
| "Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality and its treatment is critical to improve quality of life, reduce symptoms, and diminish the frequency of COPD exacerbations." | ( Panos, RJ, 2013) |
| "According to random number table, 9 AECOPD patients were randomly divided into 3 groups, numbered A, B and C and treated with ODN." | ( Hong, HH; Jing, M; Lu, GD; Rui, L; Shao, XP; Wu, WW, 2014) |
| "Optimal oxygen flow in ODN-treating AECOPD patients may be 6-7 L/min." | ( Hong, HH; Jing, M; Lu, GD; Rui, L; Shao, XP; Wu, WW, 2014) |
| "When patients with chronic obstructive lung disease (COPD) and acute on chronic respiratory insufficiency fail non-invasive ventilation (NIV) they are commonly intubated and treated with invasive mechanical ventilation (IMV) to ensure adequate gas exchange." | ( Braune, SA; Kluge, S, 2013) |
| "Pharmacotherapy to aid cessation in COPD smokers have proven to be highly cost effective." | ( Fagerström, KO; Jiménez-Ruiz, CA, 2013) |
| "The administration of a high FIO2 to COPD patients breathing spontaneously may result in hypercapnia, due to reversal of preexisting regional hypoxic pulmonary vasoconstriction, resulting in a greater dead space." | ( Boschi da Silva, É; de Mello Rieder, M; Frederico Tonietto, T; Gasparetto Maccari, J; Peçanha Antonio, AC; Pinheiro de Oliveira, R; Savi, A; Teixeira, C; Zignani, EC, 2014) |
| "In the management of chronic obstructive pulmonary disease (COPD), there is an unmet medical need for effective bronchodilator treatments that not only have a fast onset of action, but also a long duration of action and are delivered using a simple, easy-to-use device." | ( D'Andrea, P; Molimard, M, 2013) |
| "In clinical practice, the COPD pharmacotherapy is not consistent with clinical guidelines." | ( Agabiti, N; Bauleo, L; Cascini, S; Colamesta, V; Davoli, M; Di Martino, M; Fusco, D; Kirchmayer, U; Patorno, E; Perucci, CA; Pinnarelli, L; Pistelli, R, 2014) |
| "Oxygen administration for COPD patients in Bogotá significantly increased ET by decreased respiratory load, improved cardiovascular performance and oxygen transport." | ( Barrero, M; Casas, A; González-García, M; Jaramillo, C; Maldonado, D, 2014) |
| "Adiponectin may have a role in the COPD pathogenesis; it may also be a biomarker of disease severity and treatment responses in this disease." | ( Järvenpää, R; Kankaanranta, H; Kööbi, L; Lehtimäki, L; Leivo-Korpela, S; Moilanen, E; Nieminen, R; Saarelainen, S; Vuolteenaho, K, 2014) |
| "14 subjects with COPD were commenced on combination fluticasone propionate/salmeterol therapy for 3 months." | ( Diba, C; King, GG; Salome, CM; Schoeffel, RE; Thamrin, C; Timmins, SC, 2014) |
| "The clinical treatment of chronic obstructive pulmonary disease (COPD) requires not only an improvement of airflow by bronchodilation but also the suppression of emphysema by controlling inflammation." | ( Iijima, K; Ishihara, T; Kobayashi, D; Mizushima, T; Mogushi, K; Sato, K; Sugizaki, T; Suzuki, H; Tahara, K; Tanaka, H; Tanaka, K; Yamakawa, N; Yamashita, Y, 2013) |
| "The association of COPD and HF results in a worse prognosis, and COPD represents a barrier to optimisation of beta-blocker therapy." | ( Böhm, M; Borer, JS; Ford, I; Komajda, M; Lainscak, M; Robertson, M; Swedberg, K; Tavazzi, L, 2013) |
| "All 14,965 COPD patients with COPD treated LTOT in Denmark in the period 2001-2010." | ( Lange, P; Ringbaek, TJ, 2014) |
| "Twenty-three patients with AECOPD were divided into a treatment group (He/O2 = 70%/30%) and a control group (N2/O2 = 70%/30%)." | ( Han, B; Su, L; Xiao, Y; Xie, L; Zhang, X, 2014) |
| "In a mouse model of chronic obstructive pulmonary disease, GC treatment induced higher chemokine levels, and this correlated with enhanced recruitment of leukocytes." | ( Hamann, J; Hylkema, MN; Jonkers, RE; Martinez, FO; Melgert, BN; van de Garde, MD, 2014) |
| "ABPA in COPD is uncommon, but early identification and initiation of systemic corticosteroid therapy can lead to improvement in symptoms and prognosis." | ( Jin, JM; Li, R; Liu, XF; Liu, Y; Sun, YC, 2013) |
| "In patients with moderate-to-severe COPD, 12-week blinded treatment with once-daily glycopyrronium 50 μg or tiotropium 18 μg, provided similar efficacy and safety, with glycopyrronium having a faster onset of action on Day 1 versus tiotropium." | ( Bateman, ED; Beeh, KM; Beier, J; Chapman, KR; Chen, H; D'Andrea, P; D'Urzo, A; Henley, M; Nutbrown, R; Overend, T, 2014) |
| "A significant improvement in the COPD assessment test (CAT) questionnaire was shown one month after the end of the inhalatory treatment only in patients receiving sulphurous water." | ( Casolari, P; Chicca, M; Ciaccia, A; Contoli, M; Ferraro, A; Forini, G; Gnesini, G; Marku, B; Padovani, A; Papi, A; Pauletti, A; Pinamonti, S; Taurino, L, 2013) |
| "An exacerbation of COPD was defined as the increase or new onset of more than one symptom of COPD (cough, sputum, wheezing, dyspnoea, or chest tightness), with at least one of the symptoms lasting for 3 days or more and needing treatment with antibiotics or systemic glucocorticoids (moderate exacerbations), or admission to hospital (severe exacerbations)." | ( Fabbri, LM; Glaab, T; Israel, E; Kögler, H; Rabe, KF; Riemann, K; Schmidt, H; Vogelmeier, CF, 2014) |
| "Simulations suggest that COPD patients might benefit from the respiratory stimulant effect after the administration of higher doses of acetazolamide." | ( Clavel, M; Faisy, C; Fulda, V; Gacouin, A; Heming, N; Meziani, F; Planquette, B; Urien, S, 2014) |
| "Twenty-eight outpatients with COPD were treated with indacaterol (150 μg once daily for 8 weeks), and the effects on pulmonary function were evaluated using a questionnaire survey with the modified Medical Research Council (mMRC) dyspnea scale and COPD assessment test (CAT) before and after treatment." | ( Hanada, S; Muraki, M; Ohno, T; Sawaguchi, H; Tohda, Y; Wada, S, 2014) |
| "In stable COPD, levofloxacin treatment causes a short-term reduction in bacterial load." | ( Bafadhel, M; Brightling, CE; Monteiro, W; Pavord, ID; Siva, R, 2014) |
| "(ii) We treated 12 anemic COPD outpatients with the combination of ESAs and IV-iron, given once weekly for 5 weeks." | ( Chernin, G; Mor, R; Schwartz, D; Schwartz, IF; Silverberg, DS; Weu, MT, 2014) |
| "ID is common in COPD patients but is rarely looked for or treated." | ( Chernin, G; Mor, R; Schwartz, D; Schwartz, IF; Silverberg, DS; Weu, MT, 2014) |
| "Eighty COPD patients with pulmonary artery hypertension were selected and divided into two groups: the treatment group and the control group, which had 40 patients respectively." | ( Liu, J; Liu, P; Sheng, C; Tang, Y; Zeng, Y; Zhang, H, 2014) |
| "Chronic obstructive pulmonary disease (COPD) is a chronic, progressive disease and is treated with inhaled medication to optimize the patient's lung health through decreasing their symptoms, especially breathlessness." | ( Rashleigh, R; Roberts, NJ; Smith, SM, 2014) |
| "In patients with moderate-to-severe COPD, once-daily coadministration of IND and GLY provides significant and sustained improvement in bronchodilation versus IND alone from day 1, with significant improvements in patient-centered outcomes." | ( Aumann, J; Chen, H; Goyal, P; Henley, M; McBryan, D; Vincken, W, 2014) |
| "On two days, 60 COPD patients underwent dyspnea evaluation (VAS score) and pulmonary function testing at baseline and one hour after placebo or 300μg indacaterol administration." | ( Centanni, S; D'Angelo, E; Di Marco, F; Henchi, S; Pecchiari, M; Radovanovic, D; Santus, P, 2014) |
| "The prevalence of COPD among patients treated in the healthcare system in Latin America is unknown." | ( Di Boscio, V; Hernández Vecino, R; Mercurio, S; Schiavi, E; Stirbulov, R, 2014) |
| "The addition of FSC to subjects with COPD treated with tiotropium significantly improves lung function, quality of life and COPD exacerbations without increasing the risk of adverse events." | ( Li, M; Liu, Y; Mi, L; Shi, H; Sun, X; Yang, K; Zhang, D; Zhang, Y, 2014) |
| "Theophylline is often used to treat chronic obstructive pulmonary disease (COPD)." | ( Donnachie, E; Fexer, J; Hofmann, F; Keller, M; Mehring, M; Schneider, A; Wagenpfeil, S, 2014) |
| "With active treatments, COPD exacerbations were fewer (13-15% of patients reporting ≥1 exacerbation) and on average less rescue medication was required (1." | ( Brooks, J; Church, A; Donohue, JF; Niewoehner, D; O'Dell, D, 2014) |
| "Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease characterized by airflow limitation that is not fully reversible." | ( Malerba, M; Morjaria, JB; Radaeli, A, 2014) |
| "Data from 11,404 patients with chronic obstructive pulmonary disease (COPD) were pooled from 14 clinical studies of QVA149, indacaterol and glycopyrronium of ≥3 month's duration with at least two of the treatment groups: QVA149 110/50 μg, glycopyrronium 50 μg, indacaterol 150 μg, placebo or tiotropium 18 μg." | ( Banerji, D; Buhl, R; Chen, H; D'Andrea, P; Dahl, R; Fogel, R; Schubert-Tennigkeit, A; Wedzicha, JA, 2014) |
| "In stable COPD with neutrophilic bronchitis, add-on azithromycin therapy showed a trend to reduced severe exacerbations sputum neutrophils, CXCL8 levels and bacterial load." | ( Baines, KJ; Coxson, HO; Gibson, PG; Hansbro, PM; Milne, D; Powell, H; Simpson, JL, 2014) |
| "In patients with severe COPD receiving tiotropium plus salmeterol, the risk of moderate or severe exacerbations was similar among those who discontinued inhaled glucocorticoids and those who continued glucocorticoid therapy." | ( Calverley, PM; Chanez, P; Dahl, R; Decramer, M; Disse, B; Finnigan, H; Kirsten, A; Magnussen, H; Rodriguez-Roisin, R; Tetzlaff, K; Towse, L; Watz, H; Wouters, EF, 2014) |
| "Patients with the most severe COPD may be more refractory to treatment." | ( Crater, GD; Dransfield, MT; Emmett, A; Ferro, TJ; Morris, AN; Ohar, JA; Raphiou, I; Sriram, PS, 2014) |
| "In addition to the treatment for COPD, interventional group also received sertraline hydrochloride tablets 50 mg/day for 6 weeks, while the control group received placebo." | ( He, Y; Wan, Y; Wang, Z; Xu, C; Yang, H; Zheng, D; Zheng, Y; Zhou, L; Zhu, J, 2016) |
| "Chronic obstructive pulmonary disease (COPD) is a serious, yet preventable and treatable, disease." | ( Koblizek, V; Kocianova, J; Kocova, E; Kolek, V; Novotna, B; Pecen, L; Plutinsky, M; Pracharova, S; Tichopad, A; Zatloukal, J, 2014) |
| "We recruited 79 patients with COPD already treated with tiotropium or indacaterol." | ( Inui, N; Kono, M; Matsushima, S; Nakamura, Y; Shirai, T; Suda, T; Toyoshima, M; Yasui, H, 2015) |
| "Prospective registry that included COPD patients who were prescribed roflumilast added to triple therapy." | ( Diez-Ferrer, M; Dorca, J; Huertas, D; López-Sánchez, M; Manresa, F; Montón, C; Muñoz-Esquerre, M; Pomares, X; Santos, S, 2015) |
| "Twenty subjects with severe COPD were randomized into two groups: no treatment (Control, n = 10, 63." | ( Guan, WJ; Jiang, M; Li, RF; Liu, J; Luo, JY; Luo, YM; Ou, YM; Qin, YY; Wu, GF; Yu, XX; Zhong, NS; Zhou, CZ; Zhu, Z, 2015) |
| "Forty-five patients with severe chronic obstructive pulmonary disease were randomized into three groups for an intervention of 12 weeks: exercise training alone, ventilation alone and combined treatment." | ( Azcona, BV; Cortés, EB; López-Campos, JL; Márquez-Martín, E; Ramos, PC; Ruiz, FO, 2014) |
| "Time to the next COPD exacerbation did not differ in one large study that was powered to detect non-inferiority and compared five days versus 14 days of systemic corticosteroid treatment (n = 311; hazard ratio 0." | ( Tan, DJ; Walters, JA; White, CJ; Wood-Baker, R, 2014) |
| "In stable COPD patients without the standard indications for statin therapy, rosuvastatin treatment is associated with a significant attenuation of systemic inflammation and improvement in endothelial-dependent vascular function in patients with evidence of systemic inflammation." | ( Einvik, G; Hagve, TA; Høiseth, AD; Lehmann, S; Neukamm, A; Omland, T; Søyseth, V, 2015) |
| "In the Glycopyrronium bromide in chronic Obstructive pulmonary disease airWays trials, treatment with inhaled glycopyrronium bromide at 50 μg once daily achieved a significantly better lung function than placebo, as measured by the trough forced expiratory volume in 1 s in patients with moderate-to-severe COPD." | ( Incorvaia, C; Riario-Sforza, E; Riario-Sforza, GG; Ridolo, E, 2015) |
| "A total of 137 COPD patients were classified as responders or nonresponders according to FEV1 improvement after 3 months of LABA/ICS treatment in fourteen referral hospitals in Korea." | ( Kim, TH; Kim, WJ; Lee, J; Lee, JH; Lee, JS; Lee, SD; Lee, SW; Lim, SY; Oh, YM; Park, TS; Rhee, CK; Yoo, KH; Yoon, HI, 2015) |
| "Acute exacerbations of COPD (AE-COPD) often result in administration of antibiotics although more than half of exacerbations are associated with detection of respiratory viruses and potentially pathogenic bacteria can only be detected in 20-30% of cases." | ( Koch, A; Rohde, GG; Welte, T, 2015) |
| "We therefore compared the risk of COPD exacerbation in older patients with COPD commencing treatment with either valproic acid or phenytoin, an anticonvulsant that does not affect HDAC." | ( Antoniou, T; Camacho, X; Gomes, T; Juurlink, DN; Mamdani, MM; Yao, Z, 2015) |
| "Among older patients with COPD, treatment with valproic acid does not increase the risk of adverse pulmonary outcomes relative to phenytoin." | ( Antoniou, T; Camacho, X; Gomes, T; Juurlink, DN; Mamdani, MM; Yao, Z, 2015) |
| "The international guidelines on chronic obstructive pulmonary disease (COPD) recommend inhaled bronchodilators for maintenance treatment of the disease." | ( Baroni, M; Incorvaia, C; Montagni, M; Riario-Sforza, GG; Ridolo, E, 2015) |
| "In the model of chronic obstructive pulmonary disease, produced in rats by 60-day exposure to nitrogen dioxide, the effect of different options of combination therapy (corticosteroids, anticholinergics, adrenergic agonists) on the functional state of the bronchi was studied." | ( Fedin, AN; Kuzubova, NA; Lebedeva, ES; Platonova, IS, 2014) |
| "suPAR can be used as a predictor of AE-COPD and in monitoring response to treatment." | ( Altintas, N; Cinarka, H; Gumus, A; Hazıroglu, M; Karatas, M; Kirbas, A; Sahin, U, 2015) |
| "Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous disorders encompassing different phenotypes of airflow obstruction, which might differ in their response to treatment." | ( Beasley, R; Bowles, D; Charles, T; Fingleton, J; Shirtcliffe, P; Strik, R; Travers, J; Weatherall, M; Williams, M, 2015) |
| "The subjects were stable and untreated COPD outpatients with a percent predicted forced expiratory volume in 1 second (%FEV1) below 80%." | ( Futami, S; Koba, T; Komuta, K; Minami, S; Nishijima, Y; Ogata, Y; Yamamoto, S, 2015) |
| "Acute exacerbations of chronic obstructive pulmonary disease (COPD) are often treated with antibiotics." | ( Brusse-Keizer, M; Hendrix, R; Movig, K; Nijdam, L; van der Palen, J; van der Zanden, RW; VanderValk, P, 2015) |
| "Olodaterol 5 μg QD is efficacious in COPD, with a superior bronchodilatory profile compared to 2 μg BID, which is close to the same total daily dose, and a similar degree of bronchodilation over 24 h compared with double the daily dose (administered as 10 μg QD or 5 μg BID)." | ( Aalbers, R; Aumann, JL; Coeck, C; Hamilton, AL; Joos, GF; Korducki, L; Kunz, C, 2015) |
| "Moreover, the rate of CHF and/or COPD exacerbation was higher in patients treated with carvedilol compared with bisoprolol (log-rank P=0." | ( Asai, K; Furuse, E; Kubota, Y; Murai, K; Nakamura, S; Shimizu, W; Tsukada, YT, 2015) |
| "In patients with chronic obstructive pulmonary disease stage I GOLD we revealed a significant reduction of acute respiratory infections frequency after pulmonary rehabilitation using salt aerosol therapy; however, in patients with chronic obstructive pulmonary disease stage II GOLD such a reduction we have not seen." | ( Blaha, OS; Pudakova, SO; Tovt, VA; Tovt-Korshyns'ka, MI, 2014) |
| "A total of 795 COPD patients (56% male; median age: 64 years) were enrolled and treated." | ( Marth, K; Pohl, W; Schuller, E, 2015) |
| "The course of chronic obstructive pulmonary disease (COPD) is often complicated by episodes of acute worsening of respiratory symptoms, which may lead to escalation of therapy and occasionally emergency department visits and hospitalization." | ( Chow, L; Hanania, NA; Parulekar, AD, 2015) |
| "405 patients with COPD were randomised and assigned to treatment." | ( Beck, E; Fogarty, C; Hamilton, AL; Koker, P; Korducki, L; Maleki-Yazdi, MR, 2015) |
| "The clinical profile of COPD patients treated in the tiotropium trial program appears to be largely in the range of clinical characteristics, including cardiovascular comorbidities, reported for "real-life patients." | ( Celli, B; Metzdorf, N; Miravitlles, M; Price, D; Rabe, KF; Schmidt, H, 2015) |
| "Total WBC and IL-8 in all treated COPD groups, thiol group, eosinophils and neutrophils counts in treated groups with dexamethasone and two higher concentrations of the Z." | ( Boskabady, MH; Gholami Mahtaj, L, 2015) |
| "Patients with late-stage chronic obstructive pulmonary disease (COPD) are prone to CO2 retention, a condition which has been often attributed to increased ventilation-perfusion mismatch particularly during oxygen therapy." | ( Poon, CS; Song, G; Tin, C, 2015) |
| "In non-exacerbation chronic obstructive pulmonary disease (COPD) with mild lung function impairment, single bronchodilator therapy might be as effective as combined inhaled corticosteroid/bronchodilator therapy, whereas the risk of pneumonia associated with the latter would be practically absent." | ( Antoniu, SA; Boisteanu, D; Mihaltan, F; Ruxandra, U, 2015) |
| "In conclusion, among patients with COPD at high risk for lactate accumulation, metformin therapy was associated with a minor elevation of lactate concentration of doubtful clinical significance." | ( Archer, JR; Baker, EH; Hitchings, AW; Srivastava, SA, 2015) |
| "This study aims to improve COPD treatment by creating a low-dose pressurized metered dose inhaler (pMDI) inhalable formulation of TP." | ( Goud, M; Haghi, M; Traini, D; Young, PM; Zhu, B, 2015) |
| "In patients with exacerbations of chronic obstructive pulmonary disease (COPD) requiring hospitalisation, 5 days of corticosteroid therapy appears to be as effective as 14 days of corticosteroid therapy for preventing recurrences." | ( , 2014) |
| "Although useful for classical COPD, NIV has not been validated specifically as a treatment option for mustard airway disease." | ( Aliannejad, R; Ghanei, M; Peyman, M, 2015) |
| "NAC treatment in COPD patients with extremely slow/slow EPHX1 enzyme activity improves FEV1 and the SGRQ symptom score, especially in those with mild-to-moderate COPD, and polymorphism in the EPHX1 gene may have a significant role in differential responses to treatment with NAC in patients with COPD." | ( Dai, LM; Fang, LZ; Feng, JG; Fu, WP; Liu, H; Liu, L; Shu, JK; Zhang, JQ; Zhao, ZH, 2015) |
| "Seventy patients of COPD and CCP with acute exacerbation were randomly and equally divided into control group and treatment group." | ( Feng, EZ; Huang, NX; Tian, ZX; Yang, SY; Yin, H; Zhang, Y, 2014) |
| "Based on the moxifloxacin in AECOPDs (acute exacerbations of chronic obstructive pulmonary disease) trial (MAESTRAL) database, this study evaluated pretherapy demographic, clinical, sputum bacteriological factors using multivariate logistic regression analysis, with internal validation by bootstrap replicates, to investigate their possible association with clinical failure at end of therapy (EOT) and 8 weeks posttherapy." | ( Anzueto, A; Arvis, P; Haverstock, D; Miravitlles, M; Sethi, S; Trajanovic, M; Wilson, R, 2015) |
| "The current Global initiative for chronic Obstructive Lung Disease (GOLD) treatment strategy recommends the use of one or more bronchodilators according to the patient's airflow limitation, their history of exacerbations, and symptoms." | ( Banerji, D; Humphries, M; Patalano, F; Thach, C; Wang, C; Wang, L; Zhang, N; Zhong, N; Zhou, X, 2015) |
| "A new approach to the treatment of COPD includes controlling inflammation because of its important role in exacerbation of the disease." | ( Domvri, K; Hatzizisi, O; Kikidaki, V; Kioumis, I; Lampaki, S; Liaka, A; Organtzis, J; Papaioannou, A; Petridis, D; Porpodis, K; Tsirgogianni, K; Zarogoulidis, K; Zarogoulidis, P, 2015) |
| "Patients with stable slight to moderate COPD were randomized into trial group (n=109) with tiotropium 18 pg Qd or control group (n =111) with ipratropium 40 µg Qid for a treatment of four weeks." | ( Cui, SH; Huang, JA; Liu, CT; Luo, Z; Wu, CG; Wu, GM; Xia, QM; Yang, L; Ying, KJ, 2015) |
| "Pulmonary function tests, COPD assessment test (CAT), and multifrequency FOT with MostGraph-01 were performed at the beginning and after 8 weeks of treatment with indacaterol or tiotropium." | ( Enomoto, N; Fujisawa, T; Inui, N; Kato, S; Kono, M; Matsushima, S; Nakamura, Y; Suda, T; Toyoshima, M; Yasui, H, 2015) |
| "Sixty AECOPD patients with BSS were randomly assigned to the treated group and the control group, 30 in each group." | ( Chen, Y; Ji, HY; Li, CY; Ren, W; Wang, S; Zhou, Q; Zhu, CD, 2015) |
| "A total of 328 patients with COPD were randomized to receive treatment." | ( Fukuchi, Y; Hamilton, AL; Ichinose, M; Izumoto, T; Kunz, C; Tadayasu, Y; Takizawa, A, 2015) |
| "A previously published COPD Markov model accounting for disease progression and treatment discontinuation was used." | ( Asukai, Y; Costa-Scharplatz, M; Goyal, P; Gruenberger, JB; Price, D; Ställberg, B, 2015) |
| "Patients with chronic obstructive pulmonary disease (COPD), ≥ 40 years old, with exacerbation in the previous 3 years are randomised 1:1 to once-daily fluticasone furoate 100 μg/vilanterol 25 μg in a novel dry-powder inhaler versus continuing their existing therapy." | ( Bakerly, ND; Gibson, JM; Leather, D; New, JP; Vestbo, J; Woodcock, A; Wu, W, 2015) |
| "Triple therapy also reduced the COPD exacerbation rate by 40." | ( Itoh, Y; Kiatboonsri, S; Lee, SD; Ling, X; Xie, CM; Yu, WC; Yunus, F, 2016) |
| "Although pharmacological treatment of COPD exacerbation (COPDE) includes antibiotics and systemic steroids, a proportion of patients show worsening of symptoms during hospitalization that characterize treatment failure." | ( Crisafulli, E; Fernández, L; Gabarrús, A; Gimeno, A; Guerrero, M; Huerta, A; Martinez, R; Menéndez, R; Soler, N; Torres, A; Wedzicha, JA, 2016) |
| "A total of 202 patients with AECOPD requiring antibiotic therapy were enrolled." | ( Hong, X; Lai, G; Lin, Q; Lin, T; Liu, K; Liu, S, 2015) |
| "On the model of chronic obstructive pulmonary disease, the effect of therapy with low-molecular-weight peptides on restructuring and functional activity of bronchial epithelium for restoring the immune and barrier function of the lungs and prevention of inflammatory process progression was studied." | ( Dvorakovskaya, IV; Kuzubova, NA; Lebedeva, ES; Platonova, IS; Surkova, EA; Titova, ON, 2015) |
| "A recent meta-analysis of trials on COPD revealed that treatment with roflumilast was associated with a significant reduction in the rate of major cardiovascular events." | ( Amore, C; Beume, R; Dell'Elba, G; Di Santo, A; Evangelista, V; Martelli, N; Piccoli, A; Tenor, H; Totani, L, 2016) |
| "Across treatments, clinical COPD questionnaire overall score improved from baseline by 0." | ( Basu Patnaik, S; De Guia, T; El-Sorougi, W; Juvelekian, G; Kuo, HP; Pilipovic, V; Pothirat, C; Yunus, F, 2015) |
| "10 patients (9/10 with chronic airflow obstruction) undergoing supervised injectable opioid treatment for heroin addiction received their usual prescribed dose of injectable opioid (diamorphine or methadone) (IOT), and their usual prescribed dose of oral opioid (methadone or sustained release oral morphine) after 30 minutes." | ( Bell, J; Jolley, CJ; Moxham, J; Rafferty, GF; Strang, J, 2015) |
| "In a COPD population who would otherwise potentially be candidates for long-term daily azithromycin therapy, over 80 % had risk factors for complications from long-term daily azithromycin." | ( Butler, MW; Franciosi, A; Landers, S; Nicholson, TT, 2016) |
| "Pharmacologic treatment of chronic obstructive pulmonary disease has consistent beneficial and plausible effects on cardiac function and pulmonary vasculature that may contribute to favorable effects of inhaled therapies." | ( Barnes, NC; Boubertakh, R; Follows, R; James, WY; John, L; Midwinter, D; Petersen, SE; Stone, IS, 2016) |
| "Results of an NMA of COPD treatments suggest that SFC and indacaterol may reduce mortality." | ( Calverley, P; Celli, BR; Chambers, M; Clark, JF; Hawkins, N; Scott, DA; Thompson, JC; Woods, B, 2015) |
| "Serum YKL-40 levels of COPD patients were significantly higher than sputum YKL-40 levels but were not significantly changed by ICS treatment." | ( Hiemstra, PS; Kerstjens, HA; Kunz, LI; Postma, DS; Sterk, PJ; van Schadewijk, A; van't Wout, EF, 2015) |
| "Patients with exacerbations of COPD receiving controlled oxygen therapy were more likely to achieve SpO2 within the COPD-X guideline target range without being more likely to be hypoxic." | ( Chow, JW; Katechia, K; Kelly, AM; Khullar, K; Klim, S, 2016) |
| "Airway inflammation in chronic obstructive pulmonary disease (COPD) is refractory to corticosteroids and hence COPD treatment is hindered and insufficient." | ( Abdel Kawy, HS, 2016) |
| "To mimic oxidative stress-induced COPD, mice were exposed to ozone for six-weeks and treated with ISO-1, a MIF inhibitor, and/or dexamethasone before each exposure." | ( Adcock, IM; Barnes, PJ; Chung, KF; Clarke, CJ; Durham, AL; Footitt, J; Hall, SR; Hansbro, PM; Johnston, SL; Mallia, P; Russell, KE; Simpson, KD; Starkey, MR; Wiegman, CH, 2016) |
| "Patients with moderate to severe COPD already taking ICS/LABA were randomized to receive add-on therapy in cross-over fashion with either TIO 18 µg od or ACL 322 µg bid for 2-3 weeks each." | ( Lipworth, BJ; Manoharan, A; Morrison, AE, 2016) |
| "It is possible that a subgroup of COPD patients with cardiovascular indications for statins and/or systemic inflammation may obtain clinical benefit from statin treatment." | ( Thomson, NC, 2017) |
| "Chronic obstructive pulmonary disease (COPD), a preventable and treatable disease, has been described as '10% medication and 90% education'." | ( Mallikarjuna Rao, C; Manu, MK; Suhaj, A; Unnikrishnan, MK; Vijayanarayana, K, 2016) |
| "Eleven AECOPD patients, with hypercapnic respiratory failure and MA following NIV, were treated with ACET 500 mg for two consecutive days and compared to a matched control group." | ( Alessandrini, G; Bonini, M; Borgognoni, L; Ferrazza, AM; Fontana, V; Internullo, M; Marinelli, P; Palange, P; Santinelli, S; Sardo, L, 2016) |
| "Nine patients suffered from chronic obstructive pulmonary disease (COPD) before treatment, and 18 patients had a smoking history (median pack years: 48)." | ( Bremer, M; Christiansen, H; Dickgreber, N; Henkenberens, C; Janssen, S; Lavae-Mokhtari, M; Leni, K; Meyer, A, 2016) |
| "A total of 382 patients with COPD who were expected to receive mechanical ventilation for more 24 hours were randomized to the acetazolamide or placebo group and 380 were included in an intention-to treat analysis." | ( Bornstain, C; Clavel, M; Djibre, M; Duguet, A; Esvan, M; Faisy, C; Gacouin, A; Gibot, S; Heming, N; Katsahian, S; Lerolle, N; Meziani, F; Planquette, B; Rabbat, A; Ricard, JD; Ricome, JL; Sanchez, O; Schneider, F; Urien, S, 2016) |
| "Many new maintenance treatments for COPD have been approved since 2010." | ( Borrego, ME; Kharat, AA; Mapel, DW; Marshik, PL; Roberts, MH, 2016) |
| "These findings suggest that COPD subgroups classified by D(L)CO and IC show several clinical characteristics and may be helpful to predict responses to treatment." | ( Kang, X; Li, M; Lyu, J; Sun, B; Wang, X; Zhou, L, 2015) |
| "2113 COPD subjects were categorized into four medication use patterns: triple therapy with tiotropium (TIO) plus long-acting beta-agonist/inhaled-corticosteroid (ICS ± LABA), tiotropium alone, ICS ± LABA, and short-acting bronchodilators." | ( Bowler, RP; Busch, R; Dransfield, MT; Han, MK; Hersh, CP; Regan, EA; Wells, JM, 2016) |
| "Given that COPD represents such a complex and heterogeneous disease, attempts are being made to identify clinical phenotypes with clear therapeutic implications, in order to optimize the pharmacological treatment of COPD and avoid the indiscriminate use of ICS." | ( Iannella, H; Luna, C; Waterer, G, 2016) |
| "Patients with COPD show a significant reduction of the lobar hyperinflation at the functional residual capacity level in the patients who improved >120 mL in forced expiratory volume in 1 second (FEV1) after 6 months of treatment with roflumilast in addition to inhaled corticosteroids (ICSs)/long-acting beta-2 agonists (LABAs)/long-acting muscarinic antagonists (LAMAs)." | ( Bedert, L; Claes, R; De Backer, J; De Backer, W; Hajian, B; Hufkens, A; Parizel, PM; Van Holsbeke, C; Vinchurkar, S; Vos, W, 2016) |
| "In the COPD assessment test, subjective symptoms also significantly improved in patients with COPD during the LYS treatment period (improvement rates-LYS vs." | ( Arai, T; Fukuchi, Y; Ohbayashi, H; Sakata, Y; Setoguchi, Y; Shibata, K, 2016) |
| "Patients with COPD using long-term oxygen therapy (LTOT) over 15 h per day have improved outcomes." | ( Anstey, CM; Corley, A; Dunster, KR; Fraser, JF; Spooner, AJ, 2016) |
| "The incidence of AEs and COPD exacerbations, and changes in vital signs were similar for the two treatments." | ( Fahy, WA; Galkin, D; Kalberg, C; Newlands, A; O'Dell, D, 2016) |
| "Patients with COPD in groups C and D in the stable phase were stratified into a group with neither gastroesophageal reflux nor lansoprazole therapy (group A) and a group subjected to oral lansoprazole therapy (group B1 ) and a group not subjected to oral lansoprazole therapy (group B2 )." | ( Ding, W; Liu, JM; Xiong, W; Zhang, QS; Zhao, W; Zhao, YF, 2016) |
| "Currently the treatment of chronic obstructive pulmonary disease (COPD) has limited effectiveness and there is a need to develop new drugs." | ( Malerba, M; Montuschi, P; Morjaria, JB; Radaeli, A, 2016) |
| "We administered BYF to COPD rats from week 9 to 20, and found that BYF could prevent COPD by inhibiting the inflammatory cytokines expression, protease-antiprotease imbalance and collagen deposition on week 32." | ( Li, J; Li, S; Li, Y; Tian, Y; Yang, L; Zhao, P, 2016) |
| "Chronic obstructive pulmonary disease (COPD) is a debilitating, inflammatory lung disease without effective treatment." | ( Ahn, KS; Joo, M; Kim, KH; Oh, SR; Sadikot, RT; Song, HH, 2016) |
| "Unlike control mice, the lungs of the COPD mice expressed LC3-II, a biomarker for autophagy formation, which was decreased by EEAO treatment." | ( Ahn, KS; Joo, M; Kim, KH; Oh, SR; Sadikot, RT; Song, HH, 2016) |
| "A total of 260 Korean COPD patients were recruited, of which 207 were randomized to roflumilast (n=102) or placebo (n=105) treatment." | ( Hong, YK; Lee, JS; Lee, SD; Lee, SW; Oh, YM; Park, TS, 2016) |
| "In patients with moderate COPD and heightened cardiovascular risk, treatment with fluticasone furoate and vilanterol did not affect mortality or cardiovascular outcomes, reduced exacerbations, and was well tolerated." | ( Anderson, JA; Brook, RD; Calverley, PM; Celli, BR; Crim, C; Martinez, F; Newby, DE; Vestbo, J; Yates, J, 2016) |
| "Current COPD therapy involving anticholinergics, β2-adrenoceptor agonists and/or corticosteroids, do not specifically target oxidative stress, nor do they reduce chronic pulmonary inflammation and disease progression in all patients." | ( Bos, IS; Graaf, AC; Halayko, AJ; Han, B; Henning, RH; Krenning, G; Maarsingh, H; Meurs, H; Poppinga, WJ; Schmidt, M; Smit, M; Stienstra, S; van Vliet, B; Vogelaar, P; Zuidhof, AB; Zuo, H, 2016) |
| "Patients with chronic obstructive pulmonary disease, who had at least moderate airflow obstruction and were taking part in PR, were randomized to either 10 weeks of therapy with an ACE inhibitor (10 mg enalapril) or placebo." | ( Curtis, KJ; Haji, GS; Hopkinson, NS; Li, K; Man, WD; Mehta, B; Meyrick, VM; Montgomery, H; Polkey, MI, 2016) |
| "3255 patients with COPD (intent-to-treat populations) with a history of exacerbations in the past year." | ( DiSantostefano, RL; Hinds, DR; Le, HV; Pascoe, S, 2016) |
| "Mean annual COPD exacerbation rate to identify clusters of patients who benefit from adding an ICS (FF) to VI bronchodilator therapy." | ( DiSantostefano, RL; Hinds, DR; Le, HV; Pascoe, S, 2016) |
| "In the treatment of chronic obstructive pulmonary disease (COPD), bronchodilators such as long acting muscarinic antagonist (LAMA) and long acting β agonist(LABA) play key roles for improving respiratory function and symptoms, and reducing risk of exacerbation." | ( Shibata, Y, 2016) |
| "We recruited 24 patients with COPD and performed FENO analysis at multiple expiratory flows before and after treatment with inhaled β2-agonist bronchodilator therapy." | ( Amer, M; Brockway, B; Cowan, J; Dummer, J; Gray, A, 2016) |
| "Primary bronchial epithelial cells from COPD donors and healthy individuals were treated continuously with azithromycin starting 24 h before infection with rhinovirus RV16." | ( Akbarshahi, H; Bjermer, L; Menzel, M; Uller, L, 2016) |
| "In patients with moderate to severe COPD, IND/GLY is likely to be a cost-effective treatment alternative compared with SFC." | ( Carrasco, J; Chehab, S; Gruenberger, JB; Keininger, DL; Molimard, M; Pitotti, C; Price, D; Reza Maleki-Yazdi, M; Sauvage, E, 2016) |
| "Treatment of cultured COPD myotubes with the pro-oxidant molecule H2O2 resulted in increased ROS production (P = 0." | ( Blaquière, M; Gouzi, F; Hayot, M; Maury, J; Mercier, J; Pomiès, P, 2016) |
| "Compared to COPD rats, serum SOD was higher in all treatment groups (P<0." | ( Dong, YQ; Feng, SX; Li, JS; Li, LL; Li, Y; Luo, S; Mao, J; Tian, YG; Wang, LL; Wang, MH, 2016) |
| "To evolve toward precision medicine in COPD, the most appropriate biomarkers and clinical characteristics that reliably predict treatment responses need to be identified." | ( Agusti, A; Halpin, D; Martinez, FJ; Roche, N; Singh, D; Wedzicha, JA, 2016) |
| "In patients with COPD and a history of exacerbations, a once-daily treatment regimen of combined fluticasone furoate and vilanterol was associated with a lower rate of exacerbations than usual care, without a greater risk of serious adverse events." | ( Collier, S; Crawford, J; Diar Bakerly, N; Frith, L; Gibson, JM; Harvey, C; Leather, D; McCorkindale, S; New, J; Svedsater, H; Vestbo, J; Woodcock, A, 2016) |
| "The rat COPD model was established by cigarette smoke exposure combined with intratracheal administration of lipopolysaccharide." | ( Cai, Y; Chen, M; Li, Y; Shan, H; Tang, J; Xie, Y; Yan, R; Yang, X; Yin, J; Zhang, J; Zhang, M; Zhang, Q, 2016) |
| "Among patients with COPD, treatment with a fixed combination of budesonide/formoterol was associated with fewer exacerbations and a lower, but not significant, cost of illness than the treatment with fluticasone/salmeterol." | ( Buda, S; Degli Esposti, L; Perrone, V; Sangiorgi, D, 2016) |
| "Evaluation of CV safety for COPD treatments is important because many patients with COPD have underlying CV comorbidities." | ( Kardos, P; Müllerová, H; Newby, DE; Román-Rodríguez, M; Singh, D; Worsley, S, 2016) |
| "Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are generally treated with optimization of bronchodilation therapy and a course of oral corticosteroids, mostly without antibiotics." | ( Bathoorn, E; Friedrich, AW; Groenhof, F; Hendrix, R; Kerstjens, HA; Kocks, JW; Sinha, B; van der Molen, T, 2017) |
| "Trials of maintenance chronic obstructive pulmonary disease treatments focus on improvement in lung function and reductions in exacerbations, while patients are much more concerned about symptoms and health status." | ( Bennett, N; Buhl, R; Clerisme-Beaty, E; Ferguson, GT; Grönke, L; Karpel, J; Voß, F, 2017) |
| "Acute exacerbations of chronic obstructive pulmonary disease (COPD) can be prevented by inhaled treatment." | ( Balestra, A; Chartier, A; Droz-Perroteau, C; Girodet, PO; Lamarque, S; Lassalle, R; Lignot, S; Molimard, M; Moore, N; Raherison, C, 2017) |
| "A total of 204 clinically stable COPD patients were recruited and administered to inhaled fluticasone propionate/salmeterol combination (500/50 ug, twice daily) for 24 weeks." | ( Chen, J; Gao, Y; Lei, Y; Li, M; Ning, Q; Wu, X; Xie, J; Xiong, W; Xu, Y; Zhao, J, 2017) |
| "Unlike many other COPD studies, the 4-year UPLIFT trial permitted inhaled corticosteroid (ICS) use during run-in and treatment phases." | ( Morice, AH; Morjaria, JB; Rigby, A, 2017) |
| "Among patients with MA and COPD or OHS, early treatment with ACTZ did not shorten significantly the duration of MV compared with placebo." | ( Heras la Calle, G; Martín Delgado, MC; Mas Serra, A; Morán Chorro, I; Raurich Puigdevall, JM; Rialp Cervera, G; Vallverdú Perapoch, I, 2017) |
| "Participating COPD modeling groups simulated the outcomes for the placebo-treated groups of the TORCH and UPLIFT trials using baseline characteristics of the trial populations as input." | ( Asukai, Y; Briggs, AH; Feenstra, TL; Hansen, RN; Hoogendoorn, M; Leidl, R; Risebrough, N; Rutten-van Mölken, MP; Samyshkin, Y; Wacker, M, 2017) |
| "Although most of the participating COPD cost-effectiveness models reported higher total exacerbation rates than observed in the trials, estimates of the absolute treatment effect and cost-effectiveness ratios do not seem different from the trials in most models." | ( Asukai, Y; Briggs, AH; Feenstra, TL; Hansen, RN; Hoogendoorn, M; Leidl, R; Risebrough, N; Rutten-van Mölken, MP; Samyshkin, Y; Wacker, M, 2017) |
| "Chronic Obstructive Pulmonary Disease (COPD) is a chronic airway disease that can be prevented and treated." | ( Cataldo, D, 2016) |
| "In patients with COPD with moderate airflow limitation and heightened CVD risk, treatment with inhaled VI, FF or their combination has an excellent safety profile and does not impact CVD outcomes." | ( Anderson, JA; Brook, RD; Calverley, PM; Celli, BR; Crim, C; Denvir, MA; Magder, S; Martinez, FJ; Newby, DE; Rajagopalan, S; Vestbo, J; Yates, J, 2017) |
| "We identified patients with COPD who received a prescription of nicotine replacement therapy (NRT; N=10 426; reference group), bupropion (N=350) or varenicline (N=3574) in the period between January 2007 and June 2012." | ( Kotz, D; Sheikh, A; Simpson, CR; van Schayck, OCP; Viechtbauer, W; West, R, 2017) |
| "In patients with mild-to-severe COPD receiving treatment for an exacerbation in an outpatient setting, the antibiotic doxycycline added to the oral corticosteroid prednisolone did not prolong time to next exacerbation compared with prednisolone alone." | ( Baars, JJ; Bresser, P; Brinkman, P; Dagelet, JWF; Daniels, JMA; Groeneveld-Tjiong, DRGL; Jonkers, RE; Krouwels, FH; Pool, K; Prins, JM; Rudolphus, A; Sterk, PJ; Ter Riet, G; van den Berg, BTJ; van den Berg, JWK; van Kan, C; van Velzen, P, 2017) |
| "When discontinuation in COPD randomized controlled trials (RCTs) is unevenly distributed between treatments (differential dropout), the capacity to demonstrate treatment effects may be reduced." | ( Anzueto, AR; Calverley, PM; Eriksson, G; Fagerås, M; Jenkins, CR; Lindberg, M; Make, BJ; Postma, DS, 2017) |
| "Chronic obstructive pulmonary disease (COPD) is a common preventable and treatable chronic respiratory disease, which affects 210 million people globally." | ( Bhattacharya, P; Bhome, A; Brashier, B; Mehendale, SM; Pattabi, K; Rajkumar, P; Vadivoo, S, 2017) |
| "The Indacaterol effectiveness in COPD patients with Tuberculosis history (INFINITY) study assessed the efficacy and safety of once-daily inhaled indacaterol 150 µg for the treatment of Korean COPD patients with destroyed lung by TB and moderate-to-severe airflow limitation." | ( Jung, KS; Kim, CJ; Kim, S; Kim, YS; Lee, YC; Lim, SY; Oh, YM; Park, JW; Park, MJ; Shim, JJ; Yoo, CG; Yoo, KH; Yoon, HK, 2017) |
| "Of 314 patients with AECOPD randomised to 5 or 14 days of prednisone treatment, 311 were included in the analysis." | ( Engel, B; Leuppi, JD; Rutishauser, J; Schindler, C, 2017) |
| "TCM lung rehabilitation treatment of chronic obstructive pulmonary disease has obvious curative effect, it can improve the function of lung, reduce the occurrence of dyspnea, improve patients' tolerance and have obvious long-term curative effect." | ( Quanqing, M, 2017) |
| "Sprague-Dawley rats were made chronic obstructive pulmonary disease models via tobacco smoke exposure for 12 weeks and the rats were treated with 10 ml/kg hydrogen-rich saline intraperitoneally during the last 4 weeks." | ( Geng, W; Jiang, C; Li, C; Liu, Y; Liu, Z; Qin, S; Si, Y; Zhang, X; Zhang, Y; Zhao, S, 2017) |
| "Patients with moderate-to-very severe chronic obstructive pulmonary disease received 4 weeks' treatment with each of GFF MDI, placebo MDI, and open-label tiotropium (PT003011 only)." | ( Arora, S; Delacruz, L; Fakih, F; Feldman, G; Gottschlich, G; Koser, A; Krainson, J; Maes, A; Martin, U; Orevillo, C; Pudi, K; Reisner, C; Siddiqui, S; St Rose, E, 2017) |
| "Subjects represented the general COPD population with real-world characteristics including severe disease, presence of comorbidities, and receiving background COPD therapy." | ( Ferguson, GT; Goodin, T; Kerwin, E; Tosiello, R; Wheeler, A, 2017) |
| "Thirty six patients with COPD and infection with PA treated with nebulized colistin attending a day hospital during a 5-year (January 2010-December 2014) period were prospectively included." | ( Bruguera-Avila, N; Garcia-Olive, I; Gil, M; Marin, A; Prat, C; Radua, J; Ruiz-Manzano, J, 2017) |
| "A novel therapy for COPD involving the use of aerosolized hyaluronan (HA) was tested on a small cohort of COPD patients to determine both its safety and efficacy in reducing levels of desmosine and isodesmosine (DID), biomarkers for elastin degradation." | ( Cantor, J; Ma, S; Turino, G, 2017) |
| "Patients in the COPD treatment group received what was termed "lung-protective treatment" including ambroxol, budesonide and ipratropium bromide in addition to chest physiotherapy." | ( Chi, M; Fan, Y; Li, X; Lin, X; Sun, D; Wang, X; Zhang, X, 2017) |
| "Their coexistence implies that many COPD patients require anticoagulation therapy." | ( Franssen, FME; Janssen, R; Janssens, W; Piscaer, I; Vermeer, C; Wouters, EFM, 2017) |
| "Chronic obstructive pulmonary disease (COPD) is a chronic, progressive and lethal lung disease with few treatments." | ( Guan, R; Li, D; Liang, X; Long, Z; Lu, W; Wang, J; Wang, Z; Xie, J; Xu, J; Yang, Q; Zhao, L, 2018) |
| "Treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) with oxygen-driven nebulisers can result in hypercapnia and acidosis." | ( Bailey, M; Heys, D; Knowles, S; Swain, A; Waugh, A, 2018) |
| "Experimental models of COPD consistently show decreased inflammation and oxidative stress in the lungs after resveratrol treatment." | ( Beijers, RJHCG; Gosker, HR; Schols, AMWJ, 2018) |
| "Comorbidities in COPD have a complex relationship with disease severity, requiring a comprehensive therapy approach." | ( Alter, P; Greulich, T; Janciauskiene, S; Klemmer, A; Koczulla, AR; Lux, W; Vogelmeier, CF; Weist, BJD, 2017) |
| "LDO therapy has been used in COPD patients for more than 50 years." | ( Iyer, VN, 2018) |
| "Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease with variable clinical manifestations, structural changes, and treatment responses." | ( Han, SS; Hong, Y; Kim, S; Kim, WJ; Lee, SJ; Lim, MN, 2017) |
| "Bronchial wall thickening in COPD may be an indicator for predicting the better response to the treatment with bronchodilator and corticosteroid." | ( Dai, LM; Fang, LZ; Fu, WP; Li, JX; Liu, L; Tang, D; Wang, C; Zhang, JQ, 2017) |
| "A total of 51 consecutively recruited COPD patients were followed for 3 months after the initial evaluation and prescribed initial treatment (tiotropium)." | ( Bačun, T; Dumbović Dubravčić, I; Fijačko, M; Fijačko, V; Labor, M; Labor, S; Plavec, D; Popović-Grle, S; Škrinjarić-Cincar, S; Včev, A, 2018) |
| "The results showed the patients with AECOPD with good and poor response to standard corticosteroid treatment have a distinct DNA methylation pattern." | ( Chen, CH; Chuang, TY; Hsu, PW; Lee, SW; Liu, CW; Weng, JT; Wu, LS, 2018) |
| "In patients with COPD treated with formoterol, blood eosinophil count predicts exacerbation risk and the clinical response to ICS." | ( Bafadhel, M; Calverley, PM; De Blas, MA; Fagerås, M; Peterson, S; Rennard, SI; Richter, K, 2018) |
| "Those with severe COPD and increased sputum purulence should be treated with antibiotics, and first-line treatment should be amoxicillin, which is effective against the most common types of bacteria in COPD exacerbation." | ( Lange, P; Nielsen, SK, 2017) |
| "Patients treated in ED for AECOPD commonly arrive by ambulance, have a high admission rate and significant in-hospital mortality." | ( Craig, S; Graham, CA; Holdgate, A; Jones, P; Keijzers, G; Kelly, AM; Klim, S; Kuan, WS; Laribi, S; Lawoko, C, 2018) |
| "Chronic obstructive pulmonary disease (COPD) is a highly prevalent and devastating condition for which no curative treatment is available." | ( Abid, S; Adnot, S; Amsellem, V; Attwe, A; Bernard, D; Boczkowski, J; Breau, M; Derumeaux, G; Houssaini, A; Huang, J; Kebe, K; Lipskaia, L; Lukas, C; Maitre, B; Marcos, E; Meiners, S; Parpaleix, A; Pende, M; Rideau, D; Validire, P; Vienney, N; Vindrieux, D, 2018) |
| "A total of 109 patients with severe COPD treated with CC-A (39 for ≥ 24 months) comprised the LT-CC-A group (35." | ( Bullich, M; Cuevas, O; Gallego, M; Monsó, E; Montón, C; Oliva, JC; Pomares, X, 2018) |
| "In patients with symptomatic COPD, severe or very severe airflow limitation, and an exacerbation history despite maintenance therapy, extrafine BDP/FF/G significantly reduced the rate of moderate-to-severe exacerbations compared with IND/GLY, without increasing the risk of pneumonia." | ( Cohuet, G; Corradi, M; Fabbri, L; Guasconi, A; Montagna, I; Papi, A; Petruzzelli, S; Prunier, H; Roche, N; Scuri, M; Singh, D; Vestbo, J; Vezzoli, S, 2018) |
| "Clinical trials of pharmacotherapy in chronic obstructive pulmonary disease (COPD) often include older persons with moderate-to-severe airflow-obstruction, as defined by the Global Initiative for chronic Obstructive Lung Disease (GOLD)." | ( Fragoso, CAV; Gill, TM; Leo-Summers, LS; Van Ness, PH, 2018) |
| "Subjects who recovered from COPD exacerbation and were discharged without needing home oxygen therapy were defined as the improved group." | ( Abe, Y; Furuyama, K; Igarashi, A; Inoue, S; Kimura, T; Kobayashi, M; Machida, H; Minegishi, Y; Nakano, H; Nishiwaki, M; Sato, K; Sato, M; Shibata, Y; Tokairin, Y; Yamamoto, T; Yamauchi, K; Yang, S, 2018) |
| "Time to the next COPD exacerbation did not differ in one large study that was powered to detect non-inferiority and compared five days versus 14 days of systemic corticosteroid treatment (n = 311; hazard ratio 0." | ( Tan, DJ; Walters, JA; White, CJ; Wood-Baker, R, 2018) |
| "Current pharmacologic therapy of chronic obstructive pulmonary disease (COPD) can reduce respiratory symptoms and exacerbation frequency." | ( Janssen, R; Piscaer, I; Wouters, EF, 2018) |
| "To characterize subjects with chronic obstructive pulmonary disease (COPD) newly initiated on long-acting muscarinic antagonists (LAMA) or dual LAMA/long-acting β2-adrenergic agonist (LABA) therapy." | ( Nagar, S; Patel, J; Stanford, RH, 2018) |
| "In this first look, subjects with COPD initiating LAMA or LAMA+LABA therapy exhibited different clinical and resource use characteristics in the year before treatment." | ( Nagar, S; Patel, J; Stanford, RH, 2018) |
| "Areas covered: An overview of COPD and treatment landscape, focusing on GLY/eFlow CS, reviewing the published literature pertinent to the drug/device combination is reported." | ( Ferguson, GT; Kerwin, E, 2018) |
| "In patients with COPD without frequent exacerbations on long-term triple therapy, the direct de-escalation to indacaterol/glycopyrronium led to a small decrease in lung function, with no difference in exacerbations." | ( Banerji, D; Chapman, KR; Fogel, R; Frent, SM; Goyal, P; Guerin, T; Hurst, JR; Kostikas, K; Larbig, M; Patalano, F; Pfister, P; Wedzicha, JA, 2018) |
| "This study describes the course of AECOPD in these patients at the time of treatment for the symptoms of acute respiratory tract infection (RTI)." | ( Clerisme-Beaty, EM; Franceschina, J; Leidy, NK; Mannino, DM; Ting, N, 2018) |
| "It is possible that COPD history helps explain this patient's more difficult treatment course." | ( Kai, J; Liu, X; Peng, Y; Pi, G; Sun, J; Wang, S; Yan, H; Zhang, P, 2018) |
| "Chronic obstructive pulmonary disease (COPD) is a progressive disease and a composite endpoint could be an indicator of treatment effect on disease worsening." | ( Anzueto, AR; Banerji, D; Fogel, R; Kostikas, K; Larbig, M; Mezzi, K; Patalano, F; Shen, S; Wedzicha, JA, 2018) |
| "Twenty-two cases of patients with COPD were randomly divided into conventional treatmentgroup (group C) and ligustrazine treatment group(group L), 11 persons were randomly selected from healthy subjects without lung disease served as normal control group(group N)." | ( Huang, LJ; Miu, CL; Wang, WT; Wu, CY; Zhang, CC; Zhao, MP; Zheng, MX, 2016) |
| "Autophagy was also assessed in COPD myotubes treated with an antioxidant molecule, ascorbic acid." | ( Ayoub, B; Blaquière, M; Bughin, F; Catteau, M; Gouzi, F; Hayot, M; Maury, J; Mercier, J; Passerieux, E; Pomiès, P, 2018) |
| "Fifty-three stable COPD patients in therapy according to the Global initiative for chronic Obstructive Lung Disease recommendations were enrolled; 49 completed the study." | ( Bianco, A; Calabrese, C; Costigliola, A; Leone, CA; Maffei, M; Merola, E; Perna, F; Simeon, V; Tremante, E, 2018) |
| "The study cohort comprised COPD patients who received treatment between 2004 and 2008, and who were identified from the LHID2005." | ( Chen, HC; Huang, SW; Lin, HW; Lin, LF; Liou, TH, 2018) |
| "Patients with severe COPD are at high risk of experiencing disease exacerbations, which require additional treatment and are associated with elevated mortality and increased risk of future exacerbations." | ( Davies, A; Gibson, D; Kiff, C; Purkayastha, D; Ruiz, S; Varol, N, 2018) |
| "In non-COPD PBECs, combined treatments decreased only TLR2 mRNA expression." | ( Grdić Rajković, M; Heijink, IH; Hulina-Tomašković, A; Jonker, MR; Rumora, L; Somborac-Bačura, A, 2019) |
| "Sixty patients with stable COPD were randomly assigned to two treatment groups (YFN treatment, N = 30; placebo treatment, N = 30)." | ( Chen, H; Hong, C; Hong, M; Huang, J; Huang, X; Ke, G; Li, C; Li, F; Liu, Y, 2018) |
| "In exacerbations of chronic obstructive pulmonary disease, administration of high concentrations of oxygen may cause hypercapnia and increase mortality compared with oxygen titrated, if required, to achieve an oxygen saturation of 88-92%." | ( Bardsley, G; Beasley, R; Berry, J; Fingleton, J; McKinstry, S; Pilcher, J; Shirtcliffe, P; Weatherall, M, 2018) |
| "Among adults with COPD at high risk of exacerbation treated with inhaled corticosteroids, the addition of low-dose theophylline, compared with placebo, did not reduce the number COPD exacerbations over a 1-year period." | ( Barnes, PJ; Briggs, A; Burns, G; Chaudhuri, R; Chrystyn, H; Cotton, S; Davies, L; De Soyza, A; Devereux, G; Fielding, S; Gompertz, S; Haughney, J; Innes, K; Kaniewska, J; Lee, A; McMeekin, N; Morice, A; Norrie, J; Price, D; Sullivan, A; Wilson, A, 2018) |
| "Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide, and long-term oxygen therapy has been shown to reduce mortality in COPD patients with severe hypoxemia." | ( Bailey, W; Beaty, TH; Castaldi, P; Chase, R; Cho, MH; Crapo, JD; Criner, GJ; Dransfield, MT; Fuhlbrigge, AL; Hersh, CP; Parker, M; Qiu, W; Reilly, JJ; Saferali, A; Scholand, MB; Seo, M; Silverman, EK; Yun, JH, 2018) |
| "CONCLUSIONS Dementia in elderly COPD patients was mainly manifested as decreased executive function, attention, language, and delayed recall, while oxygen and donepezil therapy had beneficial effects on the symptoms." | ( Li, H; Mei, L; Wang, D; Wang, M; Wu, S; Zhang, H, 2018) |
| "In patients with mild to severe COPD treated for exacerbations in an outpatient setting, doxycycline added to prednisolone is not cost-effective compared to prednisolone plus placebo over a 2-year period." | ( Bosmans, JE; Finch, AP; Prins, JM; Sterk, PJ; Ter Riet, G; van Velzen, P, 2019) |
| "The burden of chronic obstructive lung disease (COPD) is increasing in women, with recent evidence suggesting gender differences in disease characteristics and potentially in treatment outcomes." | ( Fogel, R; Fucile, S; Goyal, P; Jenkins, C; Kostikas, K; Mezzi, K; Shen, S; Singh, D; Tsiligianni, I; Wedzicha, JA, 2019) |
| "We aimed to evaluate if COPD patients who meet the Medicare guidelines for nocturnal oxygen therapy (iNOT+) had higher serum hs-CRP and IL-6 than those who did not meet the guidelines for iNOT (iNOT-)." | ( Macrea, MM; Malhotra, A; Martin, T; Oursler, KK; Owens, RL; Smith, D, 2019) |
| "To estimate the prevalence of chronic obstructive pulmonary disease (COPD) and related risk factors in people in opioid agonist treatment (OAT), to compare airflow limitation severity and age-specific COPD prevalence rates with those in the general population, and to assess the OAT patients' willingness to adopt life-style changes and to use therapeutic offers for COPD management." | ( Bruggmann, P; Falcato, L; Grischott, T; Puhan, MA; Senn, O, 2019) |
| "Patients with COPD, exacerbation history, and receiving maintenance inhaler therapy, were randomised to initiate FF/VI 100/25 μg or continue usual care (UC) with 12 months' follow-up." | ( Bakerly, ND; Boucot, I; Collier, S; Crawford, J; Harvey, C; Leather, DA; New, JP; Vestbo, J; Woodcock, A, 2019) |
| "However, depression with COPD comorbidity is often underdiagnosed and undertreated, and pathogenic research is also insufficient." | ( Deng, X; Fu, J; Guo, Q; Ji, Z; Ma, S; Song, Y; Xu, B, 2019) |
| "In lowlanders in Central Asia with COPD traveling to a high altitude, preventive dexamethasone treatment improved nocturnal oxygen saturation, sleep apnea, and subjective sleep quality." | ( Aeschbacher, SS; Bisang, M; Bloch, KE; Emilov, B; Estebesova, B; Furian, M; Latshang, TD; Lichtblau, M; Mademilov, M; Marazhapov, NH; Osmonov, B; Sheraliev, U; Sooronbaev, TM; Ulrich, S, 2019) |
| "Individualizing treatment of each COPD patient based on unique phenotypes will maximize chances of therapeutic responsiveness." | ( Lal, C; Strange, C, 2019) |
| "Clinical trials of COPD pharmacotherapy typically involve aging populations with moderate-to-severe COPD, but the latter is often diagnosed by spirometric criteria that are not age-appropriate across the continuum of lung function." | ( Gill, TM; Leo-Summers, LS; Van Ness, PH; Vaz Fragoso, CA, 2019) |
| "In GLI-based moderate-to-severe COPD, combination therapy yields a statistically significant increased risk of pneumonia but the reductions in mortality are not statistically significant, although could potentially be clinically meaningful." | ( Gill, TM; Leo-Summers, LS; Van Ness, PH; Vaz Fragoso, CA, 2019) |
| "Adequate cognitive functioning in chronic obstructive pulmonary disease (COPD) patients is essential to understand the nature of the disease, adherence to treatment, and for leading a better quality of life." | ( Gumallapu, GC; Krishnamurthy, S; Sivagnaname, Y, 2019) |
| "Chronic obstructive pulmonary disease (COPD) is mainly treated pharmaceutically with bronchodilators." | ( Kamei, T; Matsunaga, K; Minakata, Y; Mori, Y; Nakamura, H; Nanki, N, 2019) |
| "Eligible patients had COPD, chronic bronchitis, and were receiving inhaled triple therapy for ≥2 months." | ( Beeh, KM; Colgan, B; Emirova, A; Geraci, S; Govoni, M; Kornmann, O; Leaker, B; Lucci, G; Nandeuil, MA; Singh, D; Watz, H, 2019) |
| "AITC was administered to the COPD model rats and normal rats to explore the association between Notch1 and MRP1." | ( Fang, W; Li, Z; Wang, D; Wang, X; Wu, J; Wu, Q; Yao, Z, 2019) |
| "This therapy does not worsen COPD in terms of symptoms, pulmonary function, or acute exacerbation." | ( Asada, K; Enomoto, N; Fujisawa, T; Furuhashi, K; Hayakawa, H; Hozumi, H; Imokawa, S; Inui, N; Kaida, Y; Karayama, M; Koshimizu, N; Kusagaya, H; Masuda, M; Matsuda, H; Nakamura, Y; Suda, T; Suzuki, Y; Toyoshima, M; Yamada, T; Yokomura, K, 2019) |
| "To evaluate patients with stable COPD for the presence of potentially pathogenic microorganisms (PPM), systemic inflammation and the effects of short-term antibiotic therapy in PPM positive patients." | ( Li, HQ; Ning, W; Wang, JX; Zhang, F, 2019) |
| "Dyspnoea in patients with chronic obstructive pulmonary disease (COPD) is frequent and often persists despite conventional treatment." | ( Ariyoshi, K; Hosoi, K; Inoue, Y; Iwase, S; Kaku, S; Kohashi, Y; Kusama, K; Matsuda, Y; Matsumoto, H; Morishita, H; Morita, T; Nishikawa, M; Oyamada, S; Yamaguchi, T, 2021) |
| "A rat model of COPD with IAV infection was established and treated with SFJDC and/or oseltamivir." | ( Bai, Q; Fei, GH; Ji, S; Shen, JL; Wang, S; Wu, X; Zhang, DW, 2020) |
| "Future trials of COPD therapy could be designed more efficiently, be made less costly, while improving the accuracy and precision of their data and the resulting conclusions." | ( Suissa, S, 2020) |
| "The Informing the Pathway of COPD Treatment (IMPACT) study demonstrated that single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) reduces moderate/severe exacerbation rates and improves lung function and health status versus FF/VI or UMEC/VI dual therapy in patients with symptomatic COPD and a history of exacerbations." | ( Clifton, CS; Gross, AS; Hashimoto, K; Ishii, T; Jones, CE; Kato, M; Kilbride, S; Lipson, DA; Nezu, Y; Tomii, K, 2019) |
| "Chronic obstructive pulmonary disease (COPD) is related to smoking and anti-inflammatory therapy is indicated." | ( Cornélio, ML; Girol, AP; Oliani, SM; Possebon, L; Riffo-Vasquez, Y; Sant'Ana, M; Souza, HR, 2020) |
| "The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends a short-acting bronchodilator or single long-acting bronchodilator as an initial pharmacological treatment for GOLD category A patients with COPD." | ( Arora, S; Jenkins, M; Lipworth, BJ; Martin, UJ; Martinez, FJ; Rabe, KF; Reisner, C, 2020) |
| "Many patients with chronic obstructive pulmonary disease (COPD) still experience daily symptoms, exacerbations, and accelerated lung function decline, even when receiving maximal combined treatment with inhaled long-acting bronchodilators and corticosteroids." | ( Bengtsson, T; Martinez, FJ; Maurer, BT; Singh, D; Watz, H, 2020) |
| "The concept of chronic obstructive pulmonary disease (COPD) control has been proposed to guide treatment decisions in COPD." | ( Alcazar, B; Barrecheguren, M; Kostikas, K; Mezzi, K; Miravitlles, M; Shen, S; Soler-Cataluña, JJ; Wedzicha, JA, 2020) |
| "A total of 321 AECOPD patients with moderate-to-severe exacerbation were randomly divided into three groups and treated with NB." | ( Chen, B; Li, Y; Liu, W; Liu, Y; Zhang, M; Zhang, R; Zhu, J; Zhu, S, 2020) |
| "Lung macrophages from controls and COPD patients were treated with corticosteroids; effects on gene and protein expression of CD163, CD164, CD206, MERTK, CD64, CD80 and CD86 were studied." | ( Dikwa, AB; Gaskell, R; Higham, A; Lea, S; Li, J; Montero-Fernandez, MA; Scott, T; Shah, R; Singh, D, 2020) |
| "Fungal sensitisation is prevalent in COPD and associates with frequent exacerbations representing a potential treatable trait." | ( Abisheganaden, JA; Chew, FT; Chotirmall, SH; Drautz-Moses, DI; Gaultier, NE; Hui, DSC; Ivan, FX; Jaggi, TK; Ko, FWS; Koh, MS; Lau, KJX; Mac Aogáin, M; Matta, SA; Pang, SL; Poh, ME; Schuster, SC; Sio, YY; Tee, A; Tiew, PY; Uchida, A; Xu, H, 2020) |
| "Treatment of COPD includes a combination of long-acting bronchodilators and long-acting muscarinic antagonists." | ( Berlinski, A, 2020) |
| "In patients with COPD with a history of exacerbations in the previous year, IND/GLY is a cost-effective treatment option compared with SFC." | ( Danyliv, A; Gutzwiller, FS; Lakhotia, B; Mahon, R; Nikolaev, I; Thokala, P, 2020) |
| "In a symptomatic COPD population with a history of exacerbations and a high rate of CV disease/risk, the proportion of patients with CVAESI and MACE was 10-11% and 1-3%, respectively, across treatment arms, and the risk of CVAESI was low and similar across treatment arms." | ( Criner, G; Day, NC; Dransfield, M; Halpin, DMG; Han, MK; Jones, CE; Kaisermann, MC; Kilbride, S; Kumar, S; Lange, P; Lipson, DA; Lomas, DA; Martin, N; Martinez, FJ; Singh, D; Wise, R, 2020) |
| "There were no improvements in E-RS:COPD, CAT or SGRQ-C scores in participants treated with any dose of danirixin compared to placebo; a larger than expected placebo effect was observed." | ( Ambery, C; Donald, AC; Keeley, T; Lazaar, AL; Miller, BE; Russell, J; Tal-Singer, R; Watz, H, 2020) |
| "In clinical practice, some chronic obstructive pulmonary disease (COPD) patients experienced a remarkable increase in forced vital capacity (FVC) after bronchodilator administration, whereas forced expiratory volume in the first second (FEV1) remains substantially unchanged." | ( Jiang, S; Liu, Y; Wu, Z; Zhang, X, 2020) |
| "The main goals of COPD therapy are to achieve clinical stability with minimal clinical manifestations and low risk of relapse." | ( Aisanov, ZR; Avdeev, SN; Beeh, KM; Belevsky, AS; Ignatova, GL; Kostikas, K; Leshchenko, IV; Ovcharenko, SI; Shmelev, EI; Sinopal'nikov, AI; Titova, ON; Vizel, AA; Zyryanov, SK, 2020) |
| "The phase 3 InforMing the PAthway of COPD (chronic obstructive pulmonary disease) Treatment (IMPACT) trial, single-inhaler therapy with fluticasone furoate (FF) 100 μg, umeclidinium (UMEC) 62." | ( Criner, GJ; Dransfield, MT; Halpin, DMG; Han, MK; Jones, CE; Kaisermann, MC; Kilbride, S; Lange, P; Lipson, DA; Lomas, DA; Martinez, FJ; Pascoe, S; Singh, D; Tabberer, M; Wise, RA, 2020) |
| "The 2018 Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends combination long-acting muscarinic antagonists/long-acting beta2-agonists (LAMA + LABA) as preferred maintenance therapy for patients with symptomatic chronic obstructive lung disease (COPD) after monotherapy and stepping up to triple therapy (TT; LAMA + LABA + inhaled corticosteroids [ICS]) in case of further exacerbations." | ( Anderson, AJ; Buikema, AR; DuCharme, M; Franchino-Elder, J; Frazer, M; Palli, SR, 2020) |
| "To compare health plan-paid costs, COPD exacerbations, and pneumonia diagnoses among patients newly treated with a LAMA + LABA regimen composed of tiotropium (TIO) + olodaterol (OLO) in a fixed-dose combination inhaler (TIO + OLO) or TT in a U." | ( Anderson, AJ; Buikema, AR; DuCharme, M; Franchino-Elder, J; Frazer, M; Palli, SR, 2020) |
| "This retrospective study identified COPD patients aged ≥ 40 years who were initiating TIO + OLO or TT (index regimen) between January 1, 2014, and March 31, 2018, from a national administrative claims database." | ( Anderson, AJ; Buikema, AR; DuCharme, M; Franchino-Elder, J; Frazer, M; Palli, SR, 2020) |
| "Outpatients with COPD and moderate to very severe chronic breathlessness (modified Medical Research Council [mMRC] breathlessness grades 2-4) despite optimal pharmacological and nonpharmacological treatment were included." | ( Hameleers, N; Janssen, DJA; Schols, JMGA; van den Beuken-van Everdingen, MHJ; Verberkt, CA; Wouters, EFM, 2020) |
| "Four categories of COPD-related interventions by community pharmacists were identified: 1) primary prevention; 2) early detection; 3) therapy management; and 4) long-term health management." | ( Hu, H; Hu, Y; Ung, COL; Yao, D, 2020) |
| "The study enrolled COPD patients from Taiwan NHIRD who received treatment with fluticasone/salmeterol or budesonide/formoterol for > 90 days between 2004 and 2011." | ( Chen, L; Huang, TM; Kuo, KC; Lai, CC; Wang, CY; Wang, HC; Wang, YH; Yu, CJ, 2020) |
| "In the Informing the Pathway of COPD Treatment (IMPACT) trial, single-inhaler triple-therapy fluticasone furoate (FF), umeclidinium (UMEC), and vilanterol (VI) reduced moderate/severe exacerbation rates vs FF/VI and UMEC/VI in patients with symptomatic COPD and a history of exacerbations, with a similar safety profile." | ( Criner, GJ; Dransfield, MT; Halpin, DMG; Han, MK; Hanania, NA; Jones, CE; Kilbride, S; Lima, R; Lipson, DA; Lomas, DA; Mannino, DM; Martin, N; Martinez, FJ; Singh, D; Wise, RA, 2021) |
| "The knowledge of patients with COPD about the disease and its treatment was poor at the time of enrolment." | ( Bargaje, MD; Gharat, S; Mathew, J; Sajith, M; Varghese, A, 2021) |
| "NCS is effective for patients with AECOPD, which may be an alternative treatment option." | ( Chen, Y; Han, X; Li, F; Liu, Y; Lu, L; Xu, JF; Yang, J; Yao, W; Zhang, J; Zheng, J, 2020) |
| "Patients with COPD are often prescribed ICS therapy, which, when used over a long term, can be associated with local and systemic adverse effects." | ( Criner, G; Duffy, S, 2021) |
| "The early stages of COPD may represent a "window of therapeutic opportunity" during which initiation of tiotropium and olodaterol dual bronchodilator therapy may improve lung function and quality of life and reduce exacerbations in patients with COPD." | ( Criner, G; Duffy, S, 2021) |
| "Patients with COPD ≥40 years at diagnosis were included if they initiated extrafine BDP/FF or any LABA/LAMA double therapy as a step-up from no maintenance therapy or monotherapy with inhaled corticosteroids (ICS), LAMA, or LABA and a history of ≥2 moderate/severe exacerbations in the previous two years." | ( Baldi, S; Contoli, M; Fabbri, LM; Kerkhof, M; Kerstjens, HAM; Luis López-Campos, J; Price, DB; Roche, N; Santoro, L; Singh, D; Vogelmeier, CF; Voorham, J, 2020) |
| "Treating all patients with COPD with target saturations of 88%-92% will simplify prescribing and should improve outcome." | ( Bourke, S; Echevarria, C; Steer, J; Wason, J, 2021) |
| "Chronic obstructive pulmonary disease (COPD) is an important comorbidity in heart failure (HF) with reduced ejection fraction (HFrEF), associated with worse outcomes and often suboptimal treatment because of under-prescription of beta-blockers." | ( Bengtsson, O; de Boer, RA; Desai, AS; Dewan, P; Docherty, KF; Drozdz, J; Hawkins, NM; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Merkely, B; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Verma, S, 2021) |
| "Patients with COPD were more likely to be older men with a history of smoking, worse renal function, and higher baseline N-terminal pro B-type natriuretic peptide, and less likely to be treated with a beta-blocker or mineralocorticoid receptor antagonist." | ( Bengtsson, O; de Boer, RA; Desai, AS; Dewan, P; Docherty, KF; Drozdz, J; Hawkins, NM; Inzucchi, SE; Jhund, PS; Kitakaze, M; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Merkely, B; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD; Verma, S, 2021) |
| "Dexmedetomidine is conducive to COPD treatment by downregulating PACER." | ( Du, XH; Li, L; Li, SS; Shen, W; Sun, SB; Weng, ZY; Xiong, GS; Yang, GM; Ye, XL, 2020) |
| "Prospective cohort study of COPD and asthma patients treated for acute exacerbations." | ( Dimopoulou, I; Kardara, M; Keskinidou, C; Kotanidou, A; Koutsoukou, A; Michalopoulou, P; Orfanos, SE; Rovina, N; Tsoukalas, G; Vassiliou, AG; Vitsas, V, 2020) |
| "For the first treatment of AECOPD 12,915 received AMX, and 30,721 patients received AMC." | ( Andersen, CØ; Bagge, K; Eklöf, J; Hansen, EF; Hertz, FB; Jarløv, JO; Jensen, JS; Sivapalan, P, 2021) |
| "In AECOPD, empirically adding clavulanic acid to amoxicillin is not associated with a better outcome; it seems safe for these patients to be treated with amoxicillin alone." | ( Andersen, CØ; Bagge, K; Eklöf, J; Hansen, EF; Hertz, FB; Jarløv, JO; Jensen, JS; Sivapalan, P, 2021) |
| "No significant differences in COPD Assessment Test or modified Medical Research Council dyspnea questionnaire were reported in the surveys completed after each FDC administration; no significant differences in spirometric items were observed." | ( Hanada, S; Kunita, Y; Muraki, M; Sawaguchi, H; Shirahase, K; Tohda, Y; Yamazaki, R, 2021) |
| "We show that normal and COPD bronchial basal/progenitors, even when treated with TGF-β, express both epithelial and mesenchymal markers, and that the epithelial marker E-cadherin is not a target of Slug and, moreover, positively correlates with Slug." | ( Ben Brahim, C; Cartier, A; Courageux, C; de Koning, L; de la Grange, P; Jolly, A; Leroy, P; Ouine, B, 2021) |
| "FSTL1 promotes CS-induced COPD by modulating autophagy, therefore targeting FSTL1 and autophagy may shed light on treating cigarette smoke-induced COPD." | ( Cao, L; Dong, L; Huang, S; Liu, T; Liu, X; Liu, Y; Pan, Y; Wang, J; Wu, J; Xu, J; Zhao, J; Zou, M, 2021) |
| "Airway inflammation is a key feature of chronic obstructive pulmonary disease (COPD) and inhaled corticosteroids (ICS) remain the main treatment for airway inflammation." | ( Dorscheid, DR; Leung, JM; Pieper, MP; Sin, DD; Singhera, GK; Yan, YX; Yang, N, 2021) |
| "In patients with COPD, tiotropium/olodaterol was associated with a lower risk of COPD exacerbations, pneumonia, and escalation to triple therapy versus LABA/ICS, both individually and in combination; the combined risk was reduced irrespective of baseline eosinophils or exacerbation history." | ( de la Hoz, A; Esposito, DB; He, X; Koerner, L; Miravitlles, M; Montonen, J; Quint, JK; Wallace, L, 2021) |
| "For patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) complicated by respiratory acidosis, noninvasive ventilation therapy is thought to be the first-line treatment." | ( Chen, XC; Dai, J; Liu, C; Ma, SJ; Wang, S; Yan, DD, 2021) |
| "Eligible COPD patients had an indication for treatment with single-inhaler BDP/FF/G." | ( Marth, K; Pohl, W; Renner, A, 2021) |
| "The effect of HSP72 and JNK on COPD following treatment with baicalin was assessed both in vivo and in vitro by conducting loss- and gain- function experiments." | ( Hao, D; Jiang, J; Li, Y; Shi, J, 2021) |
| "Risks of first moderate and/or severe COPD exacerbation were lower for tiotropium/olodaterol than tiotropium monotherapy (between-group differences not significant)." | ( de Souza, S; Garry, EM; Muro, S; Nakamura, S; Sakamoto, W; Suzuki, M; Wang, JR, 2021) |
| "Fifteen COPD patients were recruited to undergo spirometry and SPECT-CT lung scan following nebulization of radioactively labeled albuterol in saline solution with a jet nebulizer ("NEB") and with a combined Pulsehaler™/jet nebulizer ("PH + NEB") treatment." | ( Fink, G; Gavriely, N; Golan, H; Shpirer, I; Volkov, O, 2022) |
| "Chronic obstructive pulmonary disease (COPD) often tends to respond poorly to glucocorticoid (GC) therapy." | ( Chen, DD; Le Grange, JM; Zhang, JN; Zheng, XF; Zhou, LQ; Zhu, XL, 2021) |
| "Kaplan-Meier rates of on-treatment COPD-related exacerbations were similar between cohorts (hazard ratio at 12 months; overall: 0." | ( Duh, MS; Germain, G; Hahn, B; Laliberté, F; Mahendran, M; Moretz, C; Ray, R; Shen, Q; Slade, D, 2021) |
| "Chronic obstructive pulmonary disease (COPD) guidelines advocate treatment with combinations of long-acting bronchodilators for patients with COPD who have persistent symptoms or continue to have exacerbations while using a single bronchodilator." | ( Cook, J; Corro Ramos, I; Hoogendoorn, M; Paulsson, E; Rutten-van Mölken, M; Soini, E; Soulard, S, 2021) |
| "A previously published COPD patient-level discrete event simulation model was updated with most recent evidence to estimate lifetime quality-adjusted life years (QALYs) and costs for COPD patients receiving either tiotropium/olodaterol, tiotropium monotherapy or LABA/ICS." | ( Cook, J; Corro Ramos, I; Hoogendoorn, M; Paulsson, E; Rutten-van Mölken, M; Soini, E; Soulard, S, 2021) |
| "BACKGROUND Chronic obstructive pulmonary disease (COPD) is a disease with high heterogeneity, which is a major challenge in clinical individualized treatment." | ( Chen, X; Cheng, X; Hu, Y; Qiu, Z, 2021) |
| "We report two cases of COPD evaluated by dynamic-ventilatory DR for pulmonary function and treatment efficacy and discuss the potential of dynamic DR for evaluating COPD therapy." | ( Abo, M; Hara, J; Kasahara, K; Kimura, H; Nishikawa, S; Ogawa, N; Ohkura, N; Sone, T; Tambo, Y; Tanaka, R; Watanabe, S, 2021) |
| "A rat model of COPD was established by long-term exposure to CS, then the rats were orally administered with ISOF (0." | ( Cao, X; Chen, C; Cheng, S; Du, X; Huang, R; Li, R; Li, X; Liang, Y; Lin, H; Peng, P; Wang, L; Wang, X; Weng, Z; Wu, H; Xiao, C; Yang, W; Yang, Y; Yang, Z; Zeng, D; Zhang, R; Zhang, X, 2021) |
| "Currently recommended chronic obstructive pulmonary disease inhaled combination therapy (other than FP-SAL) should also be investigated using these methods." | ( Carpenter, JR; Douglas, I; Quint, JK; Schneeweiss, S; Smeeth, L; Williamson, E; Wing, K; Wise, L, 2021) |
| "In patients with moderate-to-severe COPD and CV risk factors, the addition of aclidinium to maintenance therapy with LABA or LABA + ICS provided further benefit." | ( Bhatt, DL; Chapman, KR; Chuecos, F; Daoud, SZ; Garcia Gil, E; Scirica, BM; Wise, RA, 2021) |
| "Some chronic obstructive pulmonary disease (COPD) patients develop hypoxemia with disease progression, with some even requiring long-term oxygen therapy (LTOT)." | ( Fujioka, N; Fujita, Y; Hontsu, S; Ibaraki, T; Muro, S; Saeki, K; Sakaguchi, K; Sato, S; Tanabe, N; Tanimura, K; Tomoda, K; Yamamoto, Y; Yamauchi, M; Yoshikawa, M, 2022) |
| ": We recruited patients with chronic obstructive pulmonary disease (COPD) or interstitial pneumonia receiving long-term oxygen therapy." | ( Hazama, D; Katsurada, N; Kobayashi, K; Murakami, S; Nagano, T; Nishimura, Y; Omori, T; Otoshi, T; Tachihara, M; Yamamoto, M, 2021) |
| "In people with COPD breathlessness is a common symptom and if mistreated can result in poor physical health and reduced quality of life." | ( Keogh, E; Williams, EM, 2021) |
| "In patients with advanced chronic obstructive pulmonary disease (COPD), it is challenging to treat breathlessness." | ( Ebihara, S; Kanezaki, M; Terada, K, 2021) |
| "A total of 68 acute exacerbation of chronic obstructive pulmonary disease patients were randomly divided into control group (34 cases) and experimental group (34 cases), who received the doxofylline treatment and combined doxofylline and salbutamol treatment for 1 week, respectively." | ( Bao, H; Du, X; Zhao, D, 2021) |
| "The study group consisted of 110 COPD patients treated with LTOT." | ( Czerw, A; Deptala, A; Mekal, D, 2021) |
| "The diet of COPD patients treated with long-term oxygen therapy was improperly balanced, with deficiencies of important nutrients." | ( Czerw, A; Deptala, A; Mekal, D, 2021) |
| "Group 3 (n = 30) - COPD received standard therapy for COPD." | ( Boldizhar, OO; Derbak, MA; Ganich, TM; Khramtsova, IO; Lazur, YV, 2021) |
| "We studied whether in patients with COPD the use of metformin for diabetes treatment was linked to a pattern of lung function decline consistent with the hypothesis of anti-aging effects of metformin." | ( Alter, P; Andreas, S; Bals, R; Behr, J; Frankenberger, M; Jörres, RA; Kahnert, K; Kellerer, C; Lehmann, M; Lucke, T; Lutter, JI; Seissler, J; Trudzinski, FC; Vogelmeier, CF; Watz, H; Welte, T; Yildirim, Ö, 2022) |
| "Patients with chronic obstructive pulmonary disease (COPD) face limited treatment options and inadequate access to palliative care." | ( Bennett, MI; Boland, AC; Chapman, EJ; Fu, Y, 2022) |
| "Chronic obstructive pulmonary disease (COPD) with eosinophilic airway inflammation represents a distinct phenotype that might respond to treatment with inhaled corticosteroids." | ( Chen, YW; Chou, KT; Feng, JY; Hsiao, YH; Ko, HK; Pan, SW; Perng, DW; Su, KC; Yu, WK, 2022) |
| "Cox regression was used to assess COPD subgroup (placebo only) associations with, and treatment effects of empagliflozin versus placebo on first hospitalization for HF (HHF), CV death, all-cause mortality, incident/worsening nephropathy, and all-cause hospitalization." | ( Anker, SD; Fitchett, DH; Inzucchi, SE; Lauer, S; Pernille Ofstad, A; Sander, LE; Vedin, O; Verma, S; Wanner, C; Yaggi, HK; Zinman, B, 2022) |
| "Triple therapy for chronic obstructive pulmonary disease (COPD) is recommended for some patients, but the inhaled corticosteroids (ICS) may differ in effectiveness and safety." | ( Dell'Aniello, S; Ernst, P; Suissa, S, 2022) |
| "Forty COPD patients in the exacerbation phase were enrolled into the study and were treated with either NAC (NAC group; n=20) or NACP (NACP group; n=20) twice daily for one month." | ( Ilić, A; Kotur-Stevuljević, J; Minić, R; Žujović, D; Žuža, O; Đorđević, B, 2022) |
| "Patients with a diagnosis of COPD or ILD who were prescribed home oxygen therapy between January 2012-December 2018 were identified." | ( Harrison, AC; Khor, YH; McDonald, CF; Robinson, JF; Tu, L, 2022) |
| "Exacerbations and symptoms of COPD, lung functions, and therapy escalation were compared among patients using tiotropium/olodaterol, umeclidinium/vilanterol and indacaterol/glycopyrronium." | ( Chan, MC; Chen, NH; Cheng, SL; Hsieh, MJ; Hsu, WH; Kuo, PH; Lin, MS; Liu, CL; Liu, SF; Tao, CW; Tsai, YH; Wei, YF; Wu, YK; Yang, TM, 2022) |
| "Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death in the world, and has no radical treatment." | ( Eto, Y; Fujikawa, H; Hayashi, M; Kai, H; Kamei, S; Kawakami, T; Kishimoto, T; Maruta, K; Nakashima, R; Nasu, A; Nohara, H; Shuto, T; Suico, MA; Takahashi, N; Ueno-Shuto, K, 2022) |
| "Standard treatment for chronic obstructive pulmonary disease (COPD) includes inhalation therapy along with mucoactive drugs." | ( Agic, A; Bogdan, M; Dugajlić, M; Ilić, M; Kolarov, V; Kotur Stevuljević, J; Kutlešić Stević, S; Tot Vereš, K; Tušek, B; Zvezdin, B, 2022) |
| "Patients admitted for asthma or COPD exacerbations, doctors, and nurses in a university-affiliated hospital were surveyed from 1 April 2021 to 30 September 2021 regarding their views on the effectiveness, ease of use, preparation and administration, side effects, and infection risk of the two administration methods." | ( Alsuwaigh, R; Binte Mohd Noor, N; Cao, Y; Chen, H; Li, XL; Liew, J; Mohamed Noor, SB; Puan, Y; Tay, TR; Ye, H; Yii, A, 2023) |
| "Long-term oxygen therapy in COPD is usually supervised through home-care respiratory programs." | ( Bernard, S; Lacasse, Y; Maltais, F; Nguyen, VH, 2022) |
| "Furthermore, BGF treatment prevented COPD-PH development, as shown by improvements in the hemodynamic and histological phenotypes four weeks after elastase treatment (right ventricular systolic pressure, p = 0." | ( Effendi, WI; Emoto, N; Hazama, D; Katsurada, N; Kobayashi, K; Nagano, T; Nishimura, Y; Ryanto, GRT; Suraya, R; Tachihara, M; Yamamoto, M, 2022) |
| "Following an AECOPD, frequent-exacerbation phenotype patients (n=46) were assigned a once-daily three-month therapy with the study drug and one year follow-up." | ( Agić, A; Buha, I; Dimic-Janjic, S; Ilić, A; Ilić, B; Milenković, B; Mirić, M; Nagorni-Obradović, L; Popević, S; Simić, M; Škodrić-Trifunović, V; Stjepanović, M, 2022) |
| "Among the 90 patients with COPD treated with ICSs, 41 experienced pneumonia more than once during the median follow-up of 29 (interquartile range, 8-35) months." | ( Heo, EY; Jin, KN; Kim, DK; Lee, HJ; Lee, HW; Lee, JK; Park, TY, 2022) |
| "Among patients with COPD treated with ICSs, radiographic phenotypes including the presence of emphysema, bronchiectasis or emphysema/bronchiectasis overlap phenotype, severity with emphysema, subtypes of centrilobular or panlobular emphysema, and upper lobe distribution of emphysema may help predict the risk of pneumonia." | ( Heo, EY; Jin, KN; Kim, DK; Lee, HJ; Lee, HW; Lee, JK; Park, TY, 2022) |
| "This retrospective study included COPD-patients admitted to the pulmonary ward and treated with HFNC from April 2016 until April 2019." | ( Duiverman, ML; Koppers, RJH; van Geffen, WH; Veeger, NJGM; Veenstra, P, 2022) |
| "We observed that COPD-relevant stimulations created damage to the epithelium as seen on immunohistochemistry sections and that treatment with ACY-1083 maintained an intact cell layer and preserved mucociliary function." | ( Abdillahi, SM; Åstrand, A; Berntsson, P; Capodanno, E; Chan, J; Collins, M; Ghosh, B; Horndahl, J; Li, J; Ripa, L; Sidhaye, VK; Svärd, R; Wingren, C, 2022) |
| "At the same time, severe COPD treatment, that often require a combination of medicaments, represents a substantial economic burden for the National Health Systems (NHS)." | ( Barbaro, MPF; Buonamico, E; Carpagnano, GE; Di Lecce, V; Lacedonia, D; Lepore, G; Panza, F; Quarato, CMI; Resta, E; Resta, O; Rossi, N; Scioscia, G, 2022) |
| "Patients with chronic obstructive pulmonary disease (COPD) may develop hypercapnia during supplemental oxygen therapy, particularly if uncontrolled." | ( Kadakol, N; Madabhavi, I; Sarkar, M, 2022) |
| "Patients with chronic obstructive pulmonary disease (COPD) may develop hypercapnia during supplemental oxygen therapy, particularly if uncontrolled." | ( Kadakol, N; Madabhavi, I; Sarkar, M, 2022) |
| "Patients with chronic obstructive pulmonary disease (COPD) may develop hypercapnia during supplemental oxygen therapy, particularly if uncontrolled." | ( Kadakol, N; Madabhavi, I; Sarkar, M, 2022) |
| "Among people with COPD and severe chronic breathlessness, daily low-dose, extended-release morphine did not significantly reduce the intensity of worst breathlessness after 1 week of treatment." | ( Agar, MR; Chang, S; Clark, KJ; Currow, DC; Eckert, DJ; Ekström, M; Fazekas, B; Ferreira, D; Johnson, MJ; Louw, S, 2022) |
| "Among people with COPD and severe chronic breathlessness, daily low-dose, extended-release morphine did not significantly reduce the intensity of worst breathlessness after 1 week of treatment." | ( Agar, MR; Chang, S; Clark, KJ; Currow, DC; Eckert, DJ; Ekström, M; Fazekas, B; Ferreira, D; Johnson, MJ; Louw, S, 2022) |
| "Among people with COPD and severe chronic breathlessness, daily low-dose, extended-release morphine did not significantly reduce the intensity of worst breathlessness after 1 week of treatment." | ( Agar, MR; Chang, S; Clark, KJ; Currow, DC; Eckert, DJ; Ekström, M; Fazekas, B; Ferreira, D; Johnson, MJ; Louw, S, 2022) |
| "Chronic breathlessness in chronic obstructive pulmonary disease (COPD) is effectively treated with pulmonary rehabilitation." | ( Browning, M; Duff, E; Finnegan, SL; Harmer, CJ; Pattinson, KTS; Rahman, NM; Reinecke, A, 2023) |
| "The prevalence of treatments for COPD management was below ideal in 2013." | ( Malta, DC; Marques, GÁ; Menezes, AMB; Montzel, M; Oliveira, PD; Sardinha, LMV; Wehrmeister, FC, 2023) |
| "Asthma and chronic obstructive pulmonary disease are currently diagnosed and treated after the demonstration of variable airflow limitation and symptoms." | ( Couillard, S; Molfino, NA; Petousi, N; Smigiel, KS, 2023) |
| "This first study of MART in COPD found that budesonide/formoterol MART might be similarly effective to fluticasone/salmeterol fixed-dose therapy in moderate to severe patients with COPD, at a lower daily ICS dosage." | ( Braunstahl, GJ; Halbersma, NJ; Heijink, IH; Imkamp, K; Kerstjens, HAM; Kocks, JWH; Kroesen, BJ; Luijk, BHD; Muiser, S; Reddel, HK; Seigers, D; van den Berg, JW; van den Berge, M; Vonk, JM, 2023) |
| "Dapsone treated both bronchitis and COPD." | ( Altschuler, E; Bourbeau, J; Choi, SH; Coleman, M; Kanwar, B; Khattak, A; Lee, JH; Lee, SJ; Park, J; Sergi, C, 2023) |
| "Many patients with COPD use RAS-inhibiting (RASi) treatment." | ( Biering-Sørensen, T; Eklöf, J; Hedsund, C; Heerfordt, CK; Hilberg, O; Jensen, JS; Kamstrup, P; Klausen, TW; Kolekar, S; Lund, TK; Pedersen, L; Sivapalan, P; Skaarup, KG; Sørensen, R; Vilstrup, F, 2023) |
| "The purpose of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) treatment is to minimize the negative impact of the current exacerbation and to prevent the development of subsequent events." | ( Gou, X; He, L; Lei, L; Li, Y, 2023) |
| "Its mechanism for treating asthma and COPD has been reported, however, how it works against IPF remains unclear." | ( Chen, M; Deng, L; Dong, J; Huang, X; Lei, Y; Shi, H; Yu, H; Zhou, Y, 2023) |
| "The recommended treatment of COPD exacerbations includes administration of short-acting bronchodilators that act to reverse bronchoconstriction, restore lung volumes, and relieve breathlessness." | ( Alsaid, A; Costello, RW; Cushen, B; Greene, G, 2023) |
| "We identified a cohort of COPD patients, aged ≥40 years, treated during 2017-2020, from the UK Clinical Practice Research Datalink, a real-world practice setting." | ( Dell'Aniello, S; Ernst, P; Li, J; Suissa, S, 2023) |
| "In a real-world setting of COPD treatment, the three dual bronchodilator combinations were similarly effective on the risk of a severe exacerbation of COPD." | ( Dell'Aniello, S; Ernst, P; Li, J; Suissa, S, 2023) |
| "Treating both healthy and COPD fibroblasts with STING inhibitor in combination with dexamethasone additively inhibited STING pathway in both groups." | ( Al-Sheakly, BK; Bajbouj, K; Hafezi, S; Halwani, R; Hamid, Q; Mdkhana, B; Ramakrishnan, RK; Saheb Sharif-Askari, F; Saheb Sharif-Askari, N, 2023) |
| "In Phase 2 studies in subjects with COPD, ensifentrine demonstrated clinically meaningful bronchodilation and improvements in symptoms and health-related quality of life when administered alone or in combination with current standard of care therapies." | ( Bengtsson, T; Donohue, JF; MacDonald-Berko, M; Rheault, T; Rickard, K, 2023) |
| "The fracture risk of patients with chronic obstructive pulmonary disease (COPD) treated with inhaled corticosteroids is controversial." | ( Du, L; Liu, X; Niu, Y; Peng, S; Tan, C; Wang, R, 2023) |
| "For patients with chronic obstructive pulmonary disease (COPD) who remain symptomatic despite maintenance treatment, clinical management guidelines recommend a stepwise escalation from monotherapy to dual therapy, and from dual therapy to triple therapy." | ( Compton, C; Ismaila, AS; Kendall, R; Martin, AA; Shah, D; Shukla, S, 2023) |
| "The validated GALAXY-COPD disease progression model was populated with patient baseline characteristics and treatment effect data from the 12-week GSK Study 207626 comparing FF/UMEC/VI with TIO in patients with moderate-to-very severe COPD." | ( Compton, C; Ismaila, AS; Kendall, R; Martin, AA; Shah, D; Shukla, S, 2023) |
| "She was diagnosed with COPD seven years ago when she had to be treated for chronic dyspnea, cough, and sputum that kept her breathless and required hospitalization." | ( Khartabil, N, 2023) |
| "Chronic obstructive pulmonary disease (COPD) is a preventable and treatable chronic lung disease." | ( Huang, Q; Li, WB; Li, Y; Suonan, GL; Wang, R; Zeng, XH; Zhang, XJ, 2023) |